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Methodology development is an essential pursuit to enable the synthesis of 
pharmaceutically-relevant targets. The emergent concept of privileged scaffolds has 
provided a framework for focused synthetic methodology development toward polycyclic 
heteroaromatic compounds with inherent and important bioactivities. This thesis explores 
novel applications of the Friedel-Crafts reaction toward three medicinal compounds and 
their privileged scaffolds: flubromazepam, a 1,4-benzodiazepine; tronocarpine, a 
tetrahydro-7,11-methanoazocino[1,2-a]indole; and rhazinicine, a tetrahydroindolizine. 
Several 1,4-benzodiazepine positional isomers were synthesized and characterized for the 
first time. Additionally, significant advances in knowledge were accomplished toward the 
reactivity and stereochemical behavior of donor-acceptor bicyclo[3.1.0]hexanes, an 
understudied class of DACPs, in intramolecular ring-opening cyclizations, and a novel 







CHAPTER 1. INTRODUCTION 
1.1 Organic Synthesis and Privileged Scaffolds 
Organic synthetic methodology development exists in a synergetic relationship with 
molecular targets, both natural and synthetic, that benefit our society. For instance, many 
pharmaceutical and some agrochemical targets are inspired by bioactive compounds 
isolated from nature, i.e. natural products. The discovery of novel natural products with 
significant bioactivities (e.g. antimalarial, antibacterial) not only offers alternatives to 
currently available therapies, but fundamentally broadens chemical understanding of how 
molecular scaffolds impart potency. Inspiration and application are therefore in a healthy 
equilibrium that continually fuels new research (Figure 1-1). 
 
Figure 1-1: Synergistic relationship between natural products and synthetic methodology. 
Over the last twenty years, general trends have been established to further guide drug 
discovery and relevant synthetic methodology development, to culminate in the concept of 
“privileged scaffolds” in medicinal targets1. One of the most prevalent structural features 
encompassed by privileged scaffolds is polycyclic, heteroaromatic core structures, 
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especially nitrogen-containing cores (e.g. indoles, pyrroles, quinolines, anilines).2 This 
more focused approach has inspired novel strategies and enabled efficient techniques to 
synthesize and evaluate vast libraries of compounds for biological survey,3 such as 
diversity-oriented synthesis (DOS),4 late-stage C-H functionalization5 and directed cross-
coupling,6 multicomponent reactions (MCRs),7 and cascade transformations.8 
1.2 The Friedel-Crafts Reaction: A Tool for Synthetic Organic Chemists 
1.2.1 Fundamentals of the Friedel-Crafts Reaction 
Among classic but extraordinarily powerful organic transformations to access 
densely functionalized heteroaromatic scaffolds is the Friedel-Crafts (F-C) reaction.9 
Found in every introductory organic chemistry textbook, this reaction is categorically an 
electrophilic aromatic substitution (EAS), whereby an arene is functionalized with an alkyl 
or acyl substituent. Regioselectivity for this transformation is largely dictated by electronic 
influences from any substituents already present on the arene. Electron-donating groups 
(EDGs, e.g. alkyl, aryl, alcohol, amino) promote EAS first at an open para position and 
next at an open ortho position (Figure 1-2a); EDGs, for this reason, are referred to as 
ortho/para directors for this class of chemistry. Electron-withdrawing groups (EWGs, e.g. 
acyl, nitro, halo), on the other hand, are meta directors (Figure 1-2b). Furthermore, EDGs 
are considered EAS-activating and EWGs, EAS-deactivating. 
The classic F-C reaction employs Lewis acids such as aluminum(III) trichloride 
(AlCl3) to activate the acylating or alkylating agent, usually an acyl chloride or an alkyl 
halide, respectively. To demonstrate the mechanism, Figure 1-2c shows a general F-C 
acylation with an EDG-substituted arene, and Figure 1-2d, a general F-C alkylation with 
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an EWG-substituted arene. The reaction begins with halogen abstraction from the 
acylating/alkylating agent by a Lewis acid catalyst, generating an acylium ion or a 
carbocatioin, respectively. This positively charged intermediate is then trapped by the 
aromatic partner, resulting in a σ-complex, in which the positive charge is delocalized 
throughout the ring. Deprotonation by the abstracted halide promotes rearomatization of 
the arene. 
 
Figure 1-2: (a) Regioselectivity for EDG-subsitutent arenes. (b) Regioselectivity for EWG-substituted 
arenes. (c) Mechanism of F-C acylation with an ortho/para director. (d) Mechanism of F-C alkylation 
with a meta director. 
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These electronic effects have important implications. First, predicting the 
regiochemical outcome of a Friedel-Crafts reaction is rather straightforward, but at the cost 
of limiting what regioisomers are accessible by this method. Second, if sufficient 
acylating/alkylating agent is available, this reaction is susceptible to over-substitution, 
especially for electron-rich arenes; in the case of alkylation, the arene becomes even more 
activated for EAS. Third, lower yields are expected for EWG-substituted arenes due to the 
electron-poorness of the system. 
1.2.2 The Friedel-Crafts Reaction Nearly a Century-and-a-Half Later 
Despite these drawbacks, the F-C reaction has seen many important advances since 
its appearance in 1877, especially in the context of total synthesis10. One significant 
application is intramolecular Friedel-Crafts-type reactions (so defined as long as the basic 
mechanistic pathway is followed) in cascade reactions, which are intricately designed, one-
pot transformations that rely on the interplay between compatible reactive moieties within 
a molecule. The result is a highly convergent manipulation strategy that facilitates the 
synthesis of vast combinatorial libraries for biological assay, often from commercially or 
readily available starting materials. Examples of cascade processes employing Friedel-
Crafts include but are certainly not limited to Pictet-Spengler (Scheme 1-1),11 Michael-
type additions (Scheme 1-2),12 and Prins-type cyclizations (Scheme 1-3).13 
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Scheme 1-1: Representative example of Pictet-Spengler cascade. (a) Classic Pictet-Spengler. (b) 
Exocyclic Pictet-Spengler from Hansen, et al. 
 
Scheme 1-2: Novel Michael addition/condensation/F-C alkylation cascade from Wang, et al. 
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Scheme 1-3: Prins cyclization/F-C alkylation cascade from Reddy, et al. 
With the advent of Friedel-Crafts-type reactions, cascade or otherwise, alternatives 
to classic acyl chloride and alkyl halide reagents have emerged. Acylating agents range 
from classic carboxylic acid derivatives, ketenes, and nitriles, to even more recent 
examples including twisted amides (Szostak)14 and aroyl triflates generated in situ from 
commercial aryl iodides and CO2 (Arndtsen).
15 Alkylating agents, too, constitute a vast 
scope of reagents, from alkynes and alkenes to epoxides, carboxylic acid derivatives, ethers 
and sulfides, and even alkanes with the advent of C-H functionalization strategies. 
Other mechanistic pathways, too, have been established for Friedel-Crafts beyond 
EAS. For instance, acyl iodides have been employed as partners for photochemical F-C 
acylation (Szostak),16 and aryldiazonium borohydrides were successful in effecting radical 
F-C acylation (Yadav).17 Douglas, in a recent publication, also demonstrated a 
regioselective F-C acylation meta to EDGs using sterically bulky salicylate esters,18 which 
is an important complement to classic F-C reactions. 
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1.3 This Thesis: Featured N-Heteroaromatic Products 
This dissertation will showcase novel methodology development guided by the 
principles of the Friedel-Crafts reaction and inspired by three bioactive targets: 
flubromazepam, tronocarpine, and rhazinicine (Figure 1-3). The unique features of these 
compounds’ molecular scaffolds presented diverse challenges in the pursuit of their total 
syntheses. These structural features and previously published strategies toward accessing 
them will be described in Chapter 1, whereas my hypotheses and synthetic attempts toward 
each target will be detailed in individual chapters. Potential applications of the Friedel-
Crafts reaction will be highlighted when relevant. 
 
Figure 1-3: Featured bioactive synthetic and natural products. 
1.4 Flubromazepam: A Synthetic Benzodiazepine 
Flubromazepam (IUPAC name: 7-bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-
benzo[e][1,4]diazepin-2-one) belongs to a class of bioactive compounds known as 
benzodiazepines. In general, benzodiazepines are highly effective pharmaceutical remedies 
for anxiety, seizures, insomnia, and opiate and alcohol withdrawals,19 and the core 
benzodiazepine scaffold is considered privileged.2b 
The syntheses of benzodiazepines including flubromazepam were extensively 
studied by Sternbach and co-workers in the early 1960s.20 By their published method, para-
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substituted anilines underwent classic Friedel-Crafts acylations with ortho-substituted 
benzoyl chlorides to form the 2-aminobenzophenone synthetic precursors to 
benzodiazepines.20c (Note: Several 2-aminobenzophenone preparations relied on N-acetyl 
or -tosyl starting materials and/or employed aluminum(III) chloride rather than zinc(II) 
chloride.) Then, one of two pathways was pursued: 1) a stepwise annulation with 2-
haloacetyl halide (X = Cl, Br) to prepare the intermediary 2-haloacetamidobenzophenone, 
followed by treatment of ammonia to promote the imination; or 2) a one-pot annulation 
effected by glycine ethyl ester hydrochloride in refluxing (Scheme 1-4).20d 
 
Scheme 1-4: Sternbach method to prepare benzodiazepines. 
 Though myriad benzodiazepines were successfully prepared by Sternbach using 
this method, the scope was generally limited to products originating from anilines with 
electron-withdrawing para substituents. This is unsurprising: given the synergistic 
substitution preferences of Friedel-Crafts acylations, 4-EWG-substituted anilines would 
facilitate acylation ortho to the amine, which is essential to enable synthesis of the 
benzodiazepine scaffold (Figure 1-4).21 These preferences are in stark contrast to the 
expected undesired acylations that would predominate with the 2- or 3-substituted anilines 
in the pursuit of novel benzophenone regioisomers. Thus, 2-aminobenzophenones with 
bromo, chloro, and nitro substituents para to the amino group are highly accessible,20b and 
there are few benzodiazepines with differing substitution patterns as a result. (Observed 
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exceptions to this rule from Sternbach’s work were often products of anilines with electron-
donating meta substituents, also favored by Friedel-Crafts chemistry.) 
 
Figure 1-4: Anticipated outcomes for Friedel-Crafts acylations of EWG-substituted anilines. 
 This limitation of classic Friedel-Crafts reactivity has led to a gap of knowledge 
surrounding the biological and analytical properties of benzodiazepine targets with varying 
substitution patterns. There are alternative approaches to F-C acylation that circumvent the 
regioselectivity issues for benzophenone synthesis, which will be discussed in Chapter 2, 
but these methodologies have largely not followed through with the syntheses of the 
corresponding benzodiazepines. Moreover, these novel methods often do not tolerate the 
bromo and/or nitro substituents characteristic of more potent pharmaceutical 
benzodiazepines. Therefore, there is an opportunity to exploit and further develop advances 
in Friedel-Crafts chemistry, such as chelation-assisted F-C acylation, to access novel 
benzodiazepine isomers. 
1.5 Tronocarpine and Rhazininicine 
In contrast to synthetic benzodiazepines like flubromazepam, which benefit from 
classic Friedel-Crafts acylation conditions, the two natural products described herein, 
tronocarpine and rhazinicine, represent significant opportunities to advance novel 
intramolecular Friedel-Crafts-type methodologies, specifically ring-opening cyclizations 
employing donor-acceptor cyclopropanes (DACPs). Therefore, a case will first be made 
 10 
for DACPs as a powerful tool, both as a synthon and in the context of Friedel-Crafts-type 
methodologies, before discussing the bioactivities of and previous synthetic attempts 
toward tronocarpine and rhazinicine. 
1.5.1 Donor-Acceptor Cyclopropanes 
As a synthon, cyclopropane benefits from inherent strain—both angular and 
torsional—and high p-character. These characteristics lend cyclopropane alkene-like 
reactivity22 and enable C—C bond cleavage to result in a transitory 1,3-dipole, which can 
subsequently perform homo-enolate, homo-conjugate, or cycloaddition chemistry (Figure 
1-5).10g This bond cleavage may be facilitated by the incorporation of electron-donating 
(e.g. –CH3, –Ph) and electron-withdrawing (e.g. –NO2, -CO2R) substituents onto vicinal 
carbons, resulting in a DACP. 
 
Figure 1-5: Donor-acceptor cyclopropane reactivity. 
It has been validated computationally that DACPs benefit from the polarized bond 
between the donor and acceptor carbons, which lowers the activation barrier for bond 
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cleavage. Additionally, the carbanion charge can be delocalized into the acceptor 
substituent, and the donor substituent contributes stabilizing electron density, making the 
carbocation more localized and persistent.23 Thus, reactivity increases as more donor and 
acceptor groups are added (to the benefit or detriment of the desired transformation), and 
the identities of these substituents also tune the energetics of the system (Figure 1-6). 
Significantly, incorporation of an additional (geminal) acceptor group increases the 
binding ability of DACPs to Lewis acids, which further facilitates ring-opening as well as 
enables catalytic activation. 
 
Figure 1-6: Substituent effects on DACP reactivity. 
DACPs were first reviewed by Reißig in 1988,24 with a key focus on their synthesis. 
The first DACP was prepared from Michael-type nucleophilic attack of a donor group onto 
an acceptor-bearing allylic halide, followed by ring-closing and displacement of the 
halide.25 There have been many synthetic strategies demonstrated since then;26 however, a 
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broadly applied method derives DACPs from cyclopropanation reactions of donor-
substituted olefins with acceptor-substituted α-diazo compounds (i.e. carbene precursors), 
typically in the presence of copper- or rhodium-based catalysts. 
Research toward developing intramolecular reactions of DACPs was pioneered by 
Stork and Grieco primarily as a method for Michael-type cyclizations afforded by 
olefin/aryl attack onto D-A cyclopropyl ketones (Scheme 1-5).27 The authors demonstrated 
acid-promoted syntheses of fused di-cyclohexanes, with the methyl substituent and the 
ketone serving as donor and acceptor, respectively. 
 
Scheme 1-5: Michael-type cyclizations of D-A cyclopropyl ketones. 
Another early method showcases the ring-opening of 1,2-dialkoxy-3-
ketylcyclopropanes followed by oxidation and aldol-type condensation to 
cyclopentenones, established by Wenkert.28 Similarly, intramolecular ring-opening 
cyclizations of DACPs onto their ester acceptor substituents yield dihydrofuran 
derivatives29 as well as γ-butyrospirolactones30 in certain cases; if the elimination route is 
available, substituted, fully unsaturated furans are the preferred product. Notably, too, 
Reißig demonstrated that DACPs with diene and dienophile substituents can perform 
intramolecular Diels-Alder reactions to yield fused bicyclic derivatives with reasonably 
good diastereoselectivity (d.r. = 6:1).31 
The France group has made valuable contributions in the field of intramolecular 
ring-opening cyclizations of DACPs, particularly toward the formal homo-Nazarov 
cyclization (Scheme 1-6). In contrast to the traditional Nazarov cyclization of divinyl 
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ketones to cyclopentenones (Scheme 1-6a),32 the classic formal homo-Nazarov reaction 
employs alkenyl cyclopropyl ketones and results in cyclohexenone products (Scheme 
1-6b). Early reports of this reaction required high temperatures and (super-)stoichiometric 
quantities of Bronsted acid, with limited applications.33 In 2009, Waser was the first to 
demonstrate this transformation catalytically, using 20 mol% of tosic acid.34 Then, in 2010, 
France and co-workers harnessed the synthetic utility of DACPs by introducing an 
additional acceptor group, an ester, beta to the ketone. The system afforded effective 
coordination to a Lewis acid and greater stabilization of the dipolar intermediate following 
ring-opening. These characteristics allowed for milder conditions, high selectivity, and 
high yields, resulting in a much more efficient homo-Nazarov cyclization (Scheme 1-6c).35 
 
Scheme 1-6: (a) Traditional Nazarov cyclization. (b) Homo-Nazarov cyclization. (c) Homo-Nazarov 
cyclization of a DACP with an additional acceptor group developed by France. 
This reactivity was quickly expanded to aromatic and heteroaromatic products. In 
2011, France and co-workers demonstrated the intramolecular Friedel-Crafts-type ring-
opening cyclization of DACPs tethered to substituted arenes and various heterocycles (e.g. 
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pyrrole, indole, furan, benzofuran, thiophene) at the 2- and 3-positions (Scheme 1-7a),36 as 
well as an analogous cyclization onto N-acylindoles to construct the hydropyrido[1,2-
a]indole core (Scheme 1-7b).37 
 
Scheme 1-7: (a) Intramolecular F-C-type ROC of C2- and C3-heteroaromatic-tethered DACPs. (b) 
Intramolecular F-C-type ROC of N-acyl indole-tethered DACPs and mechanism.  
These and further applications of formal homo-Nazarov-type38 and Friedel-Crafts-
type39 reactions—including the total synthesis of deethyleburnamonine (Scheme 1-8)40 and 
a tandem cyclopropanation-ring-opening cyclization in continuous flow41—represent 
important advances in the field with respect to facile construction of polycyclic 
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heteroaromatic scaffolds in natural products, as well as the incorporation of functionality 
where previous methods had not succeeded. 
 
Scheme 1-8: Concise total synthesis to deethyleburnamonine. 
A comprehensive review from the France group describes intramolecular ring-
opening cyclizations of donor-acceptor cyclopropanes through 2013.10g More recent 
intramolecular examples include Nishii’s stereoretentive intramolecular ring-opening 
cyclization of various aryl-tethered DACPs in the presence of superstoichiometric TiCl4;
42 
Trushkov’s synthesis of 2,3-dihydrobenzo[b]furans and -thiophenes under MgBr2
.OEt2 
catalysis;43 and Wang’s Yb(OTf)3-mediated intramolecular [4+3] cycloadditions to form 
various hydroazulenes (bicyclo[5.3.0]decanes),44 among others.45 
Intermolecular Friedel-Crafts-type reactions of DACPs have also been shown. As 
a representative example, in 2001, Kerr published the first application of intermolecular 
ring-opening cyclizations of DACPs to form heteroaromatic tricycles in the pursuit of 




Scheme 1-9: Kerr's intermolecular ring-opening cyclization toward indole-containing tricycles. 
1.5.2 Tronocarpine 
 Tronocarpine is a chippiine-type indole alkaloid isolated from T. corymbosa in 
2000.47 Though its bioactivity is currently unknown, its structural similarities to the 
chippiine indole alkaloids shown in Figure 1-7 suggest cytotoxic or anticancer activity.48 
Like most natural products in this family, tronocarpine has a pentacyclic scaffold 
containing a tryptamine core and a bridged azabicyclo[3.3.1]nonane moiety. Unlike other 
chippiines, however, tronocarpine has a seven-membered lactam bound to the bridgehead 
carbon of the bicyclic moiety. 
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Figure 1-7: Tronocarpine and related chippiine analogues. 
Synthetically, tronocarpine is an important target because it should be the most 
readily accessible in its class and may reasonably serve as a precursor to the rest of the 
chippiines through a Michael addition/rearrangement (Scheme 1-10). Additionally, 
elucidating the bioactivity of tronocarpine is dependent upon its total synthesis, as its 
relatively low abundance in nature hinders biological assay.  
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Scheme 1-10: Proposed preparation of dippinine B and 10,11-demethoxychippiine from 
tronocarpine. 
There have been several published attempts toward the total synthesis of 
tronocarpine, but none have achieved the final target. Despite this, researchers have 
generally succeeded in accessing four rings of the pentacyle. The first publication attributed 
to this effort actually preceded discovery of tronocarpine: in 1995, Mahboobi and 
coworkers showcased the syntheses of various tetracyclic frameworks from 2-malonyl 
indoles, albeit in low yields (6 steps, < 6%) (Scheme 1-11).49 Their key intermediate was 
a 3-(2-nitrovinyl)-2-dimethylmalonyl indole which could then undergo Michael-type 
additions to cyclize at the indole N. Oxidation of the alcohol, hydrogenation of the vinyl 




Scheme 1-11: Mahboobi's synthesis of the lactam-containing tetracycle in tronocarpine. 
The next study would not be until 2006, when Magolan and Kerr published a 
concise synthesis the identical compound in three steps and 20% overall yield from 1H-
indole-3-acetonitrile (Scheme 1-12).50 After N-acylation with 2-methoxycarbonyl-
pentanedioic acid chloride, their synthesis featured a Mn-mediated radical cyclization to 
generate the tricycle, followed by reduction over Raney Ni to afford the seven-membered 
lactam. 
 
Scheme 1-12: Magolan and Kerr's synthesis of the lactam-containing tetracycle in tronocarpine. 
Miranda and coworkers demonstrated an additional synthesis of this tetracycle in 
2009 (Scheme 1-13).51 Their overall strategy was similar to Mahboobi’s, but their first step 
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showcased a radical oxidative xanthate addition to a protected tryptamine to result in the 
2-malonyl indole. Subsequent cyclization, deprotection, and lactamization afforded the 
desired tetracycle, for a yield of 32% over four total steps. 
 
Scheme 1-13: Miranda's synthesis of the lactam-containing tetracycle in tronocarpine. 
Further syntheses to access this tetracyclic skeleton include work from Hájícek,52 
and from Nidhiry and Prasad.53 
The first successful synthesis of the bridged bicycle-containing tetracycle was also 
performed in 2009 by Sapeta and Kerr (Scheme 1-14).54 Their methodology relied upon a 
stepwise [3+3] annulation of an indole-tethered donor-acceptor cyclopropane and 2-
(chloromethyl)-3-trimethylsilyl-1-propene, and they accomplished this tetracycle in 6 steps 
with 31% overall yield. 
 
Scheme 1-14: Sapeta and Kerr's synthesis of the bridged bicycle-containing tetracycle in 
tronocarpine. 
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Finally, in one notable example, Martínez and coworkers achieved the entire 
pentacyclic skeleton in 2014 (Scheme 1-15).48b Building upon previous research with 
Miranda, after C2-addition of the malonyl xanthate, they incorporated additional 
functionality in their annulation step, which ultimately enabled them to generate the fifth 
ring through a Dieckmann condensation. Unfortunately, even in this case, the lack of useful 
functional handles in the final compound prevented the completion of the total synthesis. 
 
Scheme 1-15: Martínez's synthesis of the pentacyclic scaffold of tronocarpine. 
At this time, there have been no further published synthetic studies regarding 
tronocarpine, and its bioactivity remains unknown. The key limitation seems to be 
construction of the bridged bicyclic moiety under conditions tolerant of synthetic handles 
necessary to complete final functionalizations. A novel intramolecular ring-opening 
cyclization to afford this scaffold may be the avenue to achieve a total synthesis of 





Figure 1-8: Rhazinicine and analogues. 
Compared with tronocarpine, synthetic efforts toward rhazinicine and related 
compounds have been much more fruitful. From the Aspidosperma alkaloid family, 
rhazinicine is a tetracyclic 5,6,7,8-tetrahydroindolizine (THI) that has been identified as a 
potential antitumor agent (Figure 1-8). THIs in general can be prepared through reduction 
reactions of indolizines;55 pyrrolidine annulations;56 and [3+3]-cycloadditions,57 and 
synthetic analogues rhazinilam58 and rhazinal59 have been achieved by these methods. 
 
Scheme 1-16: Gaunt’s total synthesis of rhazinicine. 
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This pyrrole alkaloid natural product has two reported total syntheses. First, in 
2008, Gaunt performed a high-yielding albeit racemic total synthesis of rhazinicine through 
a regioselective C-H arylation dictated by the Boc protecting group, then a Suzuki coupling 
to form the THI core (Scheme 1-16, 21% yield over 8 steps).60 Then, in 2013, Tokuyama 
developed an enantioselective total synthesis of (-)-rhazinicine (Scheme 1-17, 9% yield 
over 14 steps).61 His synthesis featured a gold(I)-catalyzed cascade cyclization employing 
[Au(PPh3)]NTf2
62 to afford the THI core in a single step, with complete retention of 
stereochemistry. Significantly, his synthesis was also free of protecting groups, making his 
route greener and more expedient.63 
 
Scheme 1-17: Tokuyama’s total synthesis of (-)-rhazinicine. 
The structural similarities of the THI core to the hydropyrido[1,2-a]indole core 
found in indole alkaloids prompted a study to further develop the intramolecular Friedel-
Crafts ring-opening cyclization of N-acyl DACPs to include pyrrole-based scaffolds. 
Pyrroles generally do not behave as predictably as other heterocycles,64 so this would 
represent an important advancement in the field of N-heterocyclic synthetic methods. 
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1.6 Thesis Outline 
This thesis proposes novel Friedel-Crafts-inspired methodologies to access the N-
heteroaromatics featured: flubromazepam, tronocarpine, and rhazincine. Hypotheses and 
synthetic strategies will be outlined; experimental troublehooting will be discussed in 
detail; and advances in known synthetic methods will be highlighted. 
Chapter 2 will cover various efforts toward the syntheses of variably halogen-
substituted benzodiazepines, using the positional isomers of flubromazepam as a model. 
Chapter 3 will discuss the characterization data acquired for each of these positional 
isomers and offer recommendations for analytical differentiation.  
Chapter 4 will outline methodology development toward intramolecular ring-
opening cyclizations of C5-substituted donor-acceptor bicyclo[3.1.0]hexanes, inspired by 
the bridged bicyclic moiety of tronocarpine. Chapter 5 will survey an analogous class, C6-
substituted donor-acceptor bicyclo[3.1.0]hexanes, and showcase an interesting 
stereochemical outcome of a model ring-opening cyclization. Chapter 6 will discuss 
synthetic attempts toward the total syntheses of rhazinicine and tronocarpine. 
Chapter 7 will offer conclusions and future outlook for each research project herein. 
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CHAPTER 2. SYNTHESIS OF FLUBROMAZEPAM 
POSITIONAL ISOMERS FOR FORENSIC ANALYSIS 
2.1 Designer Benzodiazepines: A Growing Problem in Forensics 
Benzodiazepines constitute a large class of pharmaceutical compounds that exhibit 
sedative, depressant, and relaxant properties.1-4 Phenazepam (1), for instance, is currently 
obtainable in most states as a research chemical self-prescribed for insomnia, anxiety, and 
opiate withdrawal (Figure 2-1).5,6 Though still prescribed for medicinal purposes, many 
benzodiazepines, such as diazepam (Valium®, 2) and alprazolam (Xanax®, 3), have 
become federally controlled under Schedule IV due to their abuse and addiction potential.7 
As a result, designer benzodiazepines have entered the recreational market as legal 
alternatives to Schedule IV benzodiazepines since the early 2010s. Among them, 
flubromazepam (4), its triazole counterpart flubromazolam (5), and etizolam (6), a 
structurally similar triazolothienobenzodiazepine, were listed in the most recent annual 
Drug Enforcement Administration (DEA) Emerging Threat Report as the benzodiazepine 
designer drugs most frequently seized and analyzed in the United States.8 
 44 
 
Figure 2-1: Representative pharmaceutical benzodiazepines. 
2.1.1 Positional Isomers and the Federal Analogue Act 
An understudied class of designer benzodiazepines is the positional isomers of 
federally controlled parent benzodiazepines. Positional isomers have identical core 
structures to their parents but differ by the placement of one or two atoms or substituents. 
Because of these close structural similarities, positional isomers are expected to exhibit 
similar physiological effects to their parents, making them prime candidates for technically 
legal alternatives. The Federal Analogue Act,9 which is part of the Controlled Substances 
Act (CSA) of 1971,10 allows entire classes of “substantially similar” compounds to become 
controlled in one broad sweep.7a,11 The analogue rule applies only to Schedule I and 
Schedule II substances, however, so Schedule IV benzodiazepines, including their 
positional isomers, are processed individually as distinct substances. 
 At the time of this research, analytical reference data are not readily available to 
differentiate between many illicit benzodiazepines and their corresponding positional 
isomers. An important question was raised: if positional isomers of known benzodiazepine 
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drugs enter the recreational market as technically legal alternatives to their federally 
controlled parents, will current forensic methods rapidly identify and accurately 
differentiate between them? 
2.1.2 Flubromazepam: A Model for Positional Isomer Synthesis 
To address this deficiency, flubromazepam (4) was targeted for synthesis and 
characterization for two primary reasons. First, recent incidents have made flubromazepam 
a candidate for future scheduling, and its current uncontrolled status facilitates unrestricted 
research. Second, from a synthetic perspective, flubromazepam has twelve possible 
positional isomers (including the parent), which maximizes the available chemical space 
for synthetic, analytical, and biological survey. 
Despite its recent appearance in forensic cases, flubromazepam (4) was first 
prepared and studied by Sternbach and co-workers in the early 1960s (Scheme 2-1).12 By 
their published method, p-bromoaniline (7a) undergoes a Friedel-Crafts acylation with o-
fluorobenzoyl chloride (8a) to form the 2-aminobenzophenone 9aa.12b Then, a two-step 
annulation sequence is employed involving 2-bromoacetyl bromide (10) to first prepare the 
2-bromoacetamidobenzophenone intermediate, followed by treatment with ammonia and 
heat to promote ring closure through imine formation.12c 
 
Scheme 2-1: Sternbach synthesis of flubromazepam (4). 
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Flubromazepam was fully characterized by Moosmann and co-workers in 2013,13 
and initial biological studies showed that it has anticonvulsant properties and an 
elimination half-life of 100 hours.14 Incidents involving flubromazepam include three 
hospitalizations from acute exposure in the last four years in the US,15 thirty-three in 
Sweden between 2012-2015,16 and a severe case of poisoning from 4 mixed with synthetic 
opioid U-47700 which resulted in severe brain damage followed by patient death.13,17 
Additionally, in certain military cases, on-duty personnel in possession of the drug have 
been convicted of violating operational readiness, which is an important threat to national 
security.18 
As a side note, flubromazolam (5), which was first reported in 2016 and is directly 
prepared from 4 (Scheme 2-2), has exhibited even more potent effects.19 The synthesis of 
flubromazolam from flubromazepam was first published in 1976 as a two-step, one-pot 
annulation to install the triazole moiety.20 The benzodiazepine reacts first with di-4-
morpholinylphosphinic chloride at the amide oxygen atom, then acetylhydrazide is 
introduced to eliminate the activated oxygen, and finally self-condensation occurs to close 
the ring.12a 
 
Scheme 2-2: Synthesis of flubromazolam (5) from flubromazepam (4). 
 Though various benzodiazepines were successfully prepared by Sternbach, the 
scope was generally limited to products originating from anilines with electron-
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withdrawing para-substituents, as discussed in Chapter 1. Thus, 2-aminobenzophenones 
with bromo, chloro, and nitro substituents para to the amino group are highly accessible,21 
which explains the greater abundance of their corresponding benzodiazepines on the 
recreational drug market and thus in forensic cases. 
 Preparative methods for positional isomers of benzodiazepines, on the other hand, 
are limited in the scientific literature. That being said, there have been additional methods 
devised to access the crucial 2-aminobenzophenone core that do not proceed by a Friedel-
Crafts pathway and could thus facilitate the syntheses of benzodiazepines with previously 
unobserved substitutions. 
2.1.3 Alternative Routes to the Benzophenone Precursors to Benzodiazepines 
The earliest example of a non-Friedel-Crafts synthesis of benzophenones was from 
Lothrop and Goodwin in 194322 (though their interest in 2-aminobenzophenones was as a 
template for fluorene derivatives). Through double N-acetylation of various 2-
aminobenzoic acids, they first prepared a 3,1,4-benzoxaz-4-one, then achieved aryl 
Grignard addition followed by acidification to cleave the N-acetate (Scheme 2-3). Overall 
yields for this sequence were generally low (e.g. 14% over 3 steps for R’ = H, R” = Me). 
 
Scheme 2-3: Lothrop and Goodwin's synthesis of 2-aminobenzophenones. 
Additional literature approaches that will be explored later in this chapter include: 
directed oxidative coupling of anilines and benzaldehydes; Sugasawa coupling of anilines 
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and benzonitriles; decarboxlative coupling of phenylglyoxylic acids and phenylboronic 
acids; phenyllithiate addition onto Weinreb benzamides; and oxidative rearrangements of 
3-hydroxy-3-phenyloxindoles. However, though these studies have investigated and 
demonstrated efficient routes to various benzodiazepine precursors,23,24 most fall short of 
at least one of three important criteria: 1) they do not showcase precursors with substitution 
patterns that would lead to positional isomers of the more common parents; 2) they do not 
tolerate halo- and nitro-substituted benzodiazepines most frequently surveyed in forensic 
cases; and 3) they have failed to follow through in the actual preparation of the 
corresponding benzodiazepine products. Consequently, the characterization data to 
accompany these benzodiazepines, both analytical and biological, are nonexistent. 
 To address this gap in knowledge, I set out to develop a uniform synthetic method 
that would enable access to the positional isomers of flubromazepam (Scheme 2-4).25 An 
ideal synthesis would employ commercially available precursors and tolerate a variety of 
substituents and substitution patterns. This chapter outlines a generalized approach to 
access the twelve possible positional isomers of flubromazepam by developing a 
complementary approach to the substituted benzophenones that bypasses the issues 
associated with Friedel-Crafts regioselectivity. Both successful and unsuccessful 
approaches will be described, culminating in access to nine of the twelve isomers. Further 
attempts to the remaining three isomers, one of which has proven promising in initial 
studies, will also be detailed. Additionally, an ancillary goal was the synthesis of the 
corresponding flubromazolams, which is currently ongoing. This study serves as a proof 
of concept while establishing a roadmap for synthesizing and characterizing the isomers of 
additional benzodiazepines of interest. 
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Scheme 2-4: Synthetic roadmap to flubromazepam and flubromazolam positional isomers. 
2.2 Retrosynthetic Analysis 
For the proposed synthesis of the positional isomers of flubromazepam, three 
different approaches are outlined in the retrosynthetic analysis shown in Scheme 2-5. The 
initial goal was to mimic chelation-assisted Friedel-Crafts acylation as a complementary 
approach to the classic Friedel-Crafts reaction observed in benzodiazepine literature. 
However, it was determined early on that Friedel-Crafts-type pathways were not the ideal 
method, as will be discussed throughout the chapter. 
In Approach 1, an oxidative cross-coupling of bromoanilines 7 with 
fluorobenzaldehydes 11 was envisioned to access the 2-aminobenzophenones 9. Approach 
2 explored the potential of decarboxylative cross-coupling reactions between bromoisatins 
12 (via its hydrolysis products, X-bromo-2-(2-aminophenyl)-2-oxoacetates) and 
fluorophenylboronic acids 13. Finally, Approach 3 targeted benzophenones 9 via acylation 
of X'-fluorophenyllithiums 15 with the Weinreb 2-aminobenzamides 14. 
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Scheme 2-5: Retrosynthetic analysis for the synthesis of flubromazepam isomers. 
2.3 Approach 1: Oxidative Coupling 
2.3.1 Pd-Catalyzed Oxidative Coupling 
Initial attempts to access the functionalized benzophenones explored a Pd-
catalyzed oxidative C-H bond coupling of acetanilides and aldehydes that was reported by 
Li and Kwong (Scheme 2-6a).25 This strategy was appealing due to the commercial 
availability of each of the bromoanilines and fluorobenzaldehydes. The acetyl substituent 
serves as a directing group for the ortho C-H functionalization to access the desired 
benzophenones. Moreover, if successful, this strategy would be particularly appealing 
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since two distinct sets of regioisomeric cross-coupling adducts (17ba-17bc and 17da-
17dc) should be accessible from reactions with 3-bromoacetanilide (16b), which would 
streamline isomer synthesis (Scheme 2-6b). 
 
Scheme 2-6: (a) Li and Kwong's oxidative coupling of acetanilides and aldehydes; (b) Proposed 
divergent coupling of 3-bromoacetanilide. 
 As a starting point, 4-bromoaniline 7a was acetylated with acetic anhydride then 
separately treated with 2, 3, or 4-fluorobenzaldehyde (11a, 11b, or 11c) under the published 
conditions (Scheme 2-7). Although the protocol boasted a tolerance for both amino- and 
halo-substituted arenes, early attempts toward these cross-coupling reactions afforded 
complex mixtures and trace amounts of isolated product by preparatory TLC. These 
setbacks led to a short optimization study to probe the effects of solvent and atmosphere 
on the reaction system (Table 2-1). 
The reaction was first tested on the para-bromo acetanilide, as only one EAS 
product was expected from this precursor, under nitrogen atmosphere (entry 1). However, 
a closer review of the Supporting Information revealed that the reaction performed better 
under air. Wishing to conserve starting material, the reaction was repeated open to air with 
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simple aniline and benzaldehyde as coupling partners (entry 2). The unsubstituted model 
system greatly outperformed its halogenated counterpart, which made me optimistic that 
the atmosphere was the primary issue. Wishing to improve the yield further, solvent effects 
were evaluated, since toluene was the preferred reaction solvent. The TBHP solution in 
nonane was subjected to a solvent exchange, only to result in comparable yield (entry 3). 
Increasing the loading of TBHP, in contrast, was a detriment (entry 4). 
Table 2-1: Optimization of Pd-catalyzed oxidative coupling. 
 
Entry R’, R’’ TBHP Solution Atmosphere Yield 
1 4-Br, 2-F 5.5 M/Nonane Nitrogen 6% 
2 H, H 5.5 M/Nonane Air 48% 
3 H, H 4.13 M/Toluene Air 43% 
4 H, H 4.13 M/Toluene Air 29%a 
a Used 6 equiv. TBHP. 
These conditions were then re-applied to the desired halogenated starting materials 
(Scheme 2-7). In each case, however, the reactions continued to give a complex mixture of 
products, and isolated yields of the desired benzophenones 17 remained low (8-12%). 
These results were partially attributed to deactivation of the substitution reaction from the 
bromine substituent. Not to be deterred, since the ultimate goal was successful preparation 
of the flubromazepam isomers, a test reaction with 3-bromoacetanilide 16b was attempted 
to probe the hypothesized generation of two desired regioisomers. Unfortunately, this 
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reaction gave low yields of only one regioisomer of the benzophenone, signifying that all 
twelve fluobromazepam isomers would not be accessible by this route. 
 
Scheme 2-7: Attempted Pd-catalyzed oxidative cross-couplings between N-acetyl-4-bromoaniline (7a) 
and fluorobenzaldehydes 11. 
 Despite this disappointment, sufficient amounts of material (~10-20 mg) were 
isolated from the 4-bromoacetanilide reactions to attempt the syntheses of three 
flubromazepam isomers; namely, the (7,2')-, (7,3')-, and (7,4')-isomers. Based on previous 
benzodiazepine syntheses through Friedel-Crafts acylation, these three isomers were 
already expected to be the most accessible by distributors, as the fluorine substitution 
would likely not drastically affect reaction outcomes. Thus, it was appealing to obtain the 
corresponding characterization data early in the project. 
From the 2-acetamido-4-bromo-X'-fluorobenzophenones 17aa-ac, acid-promoted 
N-deprotection was attempted, followed by annulation of the crude product using glycine 
ethyl ester via an alternative Sternbach method (Scheme 2-8).26 No desired product could 
be isolated as only a trace amount of each isomer was detected by 1H NMR. Ultimately, 
this approach was deemed inviable to access the isomers. 
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Scheme 2-8: Attempted endgame to (7,X')-flubromazepams. 
2.3.2 Sugasawa Coupling 
As a last-ditch effort in using the bromoanilines, an alternative directed ortho-C-H 
functionalization approach was envisioned involving Sugasawa coupling27 of 3-
bromoaniline with 4-fluorobenzonitrile in the presence of BCl3 and AlCl3 (Scheme 2-9).
28 
As in Scheme 2-6, we anticipated that the use of 3-bromoaniline in the Sugasawa reaction 
would give a mixture of the regiosiomeric benzophenones. However, the reaction afforded 
22% of 9bc as the only benzophenone isomer. 
 
Scheme 2-9: Attempted Sugasawa coupling. 
Hypothesizing that the coupling could be directed to the desired acylation site by 
blocking the preferred site, the reaction was tested again with 2,5-dibromoaniline 31 
(Scheme 2-10). Unfortunately, a complex mixture of products resulted, and none of them 
appeared to be the desired 32c by 1H NMR. 
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Scheme 2-10: Attempted Sugasawa coupling with the preferred site blocked. 
2.4 Approach 2: Decarboxylative Coupling 
Changing tactics, we were inspired by the work of Qi and co-workers29 who 
demonstrated a silver-catalyzed decarboxylative acylation of phenylglyoxylic acids 22 
with phenylboronic acids 23 to afford substituted benzophenones 24 (Scheme 2-11). The 
authors particularly highlighted the method's tolerance for both halo- and amino-
substituted phenylglyoxylic acids and boronic acids. Employing (2-amino-X-
bromophenyl)glyoxylic acids would set the isomer substitution pattern at the beginning of 
the synthesis, thus simplifying purification and characterization throughout the sequence. 
 
Scheme 2-11: Qi's glyoxylic acid decarboxylative cross-coupling. 
 However, given that (2-amino-5-bromophenyl)glyoxylic acid 25a is the only 
commercially-available isomer, the synthesis of the remaining glyoxylic acids presented a 
challenge. To address this, 4-, 5-, 6-, and 7-bromoisatins (12a-d) were explored as 
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precursors to the glyoxylic acids, as each bromoisatin is commercially available and should 
be readily hydrolyzed to generate the glyoxylic acid salt. 
Starting with a model system, the saponification of unsubstituted isatin (12e) was 
evaluated in the presence of KOH or NaOH in various loadings and temperatures (Table 
2-2); conversion was determined by crude 1H NMR. In general, increasing the loading of 
hydroxide base saw a correlating increase in yield, with a plateau beyond 2 equiv. (entries 
1-4). Increasing temperature did not have a drastic impact on yield (entries 5-6, 8), but 
changing the cation from K to Na showed marked improvement (entries 7-8). Thus, the 
optimal conditions were stirring the isatin at room temperature in 2 equiv of 30% aqueous 
NaOH to readily afford the ring-opened 2-aminophenylglyoxylate salt (25e) with 76% 
conversion (entry 7).30 
Table 2-2: Optimization of isatin conversion to 2-aminophenylglyoxylate salt. 
 
Entry Base (equiv)a Solvent (conc, T) Conversionb 
1 KOH (1.3) MeOH (2.5 M, r.t.) 30% 
2 KOH (1.6) MeOH (1 M, r.t.) 52% 
3 KOH (2.0) MeOH (1 M, r.t.) 74% 
4 KOH (2.5) MeOH (1 M, r.t.) 72% 
5 KOH (1.6) MeOH (1 M, 50°C) 57% 
6 KOH (2.0) MeOH (1 M, 50°C) 65% 
7 NaOH (2.0) MeOH (1 M, r.t.) 76% 
8 NaOH (2.0) MeOH (1 M, 50°C) 74% 
a 30% aqueous solution. b Determined conversion by 1H NMR of crude reaction mixture. 
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Next, we attempted to acidify the 2-aminophenylglyoxylate salt to the 
corresponding 2-aminophenylglyoxylic acid for the subsequent decarboxylative coupling 
(Scheme 2-12). It was soon found, however, that acidic workup (to pH 3) drove the reaction 
predominantly back to isatin (Table 2-3, entries 1-3). 
 
Scheme 2-12: Attempted isatin saponification-acidification sequence. 
Hypothesizing that an electron-withdrawing substituent might hinder this process 
by making the amine less nucleophilic, the saponification-acidification sequence was 
attempted with 12a (entry 4), but mixtures of glyoxylic acid and isatin were obtained. 
Methods to separate the acid from the isatin by either chromatography (flash or 
preparative), extraction, or recrystallization failed. Next, the preparations of various 
glyoxylate salts were attempted (entries 6-14) to employ directly in the decarboxylative 
cross coupling reaction. The sodium and lithium salts were prepared by isatin treatment 
with either NaOH or LiOH. The potassium salt was prepared using K2CO3. Finally, since 
the cross-coupling procedure is catalyzed by Ag(I) salts, the silver glyoxylate salt was 
generated from Ag2O or Ag2CO3. Of these, only two salts were successfully obtained (entry 
10: Na; entry 11: Li). 
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Table 2-3: Test preparations and isolations of 2-aminophenylglyoxylic acids and 2-
aminophenylglyoxylate salts. 
 
Entry R Base (equiv) Solvent (conc, T) Yield 
1 H NaOH (2)a MeOH (1 M, r.t.) 3%b,c 
2 H NaOH (2)a MeOH (1 M, r.t.) (Not isolated)c,d 
3 H NaOH (2)a MeOH (1 M, r.t.) (Not isolated)c,e 
4 5-Br NaOH (2)a MeOH (1 M, r.t.) (Not isolated)c,e 
5 H NaOH (2)a MeOH (1 M, r.t.) (Not isolated)c,f 
6 H Ag2O (1) THF (1 M, r.t.) No reaction 
7 H Ag2O (1) DMSO (1 M, r.t.) No reaction 
8 H Ag2O (1) DMF (1 M, r.t.) No reaction 
9 H NaOH (2) MeOH (0.3 M, Δ) No reaction 
10 H NaOH (2)a MeOH (1 M, r.t.) 94% (77% pure)g,h 
11 H LiOH.H2O (2)a MeOH (1 M, r.t.) 98% (66% pure)g,h 
12 H NaOH (1)a MeOH (1 M, r.t.) No reaction 
13 H K2CO3 (1) H2O (0.2 M, Δ) No desired productg,h 
14 H Ag2CO3 (1) H2O (0.2 M, Δ) No desired productg,h 
a 30% aqueous solution. b Attempted to purify on silica. c Product reverted to starting material. d Collected 
organic layer crude. e Attempted an acid/base extraction. f Extracted with minimal MeCN in attempts to 
separate starting material from product. g Concentrated the aqueous layer to collect the glyoxylate salt. h 
Analyzed by q-NMR (DMTP internal standard). 
These two salts were then subjected to the cross coupling conditions with the 




Scheme 2-13: Unsuccessful decarboxylative coupling using glyoxylate salts. 
 In a final attempt to effect cross-coupling, several N-protection protocols were 
evaluated with hopes of stabilizing the glyoxylic acid for isolation (Table 2-4). Methyl 
chloroformate and di-tert-butyl dicarbonate (Boc2O) protections were unproductive 
(entries 1-3), but a two-step protection-saponification protocol employing ethyl 
chloroformate and Na2CO3 afforded the desired glyoxylic acid 28 in high yield (entry 4).
31 
Unfortunately, the subsequent cross coupling of 12e with 2-fluorophenylboronic acid (13a) 
did not give any observable products (Scheme 2-14). 
Table 2-4: Test preparations of N-acyl 2-aminophenylglyoxylic acids. 
 
Entry XCO2R Yield 
1 ClCO2Me 4% 
2 ClCO2Me 20%a 
3 Boc2O No reaction 
4 ClCO2Et 88%b 
aKept reaction mixture cold during workup and washed precipitate with cold solvents. bUsed Na2CO3. 
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Scheme 2-14: Failed coupling of N-protected glyoxylic acid 28. 
2.5 Approach 3: Benzoylation of Fluoro-substituted Phenyllithiums 
Following the failed cross-coupling approaches, an alternative strategy was 
undertaken involving benzoylation of fluoro-substituted phenyl anions 15 (Grignards or 
lithiates) with 2-amino-X-bromo-N-methoxy-N-methylbenzamides 14 (Scheme 2-15). 
 
Scheme 2-15: Proposed benzoylation strategy. 
2.5.1 Synthesis of the Weinreb Amide Precursors 
Preparation of each Weinreb amide involved a two-step sequence starting from a 
bromo-substituted isatin 12a-d (Scheme 2-16). Isatins 12 were treated with hydrogen 
peroxide under strongly basic conditions to produce 2-amino-X-bromobenzoic acids 31a-
d,32 which were collected in moderate to high yields as the hydrochloride salts after 
acidification. Amidation of 31a-d with N,N’-dimethylhydroxylamine hydrochloride was 
then effected in the presence of HBTU33 and N-methylmorpholine to give Weinreb amides 
14a-c in moderate to high yields. Unfortunately, obtaining 14d proved particularly 
troublesome. Though crude NMR validated its formation, 14d was inseparable from the 
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complex mixture that was formed. In hopes of still accessing the desired benzophenone 
isomer, the crude mixture of 14d was taken forward. 
 
Scheme 2-16: Two-step synthesis to prepare 2-amino-X-bromobenzoic acids 28a-d and Weinreb 
amides 14a-d from bromoisatins 12a-d. 
2.5.2 Optimizing the Benzophenone Synthesis 
Next, the conditions for benzophenone formation were explored (Table 2-5). Initial 
test reactions between amides 14a-c and phenylmagnesium bromide were promising 
(entries 1-3).34 However, in situ preparation of the fluorophenyl magnesium bromides from 
the various fluoro-substituted bromobenzenes gave inconsistent results (entries 4-7). 
Several reagents for magnesium-halogen exchange were tested, including Turbo 
Grignard35 (i-PrMgCl.LiCl), with no success. Next, lithium-halogen exchange was 
examined as a potential protocol. Gratifyingly, a test reaction between 14c and 
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phenyllithium afforded the 2-aminobenzophenone in 43% yield (entry 8); this result served 
as proof of concept to continue forward with lithium-halogen exchange. 
Table 2-5: Optimization of Grignard addition to 2-aminobenzamides. 
 
Entry R “Ar” source Yield 
1 H PhMgBr (3 M/Et2O) 22% 
2 3-Br PhMgBr (3 M/Et2O) 42% 
3 4-Br PhMgBr (3 M/Et2O) 53% 
4 H 
Bromobenzene (2.5 equiv), Mg (7.5 equiv), THF (1 M, 
60°C), 2 h 
Trace 
5 H 
Bromobenzene (2.5 equiv), Mg (7.5 equiv), 1,2-DBE (cat.), 
THF (1 M, 60°C), 2 h 
Trace 
6 N/Aa 
1-Bromo-2-fluorobenzene (1 equiv), iPrMgCl (1 eq, 2 
M/THF), 0°C, 1 h 
No desired product 
7 N/Aa 
1-Bromo-2-fluorobenzene (1 equiv), iPrMgCl.LiCl (1 eq, 1.3 
M/THF), 0°C, 1 h 
No desired product 
8 3-Br PhLi (1.9 M/THF) 46% 
a Control experiment to test Grignard formation. After 1 h, quenched with H2O and analyzed by 1H NMR. 
Lithiation of 1-bromo-4-fluorobenzene (32c) was attempted first, and treatment 
with n-butyllithium proceeded smoothly at -78 ˚C (Scheme 2-17).36 Upon transferring a 
solution of the Weinreb amide 14a dropwise via syringe to the lithiate solution, the desired 
2-amino-3-bromo-4’-fluorobenzophenone (9ac) was formed, and ultimately isolated, in 
78% yield. This order of addition was crucial to ensure that the lithiate did not thermally 
degrade. 
Having succeeded with 32c, the same approach was first applied to accessing the 
benzophenone isomers containing the 4’-fluoro substituent. Addition of the lithiate to 
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amides 14b and 14c gave the desired benzophenones 9bc and 9cc in 49% and 62% yield, 
respectively. Next, the lithium-halogen exchange reactions of 1-bromo-3-fluorobenzene 
32b were conducted. The reactions generated the respective benzophenone isomers (9ab, 
9bb, and 9cb) in 60%, 55%, and 63% yield. 
 
Scheme 2-17: Synthesis of 2-amino-X-bromobenzophenones 9 via benzoylation. 
 For 1-bromo-2-fluorobenzene 32a, lithiation was not successful at -78˚C as the 
lithiate appeared to degrade as immediately as it was formed. A quick literature search 
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revealed that lithiation of 32a could be accomplished at temperatures as low as -110˚C, so 
the reaction was attempted again at -100 ˚C. The corresponding benzophenone precursors 
9aa, 9ba, and 9ca were afforded with yields of 65%, 50%, and 56%, respectively. 
The yields for this synthetic transformation were modest due to the nucleophilic 
attack of the Weinreb amide by n-butyllithium, forming an n-butyl phenone adduct (33, 
Scheme 2-18). A test reaction with t-butyllithium to promote lithium-halogen exchange 
and reduce nucleophilic activity of the lithiating agent gave a lower yield along with a 
number of uncharacterized side products. When this approach failed, the reaction was 
monitored carefully at 15-minute time intervals. It was found that halting the reaction after 
30 minutes gave the optimal yield and prevented formation of 33, while attempting to 
increase the yield by stirring for 45 minutes allowed this side reaction to occur. 
 
Scheme 2-18: Generation of n-butyl phenome by-product. 
 Unfortunately, applying any of the reaction conditions to the crude mixture of 14d 
failed to deliver the desired benzophenones. It is hypothesized that the purification issues 
with 14d, the steric hindrance at the site of nucleophilic addition, and potential cross 
lithium-halogen exchange may have prevented the transformation from occurring. 
2.5.3 Synthesis of the Flubromazepam Isomers from the Prepared Benzophenones 
With nine of the twelve possible benzophenone precursors in hand, the conversions 
to the desired flubromazepam positional isomers were performed using the known 
literature procedures (Scheme 2-19). For each benzophenone, N-acylation was first 
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effected using 2-bromoacetyl bromide. Subsequently, the crude product was dissolved in 
7M ammonia in methanol and stirred overnight to afford the parent flubromazepam (4) and 
eight other positional isomers 19. Most yields were modest (32-77%), though isomers 19ab 
and 19cc were isolated with lower yields (< 20%) than expected. This chemistry was not 
further optimized, however, as sufficient quantities of each positional isomer were isolated 
for analysis. 
 
Scheme 2-19: Synthesis of flubromazepam positional isomers. 
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2.6 Further Efforts Toward the Elusive Benzophenones 
With nine of the twelve positional isomers of flubromazepam in hand, and with the 
considerable difficulty of accessing benzophenones 9da-dc (precursors to the three (6,X’)-
flubromazepam isomers (19da-dc), there was some debate over whether these three elusive 
isomers were worth pursuing. The primary argument for their synthesis was the obvious 
benefit of building up a complete dataset for forensic comparison; the offered 
counterargument was that, if their synthesis was so challenging to effect in a well-equipped 
synthetic organic chemistry laboratory, then these isomers would be the least likely targets 
for potential distributors. In the end, there was one alternative route based on literature 
precedent that hadn’t been incorporated into the original synthetic plan but displayed 
promise on paper: oxidative rearrangement of 4-bromo-3-(X-fluorophenyl)-3-
hydroxyoxindoles (34a-c), from the direct 3-arylation of 4-bromoisatin (12d). 
As a starting point, 4-bromoindole (35) was also considered as a precursor, as we 
envisioned that 35 could be readily accessed through reduction of 12d. This search led us 
to recent work from Kim and co-workers, who demonstrated a cesium carbonate-mediated 
oxidative rearrangement of 2-arylindoles 36 to 2-aminobenzophenones 37 (Scheme 
2-20a).37 Through their mechanistic studies, they proposed that the rearrangement must 
proceed from a 3-hydroxyoxindole intermediate; and indeed, in one example, they 
demonstrated formation of by-product 3-phenyl-3-hydroxyoxindole 38, subjected it to the 




Scheme 2-20: (a) Kim's oxidative rearrangement of 2-arylindoles to 2-aminobenzophenones; (b) 
Isolated example of 3-hydroxy-3-phenyloxindole 33 rearrangement to 2-aminobenzophenone 25. 
 This work, though promising, demonstrated a limited scope of only 5-substituted 
indole precursors and no bromine or fluorine atom substitutions. An analogous 
rearrangement from Lee and co-workers,36 however, showcased tolerance of bromine with 
the substrate 7-bromo-3-hydroxy-3-phenyloxindole (39) when potassium ferrocyanide 
(K4[Fe(CN)6]) was employed as the reaction mediator (Scheme 2-21). Though they did not 
report the yield for this particular substrate (40), a similar compound [7-chloro-3-hydroxy-
3-(2-tolyl)oxindole] was achieved at a reported 89% yield. 
 
Scheme 2-21: Oxidative rearrangement by potassium ferrocyanide from 7-bromo-3-hydroxy-3-
phenyloxindole 34 to 2-amino-3-bromobenzophenone 35. 
 Anxious to effect this rearrangement toward a 4-bromooxindole precursor, 3-
arylation methods were evaluated. The most straightforward method, a direct Grignard 
addition, was achieved readily with 12e in the presence of phenylmagnesium bromide 
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(Scheme 2-22);38 unfortunately, this same method applied to 12d resulted primarily in 
degradation products. 
 
Scheme 2-22: 3-Arylation of isatins 12e and 12d with PhMgBr. 
 Next, different transition metal-catalyzed methods were considered. Highly 
prevalent in recent literature were various rhodium-catalyzed 3-arylations with 
phenylboronic acids,39 but the catalysts and ligands employed in these studies were very 
specific and not generalizable, and there was concern that extensive (and expensive) 
optimization would delay efficient access to these targets. 
A more promising route from Zhang and co-workers showcased a milder, 
copper(II)-mediated 3-arylation of isatins 42,40 also using phenylboronic acids (23) as the 
coupling partner (Scheme 2-23a). Compared to rhodium-based methods, this work was 
optimized with low loadings of copper(II) triflate [Cu(OTf)2] catalyst and 1,10-
phenanthroline ligand (5 mol% and 10 mol%, respectively), as well as lithium hydroxide 
monohydrate (LiOH.H2O) to facilitate addition of the boronic acid. All of these reagents 
are inexpensive and very shelf-stable. Even more importantly, the authors showcased one 




Scheme 2-23: (a) Zhang’s Cu-mediated 3-arylation of substituted isatins; (b) Example of successful 
PhB(OH)2 36 coupling with 4-bromo-N-(n-butyl)isatin 37. 
 To assess this transformation, 4-bromoisatin (12d) was first protected with a benzyl 
group to form N-benzyl-4-bromoisatin (46, 86% yield);41 benzyl was chosen over n-butyl 
to facilitate deprotection later. Then, selecting 4-fluorophenylboronic acid (13c) as the 
coupling partner to minimize any potential steric hindrances, 46 was subjected to the 
prescribed conditions (Scheme 2-24). Pleasingly, the desired product 47c was afforded 
after 48 hours in 82% yield, which is on par with the literature example. Steps remaining 
to access the benzophenone core are deprotection by hydrogenolysis to afford 48c, then the 
oxidative rearrangement to 9dc. This synthesis will be replicated with 2- and 3-
fluorophenylboronic acids (13a-b), as well, to access benzophenones 9da-db. 
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Scheme 2-24: Progress toward synthesis of benzophenones 9da-dc by 3-arylation of N-benzyl-4-
bromoisatin 39 and subsequent oxidative rearrangement. 
 Armed with the knowledge that the three elusive isomers were within reach, the 
crucial rearrangement was tested on 3-hydroxy-3-phenyloxindole 38 (Scheme 2-25), which 
is much more readily accessible since the Grignard addition proceeds quantitatively and in 
a single step. A single test reaction afforded 27 in 21% isolated yield. While there is 
certainly room for optimization, the low yield may be partially attributed to solubility 
issues encountered with the literature conditions; and practically speaking, the set-up is 
more facile than the cesium carbonate method. Significantly, the fact remains that 
sufficient quantities of desired benzophenone may be isolated to carry forward to the 
flubromazepam isomers. 
 




In this study, nine of the twelve positional isomers of flubromazepam were 
successfully synthesized. The synthetic route developed was a three-step saponification, 
amidation, and lithiate addition and has not been used previously to access the 2-amino-X-
bromo-X’-fluorobenzophenone precursors to the flubromazepam positional isomers. 
Alternative approaches to synthesize the final three flubromazepam isomers were also 
explored, and the route to effect 3-arylation of N-benzyl-4-bromoisatin has proven 
promising. The chemical characterization data acquired from this study will be made 
available to forensic scientists. This method may be adapted to synthesize and characterize 
other benzodiazepines of interest. 
2.8 Experimental Details 
2.8.1 General Information 
Chromatographic purification was performed via flash chromatography with 
Silicycle SiliaFlash P60 silica gel (40-63 µm) or preparative thin-layer chromatography 
(prep-TLC) with Analtech silica gel F254 (1000 µm) plates and solvents indicated as eluent 
with 0.1-0.5 bar pressure. For quantitative flash chromatography, technical grades solvents 
were utilized. Analytical thin-layer chromatography (TLC) was also used to separate and 
purify reaction products using Silicycle SiliaPlate TLC silica gel F254 (250 µm) TLC glass 
plates. Products on the TLC plates were visualized under UV light (254 nm).  
Proton, carbon, and fluorine nuclear magnetic resonance spectra (1H NMR, 13C 
NMR, and 19F NMR, respectively) were recorded on a Bruker 500 MHz spectrometer. The 
solvent resonances were used the internal standards (1H NMR: CDCl3 at 7.26 ppm, DMSO-
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d6 at 3.50 ppm; 
13C NMR: CDCl3 at 77.0 ppm, DMSO-d6 at 39.5 ppm; 
19F NMR: locked 
to CDCl3 or DMSO-d6). MestReNova (v. 11.0) was used to analyze NMR spectra. 
1H NMR 
data are reported as follows: chemical shift (ppm), multiplicity (s = singlet, d = doublet, dd 
= doublet of doublets, dt = doublet of triplets, ddd = doublet of doublet of doublets, t = 
triplet, m = multiplet, br = broad), coupling constants (Hz), and integration. High-
resolution accurate mass-mass spectrometry (HRAM-MS) was performed using a 
ThermoFisher Q-Exactive Plus Mass Spectrometer. Samples were first separated using a 
ThermoFisher Vanquish Ultra-high pressure liquid chromatograph (UHPLC). Thermo 
QualBrowser (Xcalibur 4.1.31.9) was employed for data processing, including integrations 
and background subtractions. Infrared (IR) spectra were recorded using a Spectra Analysis 
DiscovIR-GC coupled with an Agilent 7890A Gas Chromatograph. Data were processed 
in Grams (version 9.1) for baseline correction and exported to Microsoft Excel for plotting. 
The IR bands were characterized as broad (br), weak (w), medium (m), and strong (s). 
2.8.2 Procedures for Approach 1 
2-Amino-N-(4-bromophenyl)acetamide (16a). Following the published procedure 
from Fagnou:43 In a flame-dried flask under nitrogen atmosphere, 7a (500 mg, 2.907 mmol) 
was stirred with acetic anhydride (0.33 mL, 3.488 mmol) in anhydrous CH2Cl2 (7.3 mL) at 
room temperature. After 16 h, the reaction was quenched with saturated aqueous Na2CO3. 
The aqueous layer was extracted three times with CH2Cl2, then the combined organic layers 
were dried over anhydrous magnesium sulfate, filtered through celite under reduced 
pressure, and concentrated by rotary evaporation. Compound 16a was collected (25% 
EtOAc/hexanes, Rf = 0.07) without further purification as a white solid (609.1 mg, 97% 
yield). 1H NMR (300 MHz, CDCl3) δ 7.42 (d, J = 2.2 Hz, 4H), 2.18 (s, 3H). 
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General Procedure for the Oxidative Coupling. Following the published 
procedure:26 In a dry flask open to air, 16a (75 mg, 0.350 mmol) and Pd(TFA)2 (5.8 mg, 
0.0175 mmol) were dissolved in anhydrous toluene (0.7 mL). After 5 min, X’-
fluorobenzaldehyde 11 (0.07 mL, 0.700 mmol) and TBHP (0.34 mL, 1.40 mmol, 4.13 M 
solution in toluene) were added, then the reaction was heated at 90 ˚C and stirred for 24 h. 
After cooling to room temperature, the reaction was quenched with saturated aqueous 
K2CO3. The aqueous layer was extracted three times with EtOAc, then the combined 
organic layers were dried over anhydrous Na2SO4, filtered through celite under reduced 
pressure, and concentrated by rotary evaporation. Compound 17 was isolated by silica 
prep-TLC. 
2-Acetamido-5-bromo-2'-fluorobenzophenone (17aa). The general decarboxylative 
coupling procedure was followed using 11a (0.07 mL, 0.700 mmol). The product 17aa was 
isolated by silica prep-TLC (25% EtOAc/hexanes, Rf = 0.37) to afford a yellow solid (14.8 
mg, 12% yield). 1H NMR (500 MHz, CDCl3) δ 11.17 (s, 1H), 8.68 (d, J = 9.1 Hz, 1H), 
7.67 (dd, J = 9.0, 2.3 Hz, 1H), 7.61 – 7.55 (m, 2H), 7.48 – 7.44 (m, 1H), 7.30 (td, J = 7.5, 
1.0 Hz, 1H), 7.21 (ddd, J = 9.6, 8.4, 1.0 Hz, 1H), 2.26 (s, 3H). 13C NMR (126 MHz, CDCl3) 
δ 195.86, 169.36, 159.54 (d, J = 253.0 Hz), 140.13, 138.07, 135.96 (d, J = 2.1 Hz), 133.64 
(d, J = 8.3 Hz), 130.24 (d, J = 2.3 Hz), 126.78 (d, J = 14.4 Hz), 124.49 (d, J = 3.6 Hz), 
123.91, 122.62, 116.60 (d, J = 21.4 Hz), 114.56, 25.48. 19F NMR (471 MHz, CDCl3) δ -
111.61 (dtd, J = 9.8, 7.1, 6.3, 3.6 Hz). HRAM-MS (EI) m/z [M+H]+ Calcd for 
C15H12BrFNO2 336.0030; Found 336.0025. 
2-Acetamido-5-bromo-3’-fluorobenzophenone (17ab). The general 
decarboxylative coupling procedure was followed using 11b (0.07 mL, 0.700 mmol). The 
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product 17ab was isolated by silica prep-TLC (10% EtOAc/hexanes, Rf = 0.30) to afford 
a yellow oil (13.1 mg, 11% yield). 1H NMR (500 MHz, CDCl3) δ 10.55 (s, 1H), 8.55 (d, J 
= 9.0 Hz, 1H), 7.67 (dd, J = 9.0, 2.5 Hz, 1H), 7.62 (d, J = 2.4 Hz, 1H), 7.50 (td, J = 7.9, 
5.3 Hz, 1H), 7.48 – 7.38 (m, 2H), 7.33 (tdd, J = 8.2, 2.7, 1.2 Hz, 1H), 2.22 (s, 3H). 13C 
NMR (126 MHz, CDCl3) δ 196.81 (d, J = 2.2 Hz), 169.06, 162.48 (d, J = 249.4 Hz), 139.81 
(d, J = 6.4 Hz), 139.45, 137.22, 135.25, 130.26 (d, J = 7.8 Hz), 125.66 (d, J = 3.1 Hz), 
124.33, 123.39, 120.01 (d, J = 21.4 Hz), 116.54 (d, J = 22.7 Hz), 114.59, 25.24. 19F NMR 
(471 MHz, CDCl3) δ -110.96 (td, J = 8.6, 5.5 Hz). HRAM-MS (EI) m/z [M+H]
+ Calcd for 
C15H12BrFNO2 336.0030; Found 336.0025. 
2-Acetamido-5-bromo-4’-fluorobenzophenone (17ac). The general 
decarboxylative coupling procedure was followed using 11c (0.07 mL, 0.700 mmol). The 
product 17ac was isolated by silica prep-TLC (10% EtOAc/hexanes, Rf = 0.33) to afford a 
yellow solid (9.4 mg, 8% yield). 1H NMR (500 MHz, CDCl3) δ 10.44 (s, 1H), 8.52 (d, J = 
9.0 Hz, 1H), 7.79 – 7.72 (m, 3H), 7.66 (dd, J = 9.0, 2.3 Hz, 1H), 7.61 (d, J = 2.4 Hz, 1H), 
7.23 – 7.18 (m, 2H), 2.21 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 196.55, 169.01, 165.65 
(d, J = 255.8 Hz), 139.14, 136.83, 135.00, 133.96 (d, J = 3.1 Hz), 132.62 (d, J = 9.4 Hz), 
124.94, 123.51, 115.86 (d, J = 21.8 Hz), 114.62, 25.20. 19F NMR (471 MHz, CDCl3) δ -
104.32 (tt, J = 8.3, 5.4 Hz). HRAM-MS (EI) m/z [M+H]+ Calcd for C15H12BrFNO2 
336.0030; Found 336.0023. 
General Deprotection Procedure of N-Acetylbenzophenones. In a flask equipped 
with a stir bar and a condenser under nitrogen atmosphere, 2-acetamido-X-bromo-X’-
fluorobenzophenone 17 (14.8 mg, 0.0440 mmol) was stirred with hydrochloric acid (0.15 
mL, 37 wt% H2O) at 125 ̊ C. After 3 h, the reaction was cooled to 0 ̊ C, diluted with EtOAc, 
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and quenched with saturated aqueous NaHCO3. The aqueous layer was extracted three 
times with EtOAc, then the combined organic layers were washed with H2O, dried over 
anhydrous Na2SO4, filtered through celite under reduced pressure, and concentrated by 
rotary evaporation.  
General Glycine Ethyl Ester Annulation Procedure. The crude deprotection 
product was re-dissolved in pyridine (0.09 mL) in a flask equipped with a stir bar and a 
condenser under nitrogen atmosphere, then stirred at reflux with glycine ethyl ester 
hydrochloride (18.4 mg, 0.132 mmol) and piperidine (1 drop) for 15 h. The reaction 
mixture was concentrated by rotary evaporation, then diluted with CH2Cl2. The organic 
layer was washed with H2O, dried over anhydrous MgSO4, filtered through celite under 
reduced pressure, and concentrated by rotary evaporation. 
Flubromazepam (4) from 2-acetamido-5-bromo-2’-fluorobenzophenone 17aa. The 
general deprotection and annulation procedures were followed using (14.8 mg, 0.0440 
mmol) in 0.15 mL of HCl (37 wt% H2O), then glycine ethyl ester hydrochloride (18.4 mg, 
0.132 mmol) and piperidine (1 drop) in 0.09 mL of pyridine. Compound 4 was not isolated. 
(7,3’)-Isomer (19ab) from 2-acetamido-5-bromo-3’-fluorobenzophenone 17ab. 
The general deprotection and annulation procedures were followed using 17ab (13.1 mg, 
0.0390 mmol) in 0.13 mL of HCl (37 wt% H2O), then glycine ethyl ester hydrochloride 
(16.3 mg, 0.117 mmol) and piperidine (1 drop) in 0.08 mL of pyridine. Compound 19ab 
was not isolated. 
(7,4’)-Isomer (19ac) from 2-acetamido-5-bromo-4’-fluorobenzophenone 17ac. The 
general deprotection and annulation procedures were using 17ac (9.3 mg, 0.0277 mmol) in 
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0.09 mL of HCl (37 wt% H2O), then glycine ethyl ester hydrochloride (11.6 mg, 0.0831 
mmol) and piperidine (1 drop) in 0.3 mL of pyridine. Compound 19ac was not isolated. 
Sugasawa Procedure: Modified from the published procedure:28 To a flame-dried 
flask under nitrogen equipped with a stir bar was added BCl3 (0.76 mL, 0.755 mmol, 1 M 
solution in CH2Cl2). After cooling to 0 ̊ C, 17b (100 mg, 0.581 mmol) was added dropwise, 
followed by AlCl3 (100.7 mg, 0.755 mmol), 18c (140.7 mg, 1.162 mmol), and anhydrous 
benzene (1.2 mL). The reaction was heated to 80 ˚C for 12 hours then cooled back to 0˚C. 
HCl (2.5 mL, 1 M solution) was added, then the nitrogen line was removed and the reaction 
was warmed to 80˚C for 30 min. After cooling to room temperature, the aqueous layer was 
extracted three times with CH2Cl2, then the combined organic layers were washed with 
saturated aqueous NaCl, dried over MgSO4, filtered through celite under reduced pressure, 
and concentrated by rotary evaporation. After purification by silica prep-TLC, 
benzophenone 9bc was afforded as a yellow solid (38.5 mg, 22% yield) along with 
unreacted starting materials.  
2.8.3 Procedures for Approach 2 
Standard Isatin Ring-opening Procedure: In a round-bottom flask, a 30% 
KOH/H2O (or 30% NaOH/H2O) solution was prepared. MeOH was added, then isatin was 
added and dissolved. After 24 h, the reaction was brought to pH ~3 with 1 M HCl, then the 
aqueous layer was extracted with EtOAc and the combined organic extracts were dried 
over anhydrous Na2SO4, filtered through celite under reduced pressure, and concentrated. 
(2-Ethoxycarbonylaminophenyl)glyoxylic Acid (28). Following the published 
procedure from Kraus and Guo:32 In a flame-dried flask under nitrogen equipped with a 
stir bar, 12e (500 mg, 3.398 mmol) was dissolved in dry tetrahydrofuran (8.5 mL), then 
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Et3N (0.66 mL, 4.757 mmol) was added. After stirring for 30 min, the reaction was cooled 
to 0 ˚C, and ethyl chloroformate (0.33 mL, 3.398 mmol) was added slowly. The reaction 
was allowed to warm to room temperature. After 45 min, Na2CO3 (540.2 mg, 5.097 mmol) 
and H2O (8.5 mL) were added and the reaction was heated to reflux.  After 1 h, the reaction 
was cooled to 0 ˚C and the solution pH adjusted to 1-2 with 0.5 M HCl. The aqueous layer 
was extracted three times with Et2O. The combined organic layers were washed once with 
H2O, then dried over anhydrous Na2SO4, filtered through celite under reduced pressure, 
and concentrated by rotary evaporation. The product 28 was isolated by silica column 
chromatography (10% MeOH/CH2Cl2, Rf = 0.06) to afford a yellow solid (670.8 mg, 88% 
yield). 1H NMR (500 MHz, DMSO-d6) δ 10.82 (s, 1H), 8.20 (d, J = 8.3 Hz, 1H), 7.73 (d, 
J = 7.6 Hz, 1H), 7.63 (t, J = 7.8 Hz, 1H), 7.15 (t, J = 7.3 Hz, 1H), 4.16 (q, J = 7.1 Hz, 2H), 
1.25 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 197.02, 166.83, 153.06, 141.04, 
134.99, 133.47, 122.00, 119.01, 118.64, 60.99, 14.35. HRAM-MS (EI) m/z [M-H]- Calcd 
for C11H10NO5 236.0564; Found 236.0561. HRAM-MS (EI) m/z [M-H]
- Calcd for 
C11H10NO5 236.0564; Found 236.0561. 
2.8.4 Procedures for Approach 3 
General Saponification Procedure for the Synthesis of 2-Amino-X-bromobenzoic 
Acids 31. Following the published procedure,34 X-bromoisatin 12 (1.00 g, 4.42 mmol) was 
charged to a round-bottom flask equipped with a stir bar. NaOH (5% H2O, 22 mL) was 
added, and the solution was warmed to 50 ˚C. Then, H2O2 (30 wt%/H2O, 1.1 mL, 11.06 
mmol) was added in one shot. After 30 min stirring, the solution was brought to pH ~ 4 
with 1 M HCl. The product 31 was collected under reduced pressure on a Buchner funnel, 
rinsed with cold water, and used without further purification as the hydrochloride salt. 
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2-Amino-5-bromobenzoic acid (31a). The general saponification procedure was 
followed using 12a (1.00 g, 4.424 mmol). After workup and purification (10% 
MeOH/CH2Cl2, Rf = 0.55), compound 31a was afforded as an off-white solid (957.1 mg, 
86% yield). 1H NMR (500 MHz, DMSO-d6) δ 7.74 (d, J = 2.5 Hz, 1H), 7.34 (dd, J = 8.9, 
2.5 Hz, 1H), 6.73 (d, J = 8.8 Hz, 1H). 13C NMR (126 MHz, DMSO-d6) δ 168.4, 150.6, 
136.1, 132.8, 118.7, 111.1, 104.5. GC-FTIR νmax (cm
-1): 3500, 3384, 3010, 2885, 1671, 
1615, 1584, 1549, 1482, 1424, 1316, 1291, 1231, 1161, 689. HRAM-MS (EI) m/z: [M+H]+ 
Calcd. for C7H7BrNO2 215.96547; Found 215.96517. 
2-Amino-4-bromobenzoic acid (31b). The general saponification procedure was 
followed using 12b (1.00 g, 4.424 mmol). After workup and purification (10% 
MeOH/CH2Cl2, Rf = 0.59), compound 31b was afforded as an off-white solid (799.8 mg, 
72% yield). 1H NMR (500 MHz, DMSO-d6) δ 7.59 (d, J = 8.5 Hz, 1H), 6.97 (d, J = 2.0 Hz, 
1H), 6.64 (dd, J = 8.5, 2.0 Hz, 1H). 13C NMR (126 MHz, DMSO-d6) δ 168.9, 152.5, 133.1, 
127.34, 118.1, 117.3, 108.8. GC-FTIR νmax (cm
-1): 3502, 3384, 2908, 2717, 1667, 1609, 
1580, 1547, 1482, 1428, 1312, 1237, 1156, 1094, 899. HRAM-MS (EI) m/z: [M+H]+ 
Calcd. for C7H7BrNO2 215.96547; Found 215.96523. 
2-Amino-3-bromobenzoic acid (31c). The general saponification procedure was 
followed using 12c (1.00 g, 4.424 mmol). After workup and purification (10% 
MeOH/CH2Cl2, Rf = 0.62), compound 31c was afforded as an off-white solid (594.3 mg, 
66% yield). 1H NMR (500 MHz, DMSO-d6) δ 7.78 (dd, J = 8.0, 1.6 Hz, 1H), 7.63 (dd, J = 
7.8, 1.5 Hz, 1H), 6.74 (s, 1H), 6.52 (t, J = 7.9 Hz, 1H). 13C NMR (126 MHz, DMSO-d6) δ 
169.0, 147.8, 137.12, 131.0, 115.8, 111.8, 109.5. GC-FTIR νmax (cm
-1): 3489 (s), 3369 (s), 
2998 (br), 2863 (br), 2719 (m), 2638 (m), 1667 (s), 1607 (s), 1576 (s), 1543 (s), 1449, 1418, 
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1314, 1264, 1244, 1059, 746, 692. HRAM-MS (EI) m/z: [M+H]+ Calcd. for C7H7BrNO2 
215.9655; Found 215.9652. 
2-Amino-6-bromobenzoic acid (31d). The general saponification procedure was 
followed using 12d (1.00 g, 4.424 mmol), with the following modification: after bringing 
the solution to pH ~ 4, compound 31d (10% MeOH/CH2Cl2, Rf = 0.07) was extracted into 
EtOAc, dried over anhydrous Na2SO4, filtered through celite under reduced pressure, and 
concentrated by rotary evaporation to afford a red solid (970.6 mg, 87% yield). 1H NMR 
(500 MHz, DMSO-d6) δ 7.00 – 6.96 (m, 1H), 6.76 (dd, J = 7.7, 1.0 Hz, 1H), 6.70 (dd, J = 
8.2, 1.0 Hz, 1H). 13C NMR (126 MHz, DMSO-d6) δ 168.1, 148.4, 131.4, 120.1, 119.8, 
118.7, 114.8. GC-FTIR νmax (cm
-1): 3492, 3382, 3377, 3334, 3008, 2910, 2607, 1673, 1613, 
1584, 1553, 1462, 1420, 1385, 1293, 1256, 1235, 1161, 1127, 885, 799, 774, 689. HRAM-
MS (EI) m/z [M+H]+ Calcd for C7H7BrNO2 215.96547; Found 215.96533. 
General Amidation Procedure for the Synthesis of 2-Amino-X-bromo-N-methoxy-
N-methylbenzamides 14. Following the published procedure:35 To a flame-dried round-
bottom flask equipped with a stir bar and under inert nitrogen atmosphere were charged 2-
amino-X-bromobenzoic acid hydrochloride 31 (1 equiv) and N-methoxy-N-methylamine 
hydrochloride (1.5 equiv). Anhydrous DMF (0.2 M) was added at room temperature with 
stirring, then N-methylmorpholine (4.5 equiv) and HBTU (1.5 equiv) were added. After 18 
h, the mixture was poured onto water in a separatory funnel. The aqueous layer was 
extracted three times with EtOAc. The combined organic extracts were dried over 
anhydrous Na2SO4, filtered through celite under reduced pressure, and concentrated by 
rotary evaporation. The product 14 was isolated by alumina flash chromatography (25% 
EtOAc/hexanes). 
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 2-Amino-5-bromo-N-methoxy-N-methylbenzamide (14a).  The general amidation 
procedure was followed using 31a (1.11 g, 4.38 mmol), N-methoxy-N-methylamine 
hydrochloride (641 mg, 6.57 mmol), N-methylmorpholine (2.2 mL, 19.7 mmol), and 
HBTU (2.49 g, 6.57 mmol) in 22 mL of anhydrous DMF. Compound 14a was isolated by 
alumina flash chromatography (25% EtOAc/hexanes, Rf = 0.10) as an orange solid (1.10 
g, 97% yield). 1H NMR (500 MHz, CDCl3) δ 7.50 (d, J = 2.3 Hz, 1H), 7.26 (dd, J = 8.6, 
2.3 Hz, 1H), 6.59 (d, J = 8.6 Hz, 1H), 4.67 (s, 2H), 3.59 (s, 3H), 3.34 (s, 3H). 13C NMR 
(126 MHz, CDCl3) δ 168.5, 145.9, 134.1, 131.6, 118.6, 118.2, 108.2, 61.3, 33.9. GC-FTIR 
νmax (cm
-1): 3456, 3354, 3245, 2971, 2935, 1617, 1582, 1488, 1424, 1403, 1383, 1302, 
1262, 1210, 1158, 1113, 1084, 1057, 997, 978, 903, 891, 829, 820, 770, 745, 689. HRAM-
MS (EI) m/z: [M+H]+ Calcd for C9H12BrN2O2 259.00767; Found 259.00768. 
2-Amino-4-bromo-N-methoxy-N-methylbenzamide (14b).  The general amidation 
procedure was followed using 31b (1.14 g, 4.53 mmol), N-methoxy-N-methylamine 
hydrochloride (662 mg, 6.79 mmol), N-methylmorpholine (2.2 mL, 20.4 mmol), and 
HBTU (2.58 g, 6.79 mmol) in 23 mL of anhydrous DMF. Compound 14b was isolated by 
alumina flash chromatography (25% EtOAc/hexanes, Rf = 0.16) as a red oil (1.16 g, 99% 
yield). 1H NMR (500 MHz, CDCl3) δ 7.26 (d, J = 8.4 Hz, 1H), 6.86 (d, J = 1.9 Hz, 1H), 
6.79 (dd, J = 8.3, 1.9 Hz, 1H), 4.79 (s, 2H), 3.56 (s, 3H), 3.33 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 169.2, 148.3, 130.7, 125.5, 119.7, 119.1, 115.5, 61.2, 33.9. GC-FTIR νmax (cm
-
1): 3454, 3352, 3242, 2971, 2935, 1615, 1578, 1489, 1476, 1459, 1418, 1383, 1318, 1287, 
1262, 1215, 1173, 1148, 1071, 995, 976, 903, 860, 804, 760, 721, 689. HRAM-MS (EI) 
m/z: [M+H]+ Calcd for C9H12BrN2O2 259.00767; Found 259.00726. 
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2-Amino-3-bromo-N-methoxy-N-methylbenzamide (14c).  The general amidation 
procedure was followed using 31c (1.83 g, 7.233 mmol), N-methoxy-N-methylamine 
hydrochloride (1.06 g, 10.9 mmol), N-methylmorpholine (3.6 mL, 32.6 mmol), and HBTU 
(4.12 g, 10.9 mmol) in 36 mL of anhydrous DMF. Compound 14c was isolated by alumina 
flash chromatography (25% EtOAc/hexanes, Rf = 0.29) as a light red oil (1.39 g, 74% 
yield). 1H NMR (500 MHz, CDCl3) δ 7.47 (dd, J = 7.9, 1.5 Hz, 1H), 7.32 (dd, J = 7.7, 1.5 
Hz, 1H), 6.57 (t, J = 7.8 Hz, 1H), 5.13 (s, 2H), 3.57 (s, 3H), 3.35 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ 169.1, 144.2, 134.5, 128.4, 118.1, 117.2, 110.7, 61.3, 34.1. GC-FTIR νmax 
(cm-1): 3446, 3355, 2979, 2935, 1611, 1578, 1549, 1453, 1420, 1383, 1306, 1252, 1210, 
1171, 1152, 1067, 980, 791, 750, 733. HRAM-MS (EI) m/z: [M+H]+ Calcd for 
C9H12BrN2O2 259.00767; Found 259.00729. 
2-Amino-6-bromo-N-methoxy-N-methylbenzamide (14d, crude mixture). The 
general amidation procedure was followed using 31d (968 mg, 3.83 mmol), N-methoxy-
N-methylamine hydrochloride (561 mg, 5.750 mmol), N-methylmorpholine (1.9 mL, 17.3 
mmol), and HBTU (2.18 g, 5.75 mmol) in 19 mL of anhydrous DMF. Compound 14d was 
not isolated. GC-FTIR νmax (cm
-1): 3440, 3352, 3242, 2975, 2937, 1617, 1594, 1565, 1466, 
1449, 1420, 1387, 1296, 1215, 1179, 1156, 1117, 1096, 1073, 1042, 984, 878, 781, 752, 
708, 662. HRAM-MS (EI) m/z: [M+H]+ Calcd for C9H12BrN2O2 259.00767; Found 
259.00751. 
General Lithiate Addition Procedure for the Syntheses of 2-Amino-X-bromo-Y’-
fluorobenzophenones 9. In a flame-dried flask under nitrogen equipped with a stir bar, 1-
bromo-X-fluorobenzene 32 (0.07 mL, 0.607 mmol) was dissolved in anhydrous THF (0.3 
mL). The solution was cooled to either -78 ˚C or -100 ˚C, then n-butyllithium (0.23 mL, 
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0.578 mmol, 2.5 M solution in hexanes) was added slowly. In a separate flame-dried flask 
under nitrogen, 2-amino-X-bromo-N-methoxy-N-methylbenzamide 14 (75 mg, 0.289 
mmol) was dissolved in anhydrous THF (1.2 mL) and cooled to either -78˚C or -100˚C. 
After the lithiate solution had been stirring for 1 h, the benzamide solution was added 
dropwise to it. The reaction was quenched after 15 min with saturated aqueous NH4Cl and 
allowed to warm gradually to room temperature. The aqueous layer was extracted with 
EtOAc, then the combined organic layers were dried over Na2SO4, filtered through celite 
under reduced pressure, and concentrated by rotary evaporation. The product 9 was then 
isolated by silica flash chromatography. 
2-Amino-5-bromo-2’-fluorobenzophenone (9aa). The general lithiate addition 
procedure was followed at -100 ˚C using 14a (75 mg, 0.289 mmol) and 32a (0.07 mL, 
0.607 mmol). Compound 9aa was isolated by silica flash chromatography (25% 
EtOAc/hexanes, Rf = 0.57) to afford a yellow solid (55.2 mg, 65% yield). 
1H NMR (500 
MHz, CDCl3) δ 7.50 (dddd, J = 8.3, 7.2, 5.2, 1.8 Hz, 1H), 7.43 – 7.38 (m, 2H), 7.36 (dd, J 
= 8.8, 2.4 Hz, 1H), 7.26 (s, 6H), 7.17 (ddd, J = 9.5, 8.3, 1.0 Hz, 1H), 6.63 (d, J = 8.8 Hz, 
1H), 6.38 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 194.3, 159.0 (d, J = 250.3 Hz), 149.9, 
137.7, 136.1 (d, J = 2.1 Hz), 132.2 (d, J = 8.1 Hz), 129.7 (d, J = 3.2 Hz), 127.9 (d, J = 16.3 
Hz), 124.3 (d, J = 3.6 Hz), 119.3, 118.8, 116.3 (d, J = 21.5 Hz), 106.7. 19F NMR (471 MHz, 
CDCl3) δ -113.31 – -113.39 (m). GC-FTIR νmax (cm
-1): 3456, 3346, 1613, 1582, 1538, 
1484, 1468, 1451, 1410, 1347, 1318, 1298, 1269, 1240, 1217, 1161, 1144, 1103, 1092, 
949, 939, 893, 839, 822, 785, 760, 723, 689. HRAM-MS (EI) m/z: [M+H]+ Calcd for 
C13H10BrFNO 293.99243; Found 293.99252. 
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2-Amino-5-bromo-3’-fluorobenzophenone (9ab). The general lithiate addition 
procedure was followed at -78 ̊ C using 14a (75 mg, 0.289 mmol) and 32b (0.07 mL, 0.607 
mmol). Compound 9ab was isolated by silica flash chromatography (25% EtOAc/hexanes, 
Rf = 0.50) to afford a yellow solid (51.6 mg, 60% yield). 1H NMR (500 MHz, CDCl3) δ 
7.51 (d, J = 2.4 Hz, 1H), 7.46 (td, J = 7.9, 5.4 Hz, 1H), 7.40 – 7.36 (m, 2H), 7.33 (ddd, J = 
9.0, 2.6, 1.5 Hz, 1H), 7.25 (tdd, J = 8.3, 2.6, 1.1 Hz, 1H), 6.65 (d, J = 8.8 Hz, 1H), 6.12 (s, 
2H). 13C NMR (126 MHz, CDCl3) δ 196.3, 162.4 (d, J = 248.4 Hz), 149.9, 137.2, 135.9, 
130.0 (d, J = 7.8 Hz), 124.8 (d, J = 3.1 Hz), 118.9, 118.8, 118.5 (d, J = 21.4 Hz), 115.9 (d, 
J = 22.5 Hz), 106.7. 19F NMR (471 MHz, CDCl3) δ -111.71 – -111.85 (m). GC-FTIR νmax 
(cm-1): 3467, 3350, 3070, 1634, 1611, 1584, 1538, 1472, 1437, 1408, 1314, 1298, 1271, 
1250, 1202, 1161, 1119, 986, 968, 882, 870, 820, 814, 793, 774, 735, 704, 683, 656. 
HRAM-MS (EI) m/z: [M+H]+ Calcd for C13H10BrFNO 293.99243; Found 293.99206. 
2-Amino-5-bromo-4’-fluorobenzophenone (9ac). The general lithiate addition 
procedure was followed at -78 ˚C using 14a (75 mg, 0.289 mmol) and 32c (0.07 mL, 0.607 
mmol). Compound 9ac was isolated by silica flash chromatography (25% EtOAc/hexanes, 
Rf = 0.46) to afford a yellow solid (66.7 mg, 78% yield). 1H NMR (500 MHz, CDCl3) δ 
7.67 (dd, J = 8.7, 5.4 Hz, 2H), 7.51 (d, J = 2.4 Hz, 1H), 7.37 (dd, J = 8.9, 2.4 Hz, 1H), 7.17 
(t, J = 8.6 Hz, 2H), 6.65 (d, J = 8.8 Hz, 1H), 6.01 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 
196.3, 164.8 (d, J = 252.8 Hz), 149.6, 136.9, 135.8, 135.4, 131.7 (d, J = 8.9 Hz), 119.4, 
118.9, 115.5 (d, J = 21.8 Hz), 106.7. 19F NMR (471 MHz, CDCl3) δ -107.24 (tt, J = 8.4, 
5.5 Hz). GC-FTIR νmax (cm
-1): 3469, 3352, 1611, 1599, 1580, 1538, 1507, 1474, 1408, 
1296, 1240, 1158, 1096, 1015, 951, 939, 897, 853, 820, 806, 783, 739, 716, 683. HRAM-
MS (EI) m/z: [M+H]+ Calcd for C13H10BrFNO 293.99243; Found 293.99219. 
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2-Amino-4-bromo-2’-fluorobenzophenone (9ba). The general lithiate addition 
procedure was followed at -100 ˚C using 14b (75 mg, 0.289 mmol) and 32a (0.07 mL, 
0.607 mmol). Compound 9ba was isolated by silica flash chromatography (25% 
EtOAc/hexanes, Rf = 0.54) to afford a yellow oil (42.8 mg, 50% yield). 
1H NMR (500 
MHz, CDCl3) δ 7.48 (dddd, J = 8.4, 7.2, 5.2, 1.8 Hz, 1H), 7.40 (ddd, J = 7.6, 6.8, 1.8 Hz, 
1H), 7.24 (dd, J = 7.5, 1.0 Hz, 1H), 7.19 – 7.13 (m, 2H), 6.91 (d, J = 1.8 Hz, 1H), 6.69 (dd, 
J = 8.6, 1.9 Hz, 1H), 6.42 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 194.7, 159.0 (d, J = 250.1 
Hz), 151.7, 135.8 (d, J = 2.1 Hz), 132.0 (d, J = 8.2 Hz), 130.0, 129.7 (d, J = 3.4 Hz), 128.3, 
128.2, 124.3 (d, J = 3.6 Hz), 119.2 (d, J = 15.7 Hz), 117.0, 116.1 (d, J = 21.6 Hz). 19F NMR 
(471 MHz, CDCl3) δ -113.35 (dddd, J = 9.4, 7.1, 4.0, 1.3 Hz). GC-FTIR νmax (cm
-1): 3450, 
3340, 1609, 1584, 1530, 1480, 1451, 1424, 1318, 1269, 1244, 1219, 1156, 1138, 1098, 
1049, 1032, 934, 878, 851, 824, 758, 687. HRAM-MS (EI) m/z: [M+H]+ Calcd. for 
C13H10BrFNO 293.99243; Found 293.99240. 
2-Amino-4-bromo-3’-fluorobenzophenone (9bb). The general lithiate addition 
procedure was followed at -78 ̊ C using 14b (75 mg, 0.289 mmol) and 32b (0.07 mL, 0.607 
mmol). Compound 9bb was isolated by silica flash chromatography (25% EtOAc/hexanes, 
Rf = 0.57) to afford a yellow oil (47.1 mg, 55% yield). 
1H NMR (500 MHz, CDCl3) δ 7.43 
(td, J = 7.9, 5.5 Hz, 1H), 7.37 (dt, J = 7.6, 1.3 Hz, 1H), 7.31 (ddd, J = 9.0, 2.7, 1.5 Hz, 1H), 
7.27 (d, J = 8.6 Hz, 1H), 7.23 (tdd, J = 8.3, 2.7, 1.1 Hz, 1H), 6.93 (d, J = 1.9 Hz, 1H), 6.73 
(dd, J = 8.6, 1.9 Hz, 1H), 6.19 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 196.8, 162.4 (d, J = 
248.0 Hz), 151.8, 141.7 (d, J = 6.3 Hz), 135.5, 129.9 (d, J = 7.9 Hz), 129.5, 124.7 (d, J = 
2.9 Hz), 119.5, 119.0, 118.2 (d, J = 21.3 Hz), 116.3, 115.9 (d, J = 22.7 Hz). 19F NMR (471 
MHz, CDCl3) δ -112.03 (td, J = 8.8, 5.5 Hz). GC-FTIR νmax (cm
-1): 3460, 3344, 3070, 
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1607, 1584, 1532, 1480, 1439, 1424, 1314, 1271, 1250, 1208, 1154, 1117, 1096, 1049, 
1003, 978, 965, 895, 837, 826, 806, 793, 764, 716, 698, 683, 662. HRAM-MS (EI) m/z: 
[M+H]+ Calcd for C13H10BrFNO 293.99243; Found 293.99214. 
2-Amino-4-bromo-4’-fluorobenzophenone (9bc). The general lithiation addition 
procedure was followed at -78 ˚C using 14b (75 mg, 0.289 mmol) and 32c (0.07 mL, 0.607 
mmol). Compound 9bc was isolated by silica flash chromatography (25% EtOAc/hexanes, 
Rf = 0.57) to afford a yellow solid (42.4 mg, 49% yield). 
1H NMR (500 MHz, CDCl3) δ 
7.65 (dd, J = 8.8, 5.4 Hz, 2H), 7.27 (d, 1H), 7.14 (t, J = 8.7 Hz, 2H), 6.93 (d, J = 1.9 Hz, 
1H), 6.74 (dd, J = 8.5, 1.9 Hz, 1H), 6.09 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 196.9, 
164.6 (d, J = 252.5 Hz), 151.6, 135.7 (d, J = 3.2 Hz), 135.4, 131.6 (d, J = 8.8 Hz), 129.1, 
119.4, 118.9, 116.8, 115.3 (d, J = 21.8 Hz). 19F NMR (471 MHz, CDCl3) δ -107.64 (tt, J = 
8.4, 5.5 Hz). GC-FTIR νmax (cm
-1): 3460, 3344, 3072, 1605, 1582, 1532, 1507, 1478, 1422, 
1312, 1239, 1156, 1096, 1051, 1015, 949, 932, 874, 849, 808, 768, 729, 700, 679. HRAM-
MS (EI) m/z: [M+H]+ Calcd for C13H10BrFNO 293.99243; Found 293.99223. 
2-Amino-3-bromo-2’-fluorobenzophenone (9ca). The general lithiate addition 
procedure was followed at -100 ˚C using 14c (75 mg, 0.289 mmol) and 32a (0.07 mL, 
0.607 mmol). Compound 9ca was isolated by silica flash chromatography (25% 
EtOAc/hexanes, Rf = 0.73) to afford a yellow solid (47.8 mg, 56% yield). 
1H NMR (500 
MHz, CDCl3) δ 7.61 (dd, J = 7.7, 1.5 Hz, 1H), 7.48 (dddd, J = 8.4, 7.2, 5.3, 1.9 Hz, 1H), 
7.41 (td, J = 7.3, 1.8 Hz, 1H), 7.33 (ddd, J = 8.1, 2.5, 1.5 Hz, 1H), 7.24 (dd, J = 7.5, 1.0 
Hz, 1H), 7.15 (ddd, J = 9.4, 8.3, 1.0 Hz, 1H), 6.97 (s, 2H), 6.49 (t, J = 7.9 Hz, 1H). 13C 
NMR (126 MHz, CDCl3) δ 194.8, 159.0 (d, J = 250.2 Hz), 148.0, 138.0, 134.1 (d, J = 1.8 
Hz), 132.1 (d, J = 8.2 Hz), 129.7 (d, J = 3.2 Hz), 124.2 (d, J = 3.4 Hz), 119.0, 116.1 (d, J 
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= 21.5 Hz), 116.0, 111.0. 19F NMR (471 MHz, CDCl3) δ -113.17 – -113.23 (m). GC-FTIR 
νmax (cm
-1): 3473, 3334, 1634, 1609, 1574, 1532, 1484, 1451, 1435, 1333, 1316, 1279, 
1248, 1219, 1156, 1134, 1100, 1063, 1034, 939, 826, 752, 735, 727. HRAM-MS (EI) m/z: 
[M+H]+ Calcd for C13H10BrFNO 293.99243; Found 293.99220. 
2-Amino-3-bromo-3’-fluorobenzophenone (9cb). The general lithiate addition 
procedure was followed at -78 ˚C using 14c (75 mg, 0.289 mmol) and 32b (0.07 mL, 0.607 
mmol). Compound 9cb was isolated by silica flash chromatography (25% EtOAc/hexanes, 
Rf = 0.68) to afford a yellow solid (54.0 mg, 63% yield). 
1H NMR (500 MHz, CDCl3) δ 
7.62 (dd, J = 7.7, 1.5 Hz, 1H), 7.47 – 7.38 (m, 3H), 7.33 (ddd, J = 9.0, 2.6, 1.4 Hz, 1H), 
7.26 – 7.21 (m, 1H), 6.68 (s, 2H), 6.52 (t, J = 7.9 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 
196.8, 162.3 (d, J = 248.1 Hz), 147.9, 141.6, 137.6, 133.8, 129.9 (d, J = 7.9 Hz), 124.9 (d, 
J = 3.1 Hz), 118.5, 118.3 (d, J = 21.3 Hz), 116.1 (d, J = 22.6 Hz), 115.8, 111.1. 19F NMR 
(471 MHz, CDCl3) δ -112.08 (td, J = 8.8, 5.4 Hz). GC-FTIR νmax (cm
-1): 3475, 3342, 3070, 
1632, 1607, 1584, 1572, 1532, 1484, 1439, 1314, 1268, 1250, 1208, 1154, 1113, 1061, 
970, 887, 874, 860, 826, 808, 789, 750, 718, 685, 656. HRAM-MS (EI) m/z: [M+H]+Calcd 
for C13H10BrFNO 293.99243; Found 293.99195. 
2-Amino-3-bromo-4’-fluorobenzophenone (9cc). The general lithiate addition 
procedure was followed at -78 ˚C using 14c (75 mg, 0.289 mmol) and 32c (0.07 mL, 0.607 
mmol). Compound 9cc was isolated by silica flash chromatography (25% EtOAc/hexanes, 
Rf = 0.68) to afford a yellow solid (52.7 mg, 62% yield). 
1H NMR (500 MHz, CDCl3) δ 
7.67 (dd, J = 8.8, 5.3 Hz, 2H), 7.61 (dd, J = 7.7, 1.5 Hz, 1H), 7.40 (dd, J = 8.0, 1.5 Hz, 1H), 
7.15 (t, J = 8.6 Hz, 2H), 6.57 (s, 2H), 6.52 (t, J = 7.9 Hz, 1H). 13C NMR (126 MHz, CDCl3) 
δ 196.9, 164.7 (d, J = 252.9 Hz), 147.7, 137.2, 135.6 (d, J = 3.2 Hz), 133.5, 131.8 (d, J = 
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8.8 Hz), 119.0, 115.8, 115.3 (d, J = 21.9 Hz), 111.1. 19F NMR (471 MHz, CDCl3) δ -107.43 
(tt, J = 8.5, 5.4 Hz). GC-FTIR νmax (cm
-1): 3477, 3344, 3070, 1630, 1607, 1572, 1534, 1505, 
1437, 1408, 1312, 1266, 1248, 1229, 1156, 1134, 1098, 1061, 1015, 953, 939, 851, 816, 
799, 754, 733, 718, 691. HRAM-MS (EI) m/z: [M+H]+ Calcd for C13H10BrFNO 
293.99243; Found 293.99211. 
2.8.5 Procedures for the Syntheses of (X,X’)-Flubromazepam Positional Isomers 
N-Acylation Procedure. In a flame-dried flask under nitrogen and equipped with a 
stir bar, 2-amino-X-bromo-X’-fluorobenzophenone 9 (1 equiv) was dissolved in anhydrous 
THF (0.2 M) and cooled to 0 ˚C. 2-Bromoacetyl bromide (1.3 equiv) was added slowly. 
After stirring for 1 h, the reaction was quenched with water. The aqueous layer was 
extracted three times with EtOAc, then the combined organic layers were washed with 
NaOH (0.5 M solution in water), dried over anhydrous Na2SO4, filtered through celite 
under reduced pressure, and concentrated by rotary evaporation. 
Imination Procedure. The crude N-acylation adduct was dissolved in NH3 (0.08 M, 
13 wt% in MeOH) and stirred for 18 h. After concentrating by rotary evaporation, the 
mixture was partitioned between Et2O and H2O. The aqueous layer was extracted three 
times with Et2O, then the combined organic layers were dried over anhydrous Na2SO4, 
filtered through celite under reduced pressure, and concentrated by rotary evaporation. The 
product was isolated by silica prep-TLC (5% MeOH/CH2Cl2). 
(7,2’)-Isomer (Parent compound): IUPAC name- 7-Bromo-5-(2-fluorophenyl)-1,3-
dihydro-2H-benzo[e][1,4]diazepin-2-one (flubromazepam, 4). The general N-acylation 
and imination procedures were followed using 9aa (86.6 mg, 0.294 mmol) and 2-
bromoacetyl bromide (0.03 mL, 0.382 mmol) in 2.3 mL of THF, then 3.7 mL of NH3 (13 
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wt% in MeOH). Compound 4 was isolated by silica prep-TLC (5% MeOH/CH2Cl2, Rf = 
0.15) to afford an orange oil (98.6 mg, 98% yield). 1H NMR (500 MHz, DMSO-d6) δ 10.74 
(s, 1H), 7.72 (dd, J = 8.7, 2.3 Hz, 1H), 7.57 (tdd, J = 7.4, 3.3, 1.4 Hz, 2H), 7.33 (t, J = 7.5 
Hz, 1H), 7.26 (t, 1H), 7.21 (d, J = 2.3 Hz, 1H), 7.19 (d, J = 8.7 Hz, 1H), 4.20 (s, 2H). 13C 
NMR (126 MHz, DMSO-d6) δ 169.6, 165.1, 159.6 (d, J = 248.6 Hz), 137.8, 134.4, 132.4 
(d, J = 8.5 Hz), 131.5 (d, J = 2.7 Hz), 131.3, 129.2, 127.1 (d, J = 12.3 Hz), 124.7 (d, J = 
3.5 Hz), 123.3, 116.0 (d, J = 21.4 Hz), 114.7, 57.1. 19F NMR (471 MHz, DMSO-d6) δ -
113.91 – -114.01 (m). GC-FTIR νmax (cm
-1): 3217, 3116, 3074, 2958, 1690, 1615, 1576, 
1482, 1451, 1385, 1350, 1325, 1258, 1231, 1219, 1103, 1088, 1013, 949, 822, 770, 754, 
654. HRAM-MS (EI) m/z: [M+H]+ Calcd for C15H11BrFN2O 333.00333; Found 
333.00302. 
(7,3’)-Isomer: IUPAC name- 7-bromo-5-(3-fluorophenyl)-1,3-dihydro-2H-
benzo[e][1,4]diazepin-2-one (19ab). The general N-acylation and imination procedures 
were followed using 9ab (70.9 mg, 0.241 mmol) and 2-bromoacetyl bromide (0.03 mL, 
0.313 mmol) in 1.2 mL of THF, then 3.0 mL of NH3 (13 wt% in MeOH). Compound 19ab 
was isolated by silica prep-TLC (5% MeOH/CH2Cl2, Rf = 0.15) to afford a yellow oil (14.6 
mg, 12% yield). 1H NMR (500 MHz, DMSO-d6) δ 10.68 (s, 1H), 7.76 (dd, J = 8.7, 2.3 Hz, 
1H), 7.49 (td, J = 8.0, 5.9 Hz, 1H), 7.39 – 7.31 (m, 3H), 7.22 (t, J = 8.7 Hz, 2H), 4.17 (s, 
2H). 13C NMR (126 MHz, DMSO-d6) δ 170.0, 167.2 (d, J = 2.7 Hz), 162.0 (d, J = 244.4 
Hz), 141.0 (d, J = 7.4 Hz), 139.1, 134.6, 132.5, 130.5 (d, J = 8.0 Hz), 127.7, 125.6 (d, J = 
2.7 Hz), 123.5, 117.4 (d, J = 21.2 Hz), 115.6 (d, J = 22.8 Hz), 114.5, 57.1. 19F NMR (471 
MHz, DMSO-d6) δ -112.83 (td, J = 9.4, 6.5 Hz). GC-FTIR νmax (cm
-1): 3213, 3116, 3074, 
2952, 2852, 1692, 1613, 1584, 1478, 1441, 1383, 1356, 1322, 1291, 1271, 1260, 1235, 
 89 
1200, 1148, 1121, 1088, 1019, 980, 868, 841, 826, 793, 770, 746, 696, 679. HRAM-MS 
(EI) m/z: [M+H]+ Calcd for C15H11BrFN2O 333.00333; Found 333.00284. 
(7,4’)-Isomer: IUPAC name- 7-bromo-5-(4-fluorophenyl)-1,3-dihydro-2H-
benzo[e][1,4]diazepin-2-one (19ac). The general N-acylation and imination procedures 
were followed using 9ac (122.4 mg, 0.416 mmol) and 2-bromoacetyl bromide (0.05 mL, 
0.541 mmol) in 2.1 mL of THF, then 5.2 mL of NH3 (13 wt% in MeOH). Compound 19ac 
was isolated by silica prep-TLC (5% MeOH/CH2Cl2, Rf = 0.56) to afford a light orange 
solid (45.8 mg, 52% yield). 1H NMR (500 MHz, DMSO-d6) δ 10.65 (s, 1H), 7.76 (dd, J = 
8.7, 2.3 Hz, 1H), 7.53 (dd, J = 8.7, 5.6 Hz, 2H), 7.36 (d, J = 2.3 Hz, 1H), 7.28 (t, J = 8.8 
Hz, 2H), 7.21 (d, J = 8.7 Hz, 1H), 4.15 (s, 2H). 13C NMR (126 MHz, DMSO-d6) δ 170.4, 
167.5, 163.7 (d, J = 248.4 Hz), 139.3, 135.4 (d, J = 2.9 Hz), 134.7, 132.8, 131.9 (d, J = 8.8 
Hz), 128.2, 123.7, 115.6 (d, J = 21.7 Hz), 114.7, 57.2. 19F NMR (471 MHz, DMSO-d6) δ -
110.68 (tt, J = 8.9, 5.7 Hz). GC-FTIR νmax (cm
-1): 3213, 3120, 3074, 2950, 2946, 2848, 
1690, 1611, 1597, 1569, 1507, 1482, 1408, 1383, 1347, 1322, 1287, 1258, 1233, 1194, 
1158, 1131, 1098, 1015, 947, 843, 824, 772, 756. HRAM-MS (EI) m/z: [M+H]+ Calcd for 
C15H11BrFN2O 333.00333; Found 333.00290. 
(8,2’)-Isomer: IUPAC name- 8-bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-
benzo[e][1,4]diazepin-2-one (19ba). The general N-acylation and imination procedures 
were followed using 9ba (86.6 mg, 0.294 mmol) and 2-bromoacetyl bromide (0.03 mL, 
0.382 mmol) in 2.3 mL THF, then 3.7 mL of NH3 (13 wt% in MeOH). Compound 19ba 
was isolated by silica prep-TLC (5% MeOH/CH2Cl2, Rf = 0.15) to afford an off-white 
fluffy solid (62.6 mg, 65% yield). 1H NMR (500 MHz, DMSO-d6) δ 10.72 (s, 1H), 7.58 – 
7.52 (m, 2H), 7.42 (d, J = 2.0 Hz, 1H), 7.34 – 7.30 (m, 2H), 7.24 (ddd, J = 10.8, 8.7, 1.1 
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Hz, 1H), 7.06 (d, J = 8.5 Hz, 1H), 4.20 (s, 2H). 13C NMR (126 MHz, DMSO-d6) δ 169.7, 
165.8, 159.7 (d, J = 248.7 Hz), 139.8, 132.3 (d, J = 8.2 Hz), 131.5 (d, J = 7.2 Hz), 127.3 
(d, J = 12.8 Hz), 126.5, 125.9, 124.6 (d, J = 3.4 Hz), 124.4, 123.3, 116.0 (d, J = 21.4 Hz), 
57.1. 19F NMR (471 MHz, DMSO-d6) δ -113.90 (dt, J = 12.0, 6.7 Hz). GC-FTIR νmax (cm
-
1): 3207, 3128, 3045, 2962, 1688, 1615, 1596, 1567, 1488, 1478, 1451, 1379, 1360, 1329, 
1260, 1215, 1165, 1154, 1103, 1086, 1017, 951, 930, 874, 822, 768, 748, 721, 673. HRAM-
MS (EI) m/z: [M+H]+ Calcd for C15H11BrFN2O 333.00333; Found 333.00311. 
(8,3’)-Isomer: IUPAC name- 8-bromo-5-(3-fluorophenyl)-1,3-dihydro-2H-
benzo[e][1,4]diazepin-2-one (19bb). The general N-acylation and imination procedures 
were followed using 9bb (70.9 mg, 0.241 mmol) and 2-bromoacetyl bromide (0.03 mL, 
0.313 mmol) in 1.2 mL of THF, then 3.0 mL of NH3 (13 wt% in MeOH). Compound 19bb 
was isolated by silica prep-TLC (5% MeOH/CH2Cl2, Rf = 0.19) to afford an off-white 
granular solid (62.5 mg, 66% yield). 1H NMR (500 MHz, DMSO-d6) δ 10.66 (s, 1H), 7.50 
– 7.44 (m, 2H), 7.39 – 7.30 (m, 3H), 7.25 (dt, J = 7.7, 1.2 Hz, 1H), 7.21 (d, J = 8.4 Hz, 
1H), 4.18 (s, 2H). 13C NMR (126 MHz, DMSO-d6) δ 170.0, 167.9 (d, J = 2.9 Hz), 161.9 
(d, J = 244.3 Hz), 141.1 (d, J = 7.2 Hz), 141.0, 132.5, 130.4 (d, J = 8.3 Hz), 125.6 (d, J = 
5.4 Hz), 124.9, 124.6, 123.5, 117.2 (d, J = 21.3 Hz), 115.6 (d, J = 22.8 Hz), 57.1. 19F NMR 
(471 MHz, DMSO-d6) δ -112.98 (td, J = 9.4, 6.1 Hz). GC-FTIR νmax (cm
-1): 3213, 3124, 
3099, 3078, 3043, 2962, 2848, 1690, 1611, 1594, 1565, 1476, 1443, 1379, 1358, 1323, 
1298, 1271, 1229, 1206, 1146, 1123, 1086, 1022, 1003, 968, 943, 878, 841, 820, 793, 758, 
735, 696, 656. HRAM-MS (EI) m/z: [M+H]+ Calcd for C15H11BrFN2O 333.00333; Found 
333.00272. 
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(8,4’)-Isomer: IUPAC name: 8-bromo-5-(4-fluorophenyl)-1,3-dihydro-2H-
benzo[e][1,4]diazepin-2-one (19bc). The general N-acylation and imination procedures 
were followed using 9bc (122.4 mg, 0.416 mmol) and 2-bromoacetyl bromide (0.05 mL, 
0.541 mmol) in 2.1 mL of THF, then 5.2 mL of NH3 (13% wt% in MeOH). Compound 
19bc was isolated by silica prep-TLC (5% MeOH/CH2Cl2, Rf = 0.15) to afford a yellow 
granular solid (71.2 mg, 77% yield). 1H NMR (500 MHz, DMSO-d6) δ 10.64 (s, 1H), 7.53 
(dd, J = 8.7, 5.6 Hz, 2H), 7.44 (d, J = 2.0 Hz, 1H), 7.37 (dd, J = 8.4, 2.0 Hz, 1H), 7.26 (t, 
J = 8.8 Hz, 2H), 7.19 (d, J = 8.4 Hz, 1H), 4.15 (s, 2H). 13C NMR (126 MHz, DMSO-d6) δ 
170.5, 168.2, 163.7 (d, J = 248.0 Hz), 141.3, 135.6 (d, J = 3.2 Hz), 132.8, 131.9 (d, J = 8.6 
Hz), 125.8, 125.5, 124.8, 123.7, 115.5 (d, J = 21.8 Hz), 57.3. 19F NMR (471 MHz, DMSO-
d6) δ -110.78 (tt, J = 8.8, 5.5 Hz). GC-FTIR νmax (cm
-1): 3213, 3124, 2958, 2848, 1688, 
1613, 1594, 1563, 1509, 1476, 1408, 1379, 1354, 1323, 1262, 1227, 1200, 1156, 1086, 
1019, 951, 924, 874, 843, 816, 758, 743, 714, 694, 671. HRAM-MS (EI) m/z: [M+H]+ 
Calcd for C15H11BrFN2O 333.00333; Found 333.00272. 
(9,2’)-Isomer: IUPAC name- 9-bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-
benzo[e][1,4]diazepin-2-one (19ca). The general N-acylation and imination procedures 
were followed using 9ca (86.6 mg, 0.294 mmol) and 2-bromoacetyl bromide (0.03 mL, 
0.382 mmol) in 2.3 mL of THF, then 3.7 mL of NH3 (13 wt% in MeOH). Compound 19ca 
was isolated by silica prep-TLC (5% MeOH/CH2Cl2, Rf = 0.19) to afford a yellow oil (36.8 
mg, 35% yield). 1H NMR (500 MHz, DMSO-d6) δ 9.98 (s, 1H), 7.89 (dd, J = 7.6, 1.7 Hz, 
1H), 7.63 – 7.54 (m, 2H), 7.33 (td, J = 7.5, 1.1 Hz, 1H), 7.24 (ddd, J = 10.9, 8.2, 1.1 Hz, 
1H), 7.16 (dd, J = 7.9, 1.7 Hz, 1H), 7.12 (t, J = 7.7 Hz, 1H), 4.18 (s, 2H). 13C NMR (126 
MHz, DMSO-d6) δ 169.1, 165.7, 159.7 (d, J = 248.9 Hz), 135.8, 135.4, 132.4 (d, J = 8.4 
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Hz), 131.4 (d, J = 2.6 Hz), 130.6, 128.7, 127.2 (d, J = 12.2 Hz), 125.4, 124.7 (d, J = 3.5 
Hz), 116.4, 116.0 (d, J = 21.4 Hz), 56.8. 19F NMR (471 MHz, DMSO-d6) δ -113.39 – -
113.50 (m). GC-FTIR νmax (cm
-1): 3367, 3309, 3305, 3296, 3284, 3280, 3272, 3224, 3213, 
3205, 3195, 3168, 3137, 3122, 3105, 3074, 3043, 3025, 3012, 3000, 2989, 2981, 2956, 
2885, 1694, 1615, 1592, 1557, 1486, 1472, 1457, 1453, 1414, 1320, 1258, 1239, 1225, 
1212, 1185, 1136, 1103, 1036, 1015, 858, 822, 797, 766, 754, 739, 718. HRAM-MS (EI) 
m/z: [M+H]+ Calcd for C15H11BrFN2O 333.00333; Found 333.00333. 
(9,3’)-Isomer: IUPAC name: 9-bromo-5-(3-fluorophenyl)-1,3-dihydro-2H-
benzo[e][1,4]diazepin-2-one (19cb). The general N-acylation and imination procedures 
were followed using 9cb (70.9 mg, 0.241 mmol) and 2-bromoacetyl bromide (0.03 mL, 
0.313 mmol) in 1.2 mL of THF, then 3.0 mL of NH3 (13 wt% in MeOH). Compound 19cb 
was isolated by silica prep-TLC (5% MeOH/CH2Cl2, Rf = 0.26) to afford a gold oil (25.4 
mg, 31% yield). 1H NMR (500 MHz, DMSO-d6) δ 9.66 (s, 1H), 7.92 (dd, J = 7.9, 1.4 Hz, 
1H), 7.52 – 7.45 (m, 1H), 7.35 (d, J = 8.4 Hz, 2H), 7.30 (d, J = 7.9 Hz, 2H), 7.19 (t, J = 7.9 
Hz, 1H), 4.17 (s, 2H). 13C NMR (126 MHz, DMSO-d6) δ 169.5, 167.7 (d, J = 2.7 Hz), 
162.0 (d, J = 244.3 Hz), 140.9 (d, J = 7.3 Hz), 137.0, 135.6, 130.5 (d, J = 8.2 Hz), 129.9, 
129.0, 125.6 (d, J = 2.7 Hz), 125.2, 117.4 (d, J = 21.1 Hz), 116.6, 115.5 (d, J = 22.8 Hz), 
56.8. 19F NMR (471 MHz, DMSO-d6) δ -112.81 (td, J = 9.4, 6.1 Hz). GC-FTIR νmax (cm
-
1): 3367, 3209, 3139, 3076, 1696, 1613, 1584, 1474, 1459, 1443, 1412, 1314, 1271, 1240, 
1229, 1202, 1185, 1148, 1119, 1080, 1019, 986, 920, 883, 868, 843, 801, 754, 737, 712, 
679. HRAM-MS (EI) m/z: [M+H]+ Calcd for C15H11BrFN2O 333.00333; Found 
333.00336. 
 93 
(9,4’)-Isomer: IUPAC name- 9-bromo-5-(4-fluorophenyl)-1,3-dihydro-2H-
benzo[e][1,4]diazepin-2-one (19cc). The general N-acylation and imination procedures 
were followed using 9cc (122.4 mg, 0.416 mmol) and 2-bromoacetyl bromide (0.05 mL, 
0.541 mmol) in 2.1 mL of THF, then 5.2 mL of NH3 (13 wt% in MeOH). Compound 19cc 
was isolated by silica prep-TLC (5% MeOH/CH2Cl2, Rf = 0.26) to afford a gold film (25.0 
mg, 18% yield). 1H NMR (500 MHz, DMSO-d6) δ 9.63 (s, 1H), 7.92 (dd, J = 7.9, 1.4 Hz, 
1H), 7.58 (dd, J = 8.8, 5.6 Hz, 2H), 7.30 – 7.22 (m, 3H), 7.18 (t, J = 7.9 Hz, 1H), 4.14 (s, 
2H). 13C NMR (126 MHz, DMSO-d6) δ 169.6, 167.7, 163.4 (d, J = 248.2 Hz), 137.0, 135.4, 
135.0 (d, J = 2.9 Hz), 131.5 (d, J = 8.7 Hz), 129.9, 129.2, 125.1, 116.6, 115.3 (d, J = 21.8 
Hz), 56.7. 19F NMR (471 MHz, DMSO-d6) δ -110.56 (tt, J = 8.8, 5.5 Hz). GC-FTIR νmax 
(cm-1): 3367, 3217, 3135, 3074, 1692, 1613, 1594, 1507, 1472, 1459, 1408, 1314, 1225, 
1185, 1156, 1134, 1096, 1013, 843, 818, 797, 756, 737, 714, 681. HRAM-MS (EI) m/z: 
[M+H]+ Calcd for C15H11BrFN2O 333.00333; Found 333.00336. 
2.8.6 Procedures for the Synthesis of 2-Amino-6-bromo-X’-fluorobenzophenones 9da-dc 
3-Hydroxy-3-phenyloxindole (38). Following the published procedure from 
Stoltz:38 In a flame-dried flask under N2, 12e (250 mg, 1.70 mmol) was dissolved in 17 mL 
of anhydrous THF. The solution was cooled to -40°C. PhMgBr (1.4 mL, 4.25 mmol, 3 
M/Et2O) was added, then the solution was allowed to warm to room temperature. After 1.5 
hours, the reaction was quenched with 1 M HCl. The aqueous layer was extracted with 
Et2O, and the combined organic extracts were dried over anhydrous Na2SO4, filtered 
through celite under reduced pressure, and concentrated by rotary evaporation. Compound 
38 was isolated by silica flash chromatography (25% EtOAc/hexanes) in quantitative yield. 
NMR data were consistent with previously reported results. 
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N-Benzyl-4-bromoisatin (46). Following the published procedure from Zhao:41 In 
a flame-dried flask under N2, 12d (500 mg, 2.21 mmol) was dissolved in anhydrous DMF 
(4.4 mL). The solution was cooled to 0°C, then NaH (97.3 mg, 2.43 mmol, 60% dispersion 
in mineral oil) was added in portions. After the color changed from orange to purple and 
the bubbling stopped, benzyl bromide (0.32 mL, 2.65 mmol) was added slowly; the 
reaction color changed again to reddish-brown. The reaction mixture was allowed to warm 
to room temperature. After stirring for an hour, 22 mL of H2O were added to precipitate 
the product, which was filtered through a Buchner funnel and washed with cold hexanes. 
Compound 46 was collected as an orange solid (601.8 mg, 86% yield). NMR data were 
consistent with previously reported results. 
N-Benzyl-4-bromo-3-(4-fluorophenyl)-3-hydroxyoxindole (47c). Following the 
published procedure from Kim:37 To a sealed tube under air, 46 (100 mg, 0.316 mmol), 
13c (141.0 mg, 0.632 mmol), Cu(OTf)2 (5.7 mg, 0.0158 mmol), 1,10-phenanthroline (5.7 
mg, 0.0316 mmol), and LiOH.H2O (39.8 mg, 0.948 mmol) were all combined in 3.2 mL of 
anhydrous CH2Cl2 and warmed to 80°C over 48 hours. Then, the reaction mixture was 
allowed to cool to room temperature, diluted with EtOAc, filtered through a plug of silica 
under reduced pressure using EtOAc as the eluent, and concentrated by rotary evaporation. 
After purification by silica flash chromatography (25% EtOAc/hexanes, Rf = 0.24), 
compound 47c was afforded as a light brown solid (107.6 mg, 82% yield). 1H NMR (500 
MHz, CDCl3) δ 7.38 – 7.35 (m, 2H), 7.31 (ddd, J = 12.5, 7.7, 5.9 Hz, 3H), 7.26 – 7.23 (m, 
2H), 7.19 (dd, J = 8.3, 1.0 Hz, 1H), 7.15 (t, J = 7.9 Hz, 1H), 7.05 (t, J = 8.7 Hz, 2H), 6.76 
(dd, J = 7.6, 1.1 Hz, 1H), 4.97 (d, J = 15.6 Hz, 1H), 4.80 (d, J = 15.7 Hz, 1H), 3.37 – 3.34 
(m, 1H). 13C NMR (126 MHz, CDCl3) δ 175.45, 162.90 (d, J = 247.5 Hz), 144.82, 134.85, 
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133.51, 131.51, 129.48, 128.96, 127.99, 127.55 (d, J = 8.5 Hz), 127.27, 127.22, 119.97, 
115.65 (d, J = 21.8 Hz), 108.80, 78.65, 44.14. 
2-Aminobenzophenone (27). Following the published procedure from Lee:36 In a 
round-bottom flask equipped with a condenser, K4[Fe(CN)6] (487.4 mg, 1.15 mmol), 
NaHCO3 (100.7 mg, 1.20 mmol), and NaOH (17.8 mg, 0.444 mmol) were dissolved in 4.4 
mL of H2O and stirred at 100°C. After 30 minutes, 34e (100 mg, 0.444 mmol) in 1.6 mL 
of THF was added dropwise over 5 minutes, then stirred at 100°C overnight. Then, the 
reaction mixture was allowed to cool to room temperature and diluted with saturated 
aqueous NaHCO3. The aqueous layer was extracted with EtOAc, then the combined 
organic layers were treated with activated charcoal, dried over anhydrous MgSO4, filtered 
through celite under reduced pressure, and concentrated by rotary evaporation. After 
purification by silica flash chromatography (10% MeOH/CH2Cl2), compound 25 was 
afforded as a yellow solid (18.2 mg, 21% yield). NMR data were consistent with previously 
reported results. 
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CHAPTER 3. ANALYSIS OF FLUBROMAZEPAM POSITIONAL 
ISOMERS FOR FORENSIC DIFFERENTIATION 
3.1 Purpose: Positional Isomer Differentiation 
As discussed in Chapter 2, positional isomers of benzodiazepine drugs are nearly 
identical structurally and thus expected to exhibit similar bioactivity as their parent 
benzodiazepines, many of which are federally controlled. However, due to the technically 
legal status of various benzodiazepine isomers, as the analogue rule does not apply to 
benzodiazepines, they represent potentially attractive substitutes for drug abuse. In this 
study, flubromazepam, a recognized designer benzodiazepine since 2012, was targeted for 
synthesis and characterization due to its potential for federal scheduling and current legal 
status within the United States. Significantly, flubromazepam has twelve positional 
isomers including the parent drug, which opens up a broad chemical space for analytical 
study. 
Nine of twelve positional isomers were successfully obtained for analysis (Figure 
3-1), and the syntheses of the remaining three isomers are in progress. Then, the 
corresponding analytical reference spectra for each positional isomer of flubromazepam 
were collected. This chapter will discuss the structural identification and validation of 
synthesized flubromazepam isomers using liquid chromatography-high resolution 
accurate-mass mass spectrometry (LC-HRAM-MS) and proton, carbon, and fluorine 
nuclear magnetic resonance (1H, 13C, 19F NMR). Then, the characterization data acquired 
using traditional forensic analytical techniques such as gas chromatography-mass 
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spectrometry (GC-MS), liquid chromatography-mass spectrometry (LC-MS), and gas 
chromatography-solid phase infrared spectroscopy (GC-IR) will be presented. From this 
data, an analytical roadmap may be developed to differentiate between each positional 
isomer of flubromazepam, and recommendations may be offered to forensic examiners to 
differentiate between benzodiazepine positional isomers without pre-existing reference 
data. 
 
Figure 3-1: Nine successfully acquired flubromazepam isomers. 
3.2 Discussion of Acquired Analytical Data 
3.2.1 LC-HRAM-MS Results 
Exact mass data were collected by LC-HRAM-MS for all flubromazepam targets 
and synthetic precursors as primary validation for the novel compounds. All molecular ion 
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peaks reported correspond to [M+H]+ and exhibit the expected 1:1 [M+H]+/[M+2+H]+ 
isotope pattern indicative of the presence of a bromine atom. For flubromazepam [M+H]+ 
(molecular formula: C15H11BrFN2O), the calculated mass was 333.00333 amu, and 
experimental masses for every positional isomer fell within 2 ppm of this value (Table 3-1). 
For reference, the instrumental calibration allowed for up to 3 ppm error. 
Table 3-1: LC-HRAMS Exact Mass Data for (X,X’)-Flubromazepam Isomers 
Isomer Experimental Mass (amu) Error (ppm) 
(7,2') 333.00302 0.9 
(7,3') 333.00284 1.5 
(7,4') 333.00290 1.3 
(8,2') 333.00311 0.7 
(8,3') 333.00272 1.8 
(8,4') 333.00272 1.8 
(9,2') 333.00333 0.0 
(9,3') 333.00336 0.1 
(9,4') 333.00336 0.1 
Calculateda 333.00333 N/A 
a Calculated for [M+H]+. 
3.2.2 NMR Results 
3.2.2.1 1H NMR 
Like the exact mass data, 1H and 13C NMR served as primary validation methods 
for the identity of each flubromazepam positional isomer and all new precursor 
compounds. (Copies of NMR spectra may be found at the end of Chapter 2.) The 1H NMR 
spectrum for parent flubromazepam agreed well with previously reported results (Table 
3-2).1 
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Table 3-2: 1H NMR Data for Parent Flubromazepam Compared to Literature 
Literature Chemical Shift (ppm) 
(Multiplicity, Integration)a 
Experimental Chemical Shift (ppm) 
(Multiplicity, Integration)a 
10.74 (s, 1H) 10.73 (s, 1H) (a) 
7.71, (dd, 1H) 7.72 (dd, 1H) (b) 
7.52-7.59 (m, 2H) 7.53-7.60 (m, 2H) (c) 
7.15-7.34 (m, 4H) 7.19-7.33 (m, 4H) (d) 
4.20 (s, 2H) 4.20 (s, 2H) (e) 
a Solvent: DMSO-d6 (multiplicity: s = singlet; dd = doublet of doublets; m = undefined multiplet). 
Furthermore, every flubromazepam isomer exhibited a sharp singlet between 9.0-
11.0 ppm and a broad singlet between 4.1-4.3 ppm, corresponding to the NH and CH2 
protons, respectively. The aromatic regions (6.5-8.0 ppm) also showcased expected 
integrations of 7 aromatic protons total, J values consistent with ortho (proximal) and meta 
(long-distance) couplings, and splitting patterns dictated by changes in bromine and 
fluorine positioning on the benzene rings (Table 3-3). Significantly, these splitting patterns 
are unique to each isomer (Figure 3-2); thus, these results strongly suggest that 1H NMR is 
useful for both structural validation and isomeric differentiation of benzodiazepine 
positional isomers in general. 
Table 3-3: 1H NMR Data for (X,X’)-Flubromazepam Isomers 
Isomer Chemical Shift (ppm) (Multiplicity, J Value, Integration)a 
(7,2’) 
(parent) 
10.74 (s, 1H), 7.72 (dd, J = 8.7, 2.3 Hz, 1H), 7.57 (tdd, J = 7.4, 3.3, 1.4 Hz, 2H), 7.33 (t, J = 
7.5 Hz, 1H), 7.26 (t, 1H), 7.21 (d, J = 2.3 Hz, 1H), 7.19 (d, J = 8.7 Hz, 1H), 4.20 (s, 2H) 
(7,3’) 
10.68 (s, 1H), 7.76 (dd, J = 8.7, 2.3 Hz, 1H), 7.49 (td, J = 8.0, 5.9 Hz, 1H), 7.39 – 7.31 (m, 
3H), 7.22 (t, J = 8.7 Hz, 2H), 4.17 (s, 2H) 
(7,4’) 
10.65 (s, 1H), 7.76 (dd, J = 8.7, 2.3 Hz, 1H), 7.53 (dd, J = 8.7, 5.6 Hz, 2H), 7.36 (d, J = 2.3 
Hz, 1H), 7.28 (t, J = 8.8 Hz, 2H), 7.21 (d, J = 8.7 Hz, 1H), 4.15 (s, 2H) 
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(8,2’) 
10.72 (s, 1H), 7.58 – 7.52 (m, 2H), 7.42 (d, J = 2.0 Hz, 1H), 7.34 – 7.30 (m, 2H), 7.24 (ddd, J 
= 10.8, 8.7, 1.1 Hz, 1H), 7.06 (d, J = 8.5 Hz, 1H), 4.20 (s, 2H). 
(8,3’) 
10.66 (s, 1H), 7.50 – 7.44 (m, 2H), 7.39 – 7.30 (m, 3H), 7.25 (dt, J = 7.7, 1.2 Hz, 1H), 7.21 
(d, J = 8.4 Hz, 1H), 4.18 (s, 2H) 
(8,4’) 
10.64 (s, 1H), 7.53 (dd, J = 8.7, 5.6 Hz, 2H), 7.44 (d, J = 2.0 Hz, 1H), 7.37 (dd, J = 8.4, 2.0 
Hz, 1H), 7.26 (t, J = 8.8 Hz, 2H), 7.19 (d, J = 8.4 Hz, 1H), 4.15 (s, 2H) 
(9,2’) 
9.98 (s, 1H), 7.89 (dd, J = 7.6, 1.7 Hz, 1H), 7.63 – 7.54 (m, 2H), 7.33 (td, J = 7.5, 1.1 Hz, 
1H), 7.24 (ddd, J = 10.9, 8.2, 1.1 Hz, 1H), 7.16 (dd, J = 7.9, 1.7 Hz, 1H), 7.12 (t, J = 7.7 Hz, 
1H), 4.18 (s, 2H) 
(9,3’) 
9.66 (s, 1H), 7.92 (dd, J = 7.9, 1.4 Hz, 1H), 7.52 – 7.45 (m, 1H), 7.35 (d, J = 8.4 Hz, 2H), 
7.30 (d, J = 7.9 Hz, 2H), 7.19 (t, J = 7.9 Hz, 1H), 4.17 (s, 2H) 
(9,4’) 
9.63 (s, 1H), 7.92 (dd, J = 7.9, 1.4 Hz, 1H), 7.58 (dd, J = 8.8, 5.6 Hz, 2H), 7.30 – 7.22 (m, 
3H), 7.18 (t, J = 7.9 Hz, 1H), 4.14 (s, 2H) 
a Solvent: DMSO-d6 (multiplicity: s = singlet; d = doublet; dd = doublet of doublets; ddd = doublet of 
doublets of doublets; dt = doublet of triplets; t = triplet; td = triplet of doublets; tdd = triplet of doublets of 
doublets; m = undefined multiplet). 
 
Figure 3-2: Overlay of (X,X’)-flubromazepam positional isomer 1H NMR spectra. 
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3.2.2.2 13C NMR 
The 13C NMR spectrum, though not previously reported in the literature for parent 
flubromazepam, is consistent with previous spectroscopic studies of fluorine-containing 
benzodiazepines.2 Easily distinguishable functional groups include the amide carbonyl 
carbon (C=O), the imine carbon (C=N), and the lone aliphatic carbon (CH2) at 169.59, 
165.10, and 57.06 ppm, respectively (Figure 3-3). 
 
Figure 3-3: 13C NMR spectrum for parent flubromazepam. 
The remaining carbon atoms fall within the aromatic region (115-165 ppm) and 
exhibit additional peaks due to splitting from the fluorine atom (Table 3-4). As expected, 
the six aromatic carbons on the fluorine-containing phenyl ring are split into doublets, and 
the corresponding J values agree with previously reported J values for benzodiazepines 
with 2-fluoro substitutions. These trends hold across the spectra recorded for the novel 
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flubromazepam isomers, with some notable differences. First, only four aromatic carbon 
peaks split into doublets in the 4-fluoro targets due to symmetry. Second, and interestingly, 
doublet splitting was also observed in the 3-fluoro targets at the imine carbon, with a 
reasonable long-range splitting frequency of about 3 Hz. 
Table 3-4: 13C NMR Data for (X,X’)-Flubromazepam Isomers 
Isomer Chemical Shift (ppm) (Multiplicity, J Value)a 
(7,2’) 
(parent) 
169.59, 165.10, 159.64 (d, J = 248.6 Hz), 137.83, 134.39, 132.43 (d, J = 8.5 Hz), 131.54 (d, J 
= 2.7 Hz), 131.33, 129.23, 127.10 (d, J = 12.3 Hz), 124.69 (d, J = 3.5 Hz), 123.31, 116.01 (d, 
J = 21.4 Hz), 114.65, 57.06 
(7,3’) 
170.03, 167.24 (d, J = 2.7 Hz), 161.97 (d, J = 244.4 Hz), 140.98 (d, J = 7.4 Hz), 139.05, 
134.57, 132.52, 130.46 (d, J = 8.0 Hz), 127.65, 125.61 (d, J = 2.7 Hz), 123.46, 117.37 (d, J = 
21.2 Hz), 115.58 (d, J = 22.8 Hz), 114.47, 57.08 
(7,4’) 
170.44, 167.53, 163.70 (d, J = 248.4 Hz), 139.29, 135.42 (d, J = 2.9 Hz), 134.71, 132.83, 
131.85 (d, J = 8.8 Hz), 128.20, 123.68, 115.63 (d, J = 21.7 Hz), 114.69, 57.24 
(8,2’) 
169.65, 165.82, 159.66 (d, J = 248.7 Hz), 139.76, 132.29 (d, J = 8.2 Hz), 131.46 (d, J = 7.2 
Hz), 127.33 (d, J = 12.8 Hz), 126.53, 125.91, 124.64 (d, J = 3.4 Hz), 124.43, 123.28, 115.98 
(d, J = 21.4 Hz), 57.07 
(8,3’) 
170.03, 167.88 (d, J = 2.9 Hz), 161.89 (d, J = 244.3 Hz), 141.06 (d, J = 7.2 Hz), 140.97, 
132.48, 130.35 (d, J = 8.3 Hz), 125.60 (d, J = 5.4 Hz), 124.90, 124.59, 123.46, 117.24 (d, J = 
21.3 Hz), 115.61 (d, J = 22.8 Hz), 57.07 
(8,4’) 
170.50, 168.23, 163.67 (d, J = 248.0 Hz), 141.25, 135.55 (d, J = 3.2 Hz), 132.84, 131.90 (d, J 
= 8.6 Hz), 125.84, 125.49, 124.76, 123.71, 115.53 (d, J = 21.8 Hz), 57.25 
(9,2’) 
169.07, 165.69, 159.71 (d, J = 248.9 Hz), 135.83, 135.39, 132.44 (d, J = 8.4 Hz), 131.37 (d, J 
= 2.6 Hz), 130.57, 128.66, 127.16 (d, J = 12.2 Hz), 125.41, 124.70 (d, J = 3.5 Hz), 116.37, 
116.04 (d, J = 21.4 Hz), 56.80 
(9,3’) 
169.48, 167.66 (d, J = 2.7 Hz), 161.96 (d, J = 244.3 Hz), 140.85 (d, J = 7.3 Hz), 137.00, 
135.58, 130.48 (d, J = 8.2 Hz), 129.88, 128.95, 125.56 (d, J = 2.7 Hz), 125.15, 117.40 (d, J = 
21.1 Hz), 116.60, 115.46 (d, J = 22.8 Hz), 56.82 
(9,4’) 
169.59, 167.67, 163.43 (d, J = 248.2 Hz), 136.96, 135.44, 135.04 (d, J = 2.9 Hz), 131.50 (d, J 
= 8.7 Hz), 129.91, 129.23, 125.09, 116.57, 115.33 (d, J = 21.8 Hz), 56.68 
a Solvent: DMSO-d6 (multiplicity: d = doublet). 
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3.2.2.3 19F NMR 
Similarly, no 19F NMR spectrum was previously reported for parent 
flubromazepam. There are clear trends, however, across the 19F NMR spectra for the 
positional isomers (Table 3-5). All (X,2’) isomers exhibited multiplets in the -113.3 – -
114.0 ppm range, only one of which, the (8,2’) isomer spectrum, was well-resolved; while 
the (X,3’) and (X,4’) isomers manifested more resolved splitting patterns in the -112.8 – -
113.0 and -110.5 – -110.8 ppm ranges, respectively. Although 13C NMR has already been 
demonstrated as a diagnostic technique for fluorine substitution pattern, 19F NMR is 
substantially more powerful for isomeric differentiation. Significantly, due to the similar 
natural abundances of proton and fluorine atoms, 19F NMR acquisitions were achieved in 
shorter times (under a minute) and with greater resolution (471 MHz vs 126 MHz) than 
13C NMR. 
Table 3-5: 19F NMR Data for (X,X’)-Flubromazepam Isomers 
Isomer Chemical Shift (ppm) (Multiplicity, J Value) 
(7,2’) 
(parent) 
-113.91 – -114.01 (m) 
(7,3’) -112.83 (td, J = 9.4, 6.5 Hz) 
(7,4’) -110.68 (tt, J = 8.9, 5.7 Hz) 
(8,2’) -113.90 (dt, J = 12.0, 6.7 Hz) 
(8,3’) -112.98 (td, J = 9.4, 6.1 Hz) 
(8,4’) -110.78 (tt, J = 8.8, 5.5 Hz) 
(9,2’) -113.39 – -113.50 (m) 
(9,3’) -112.81 (td, J = 9.4, 6.1 Hz) 
(9,4’) -110.56 (tt, J = 8.8, 5.5 Hz) 
a Solvent: DMSO-d6 (multiplicity: m = multiplet, dt = doublet of triplets, td = triplet of doublets, tt = triplet 
of triplets.) 
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3.2.3 GC-MS Results 
3.2.3.1 GC Retention Times 
Retention times for flubromazepam positional isomers and corresponding synthetic 
precursors were reported from GC data following the method described in Section 3.5.3.3 
(Table 3-6). Though GC retention time had initially been hypothesized as a distinguishing 
test for the identity of flubromazepam positional isomers, the retention times were resolved 
for only 65% of the nine positional isomers based on the 2% difference threshold allowed 
by the screening method (Table 3-7). 
Table 3-6: GC Retention Times for (X,X’)-Flubromazepam Isomers 






7.610 7.699 7.716 7.969 8.093 8.116 7.887 8.075 8.087 
Table 3-7: Percent Differences Between (X,X’)-Flubromazepam Isomers Based on Retention Time 
Isomera (7,4’) (7,3’) (7,2’) (8,4’) (8,3’) (8,2’) (9,4’) (9,3’) (9,2’) 
(9,2’) 6.1% 5.9% 3.6% 6.4% 6.2% 4.6% 1.4% 1.2% N/A 
(9,3’) 4.9% 4.8% 2.4% 5.3% 5.0% 3.4% 0.2% N/A 1.2% 
(9,4’) 4.7% 4.5% 2.2% 5.1% 4.8% 3.2% N/A 0.2% 1.4% 
(8,2’) 1.5% 1.3% 1.0% 1.8% 1.5% N/A 3.2% 3.4% 4.6% 
(8,3’) 0.1% 0.2% 2.6% 0.3% N/A 1.5% 4.8% 5.0% 6.2% 
(8,4’) 0.4% 0.5% 2.9% N/A 0.3% 1.8% 5.1% 5.3% 6.4% 
(7,2’) 2.5% 2.4% N/A 2.9% 2.6% 1.0% 2.2% 2.4% 3.6% 
(7,3’) 0.1% N/A 2.4% 0.5% 0.2% 1.3% 4.5% 4.8% 5.9% 
(7,4’) N/A 0.1% 2.5% 0.4% 0.1% 1.5% 4.7% 4.9% 6.1% 
a Differentiation Threshold: ≥ 2.0%. (Green cells: ≥ 2.0%; orange cells: 1.0%-1.9%; red cells: < 1.0%; gray 
cells: duplicates or overlaps.) 
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However, the nine isomers evaluated were resolvable 80% of the time at a 1% 
threshold, which suggests that a new screening method could be developed to enable 
differentiation between benzodiazepine positional isomers. Moreover, an instrument with 
greater precision, or a different column, could allow for a lower threshold than 2% for 
differentiation. 
3.2.3.2 EI Mass Spectral Data 
 The mass spectrum acquired by GC-MS for parent flubromazepam matched the 
NIST drug library reference and previously reported data by Moosmann, et al.3 The 
expected molecular ion peak M.+ (chemical formula C15H10BrFN2O, 332 m/z) was 
present, as well as the [M+2].+ peak (334 m/z) at nearly equivalent relative abundance 
correlating to the presence of a bromine atom. Mass spectra for the eight flubromazepam 
positional isomers also registered hits with ≥ 90% confidence against parent 
flubromazepam in the NIST drug library (Table 3-8). Major fragments included loss of 
CO, [M-28] and [M-26] (304 m/z and 306 m/z, respectively); loss of bromine, [M-79] (253 
m/z); and loss of both CO and bromine [M-107] (223 m/z). Combined MS data are 
represented in Table 3-7; peaks were selected at ≥ 10% relative abundance based on 








(7,3) (7,4’) (8,2’) (8,3’) (8,4’) (9,2’) (9,3’) (9,4’) 
63 13%         
75 21% 19% 16% 14% 17% 15% 16% 23% 13% 
76 13%       11%  
77 15% 11%  11% 10%  11% 12%  
81 11%         
85 15% 14% 14% 11% 11% 12%  14% 11% 
89 11%         
95  11%   11%   11%  
98 11%         
99 13% 12%      12%  
102 30% 11%  17%   18% 12%  
103       12%   
104        10%  
107 11%         
109 10%         
112 18% 28% 21% 16% 15% 15% 13% 28% 17% 
168 10%         
169 13% 13% 14% 11% 13% 13% 14% 19% 17% 
170 15% 16% 15% 13% 15% 13% 11% 18% 15% 
177 11%   11%      
182 12% 11%        
195 13% 12% 12% 10% 11% 11% 16% 19% 16% 
196 15% 15% 15% 12% 15% 13% 15% 18% 18% 
197 21% 23% 23% 18% 20% 21% 16% 21% 19% 
198 12% 12% 11%     11%  
223 22% 28% 26% 17% 23% 22% 17% 25% 22% 
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224 15% 16% 15% 13% 14% 13% 14% 18% 17% 
225 18% 21% 20% 13% 17% 17% 18% 24% 22% 
252        11%  
253 11% 17% 19% 14% 18% 21% 12% 15% 18% 
303 88% 77% 66% 63% 58% 53% 65% 74% 69% 
304 90% 97% 100% 98% 100% 100% 60% 67% 83% 
305 100% 100% 86% 94% 82% 71% 100% 100% 100% 
306 89% 97% 94% 100% 100% 98% 57% 66% 77% 
307 27% 28% 22% 25% 25% 20% 30% 33% 27% 
313 21%   22%   25%   
315 23%   23%   28%   
331 68% 63% 57% 65% 63% 54% 74% 82% 85% 
332 77% 75% 59% 55% 51% 44% 64% 66% 61% 
333 66% 75% 65% 67% 69% 59% 85% 94% 90% 
334 73% 72% 59% 53% 51% 41% 60% 67% 59% 
335 14% 12%        
Table 3-9: Confidence Window for EI-MS Differentiation 
Relative Intensity Ion Abundance Precision 
> 50 % ± 10 % 
20 - 50 % ± 15 % 
10 - 20 % ± 20 % 
< 10 % ± 50 % 
Unfortunately, due to these shared fragmentation patterns among flubromazepam 
isomers, mass spectrometry alone is likely not a suitable diagnostic for positional isomer 
differentiation. More rigorous statistical analysis will be required to determine if any 
individual diagnostic peaks based on relative abundance exist. 
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Interestingly, though, a key fragmentation pattern corresponding to the loss of 
fluorine, [M-19].+ and [M-17].+ (313 m/z and 315 m/z, respectively), is present at about 
25% relative abundance for only the (X,2’)-flubromazepam isomers; in contrast, for the 
other isomers, these peaks are present but at lower than 10% relative abundance, which is 
outside the recommended confidence window. Therefore, this mass spectrometry method 
could be employed to quickly gauge whether or not the fluorine atom is substituted at the 
2’ position. 
3.2.4 GC-IR Results 
Complete IR data for the flubromazepam are available in Section 3.7. Functional 
groups in the 4000-1600 cm-1 region were confidently assigned: the flubromazepam targets 
all exhibited a single N-H stretch with the amide formation, sp2- and sp3-C-H stretches as 
expected, and two strong peaks in the 1650-1550 cm-1 region corresponding to the amide 
C=O and imine C=N stretches. 
 Stretching and bending patterns were more distinctive in the fingerprint region of 
the IR based on the substitution patterns of the bromine and fluorine atoms on the two 
aromatic rings. More rigorous statistical analysis will be required, but it is interesting to 
note that isomers with the same bromine substitution but different fluorine substitution 
(and vice versa) display noticeable pattern similarities but have different spectra when 
taken as a whole (Figure 3-4). One highly evident example is the W-shape pattern from 
1375-1320 cm-1 that is strong for the (7,3’), (7,4’), (8,3’), and (8,4’) isomers, weak for the 




Figure 3-4: IR overlay for (X,X’)-flubromazepam positional isomers. 
3.3 Analytical Roadmap 
Taking into account the characterization techniques available and results collected 
from the flubromazepam positional isomer standards, the following scheme may be 
recommended to distinguish between positional isomers. 
 First, GC-MS may be used as a baseline diagnostic for flubromazepam identity. 
The GC retention time (under the GC-MS Screen method described previously) should be 
within 7.6-8.1 minutes, and the mass spectrum should manifest a molecular ion peak of 
332 m/z with a 1:1 M.+:[M+2].+ pattern and a primary fragment at 304 m/z, also in a 1:1 




















(7,2') (7,3') (7,4') (8,2') (8,3')
(8,4') (9,2') (9,3') (9,4')
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for 315 m/z in a 1:1 M.+:[M+2].+ pattern has been identified for (X,2’)-flubromazepam 
isomers. 
 Next, IR is essential for determining isomeric identity. Primary differences between 
isomers are evident especially in the region from 1400-650 cm-1. Direct comparison to 
standard reference data generated by this study is the most straightforward method to 
determine which isomer is present. It is possible also to choose representative peaks in one 
spectrum and compare manually to the other eleven isomer spectra to identify diagnostic 
peaks for a single isomer. 
 If IR should fail, or if the representative IR data is unavailable for the suspected 
isomer, NMR is a reliable method even without reference data, as it provides precise 
structural elucidation that isn’t available with the other analytical techniques. With help 
from 13C and 19F NMR, which allow for confident assignment of the fluorine substitution, 
1H NMR may be employed to determine the exact bromine and fluorine substitutions on 
the ring based on multiplicity, coupling constant, and chemical shift. 
3.4 Summary 
In this study, characterization data were acquired for nine of the twelve possible 
positional isomers of flubromazepam. From these data sets, initial differentiation of the 
isomers was achieved, and an analytical roadmap was established. This roadmap may be 
employed in the future as a template to differentiate between positional isomers of 
additional benzodiazepines of interest. 
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3.5 Analytical Methods 
3.5.1 Materials 
1-Bromo-2-fluorobenzene (99% purity), 1-bromo-3-fluorobenzene (≥99% purity), 
1-bromo-4-fluorobenzene (99% purity), hydrogen peroxide (30wt%/H2O, ACS reagent), 
and n-butyllithium (2.5M/hexanes) were all purchased from Sigma-Aldrich. 3-Bromoisatin 
(>95% purity), 4-bromoisatin (98% purity), and 6-bromoisatin were purchased from Ark 
Pharm, Inc. 5-Bromoisatin (98% purity) and ammonia (7N/MeOH) were purchased from 
Acros Organics. N,O-Dimethylhydroxylamine hydrochloride (98% purity) was purchased 
from Oakwood Products. 2-(1H-Benzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HBTU, 98% purity) and 2-bromoacetylbromide (98% purity) were 
purchased from Alfa Aesar. Anhydrous dimethylformamide (DriSolv) and tetrahydrofuran 
(OmniSolv, unstabilized, HPLC/GC grade) were purchased from EMD Millipore. All 
reagents except for tetrahydrofuran were used directly without any additional purification. 
Tetrahydrofuran was distilled over sodium and benzophenone prior to use. 
 Solvents used for extraction and purification were: dichloromethane, diethyl ether, 
ethyl acetate, and hexanes, all ACS grade. Methanol (Optima grade) was purchased from 
Fisher Chemical and used to prepare GC and LC samples. For NMR analysis, deuterated 
dimethylsulfoxide (DMSO-d6, 99.8% purity) was purchased from Acros Organics and 
deuterated chloroform (CDCl3, 99.8% purity) was purchased from Cambridge Isotopic 
Laboratories, Inc. 
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 Ammonium acetate buffer (15 mM, pH ~ 4 with acetic acid) was prepared for the 
polar LC mobile phase. Acetonitrile (Optima LC-MS grade) was purchased from Fisher 
Chemical and used for the non-polar LC mobile phase. 
3.5.2 Sample Preparation 
NMR samples were prepared at a concentration of 10mg/ml. Acid precursors and 
flubromazepam isomers were dissolved in deuterated dimethyl sulfoxide (DMSO-d6); 
amide and benzophenone precursors were dissolved in deuterated chloroform (CDCl3). 
Samples were prepared for GC-MS, GC-IR, and LC-MS from the NMR samples at a 
1mg/ml concentration in MeOH. 
3.5.3 Instrumental Methods 
Flubromazepam targets and precursors were analyzed by liquid chromatography-
high resolution accurate mass spectrometry (LC-HRAM-MSS) to determine exact mass, 
proton and carbon nuclear magnetic resonance (1H/13C NMR) for structural validation, and 
subsequently analyzed by gas chromatography-mass spectrometry (GC-MS) and gas 
chromatography-infrared spectroscopy (GC-IR). 
3.5.3.1 LC-HRAM-MS 
A ThermoFisher Q-Exactive quadrupole Orbitrap tandem Mass Spectrometer 
(MSD) was coupled to a ThermoFisher Vanquish Liquid Chromatograph (LC) to determine 
the exact masses for the flubromazepam isomers. A sample volume of 10 μL was injected 
into the LC column at 35°C and a flow rate of 0.4 mL/min. Total run time was ten minutes. 
The mobile phase for the first 1.5 minutes was 3% acetonitrile (MeCN)/97% ammonium 
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acetate buffer, followed by a ramp up to 50% MeCN over 5 minutes. This mobile phase 
concentration was maintained for 1.5 minutes, then ramped down to 3% MeCN over 1 
minute, followed by a 1-minute hold. The sample was transferred to the MSD via 
electrospray ionization in positive polarity mode, with a spray voltage of 3.5 kV and a 
capillary temperature of 350°C. The scanning range was 100-650 m/z, and the instrument 
calibrated for accuracy within 3 ppm. Thermo QualBrowser was employed for initial 
processing of exact mass data, including integrations and background subtractions. 
Molecular ion peaks were represented as [M+H]+, and up to 5 decimal places were 
reported. Observed values were compared to values calculated by the QualBrowser 
software, and data were exported and plotted in Microsoft Excel 2010.  
3.5.3.2 NMR 
A Bruker 500-MHz spectrometer was used to record NMR data for the 
flubromazepam isomers. Locking, shimming, and tuning were performed automatically 
using the Bruker Topspin 3.2 software. Average spin speed per sample was 22 Hz. For 1H 
NMR, sixteen scans at 3.28 seconds each were run. For 13C NMR, which was proton-
decoupled, up to 2048 scans at 3.28 seconds each were run, until the signal-to-noise ratio 
was at least 3:1. For 19F NMR, which was proton-coupled, sixteen scans at 2.69 seconds 
each were run. 
Deuterated dimethylsulfoxide [DMSO-d6, (CD3)2SO] (
1H: 2.50 ppm; 13C: 39.5 
ppm) was employed as an internal resonance standard. NMR spectra were analyzed using 
MestreNova software (v. 11.0). Integration and peak picking were performed manually, 
and multiplet analysis and J value reporting were performed automatically on the selected 
peaks. 1H NMR data are reported as follows: chemical shift (ppm), multiplicity (s = singlet, 
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d = doublet, t = triplet, m = multiplet, br = broad), coupling constants (Hz), and integration. 
13C NMR data are reported as proton-decoupled chemical shifts (ppm); when coupled to a 
fluorine atom, multiplicities (d = doublet) and coupling constants (Hz) are also reported. 
19F NMR data are proton-coupled and reported as follows: chemical shift (ppm), 
multiplicity (s = singlet, d = doublet, t = triplet, m = multiplet, br = broad), and coupling 
constants (Hz). 
3.5.3.3 GC-MS 
An Agilent 5977A quadrupole MSD coupled with an Agilent 7890B Gas 
Chromatograph (GC) was used to analyze the flubromazepam isomers. The GC inlet was 
heated to 250°C, and 1.0 µL of the sample was injected into a splitless, single taper, ultra-
inert liner (Agilent 5190-2293) with a 100:1 split. Hydrogen carrier gas moved the 
vaporized sample at a flow rate of 1 ml/min onto a Restek Rxi-1ms column (13302, 20m x 
180 um x 0.18 um) with initial oven temperature of 120°C. After a hold time of 2 minutes, 
temperature increased at a ramp rate of 25°C/min until oven temperature reached 300°C, 
followed by a 4-minute hold time. The sample was transferred through the MSD transfer 
line at 250°C, followed by electron impact ionization (70 eV). Data collection began after 
a solvent delay of 0.5 minutes. Total run time was 13.2 minutes. Data were exported from 
MassHunter Enhanced Data Analysis and plotted in Microsoft Excel 2010. Purity of each 
peak was validated by the Percent Report and Peak Purity features. Retention times were 
reported up to 3 decimal places, and the corresponding mass spectra were analyzed for 
major fragmentation patterns. Peaks with greater than or equal to 10% abundance relative 
to the base peak were considered. The confidence window employed for potential 
differentiation based on mass spectral relative abundance is shown in Table 3-9. 
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3.5.3.4 GC-IR 
A Spectra Analysis DiscovIR-GC coupled with an Agilent 7890A GC was used to 
analyze the flubromazepam isomers. The GC inlet was heated to 250°C, and 1.0 µL of the 
sample was injected with a 2:1 split. Nitrogen carrier gas moved the vaporized sample (gas 
pressure: 25.36 psi) onto a 5ms column (5% diphenyl/95% dimethyl: 30m x 250 um x 0.25 
um) with initial oven temperature of 120°C. After a hold time of 1 minute, temperature 
increased at a ramp rate of 25°C/min until oven temperature reached 290°C, followed by a 
7.2-minute hold time. The sample was transferred through the IR transfer line at 250°C, 
then deposited onto a disk at -40°C to form a plasma. Disk spin speed was 3 mm/min. Total 
run time was 15 minutes. IR data were processed in Grams for baseline correction, then 
exported to Microsoft Excel 2010 for plotting. Peaks were selected for analysis by setting 
signal-to-noise at 10:1 relative to the total range and determining local minima. Manual 
de-selection was performed to remove duplicates or ill-defined humps from major peaks. 
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CHAPTER 4. TOWARD AN INTRAMOLECULAR FRIEDEL-
CRAFTS-TYPE RING-OPENING CYCLIZATION OF DONOR-
ACCEPTOR C5-SUBSTITUTED BICYCLO[3.1.0]HEXANES 
4.1 Donor-Acceptor Bicyclo[3.1.0]hexanes: An Understudied Class of DACPs 
Donor-acceptor cyclopropanes (DACPs) have been showcased by the France lab 
and others as valuable synthons in ring-expansion chemistries to access complex, richly 
substituted hetero- and polycyclic frameworks found in important natural products.1 
Chapters 4 and 5 focus on recent efforts directed toward an understudied class of DACPs, 
donor-acceptor bicyclo[3.1.0]hexanes, as viable precursors to bioactive natural products 
containing fused or bridged bicyclic moieties. These compounds are essentially tethered 
DACPs, as the acceptor carbon is tethered to one of the vicinal carbons (C6 or C5; Scheme 
4-1) by a three-atom linker. 
In the left-hand reaction pathway, a donor-acceptor bicyclo[3.1.0]hexane with the 
electron-donating group situated at C6 results in a five-membered cyclic 1,3-dipole with 
an acyclic secondary carbocation upon ring-opening and a fused bicyclic scaffold upon 
cyclization. This transformation will be discussed in Chapter 5. 
In the right-hand reaction pathway, a bicyclo[3.1.0]hexane with the electron-
donating group situated at C5 results in a six-membered cyclic 1,3-dipole with an 
endocyclic tertiary carbocation upon ring-opening and a bridged bicyclic scaffold upon 
cyclization. A representative example of this latter scaffold is found in tronocarpine, which 
was a key part of the inspiration for this chapter. 
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Scheme 4-1: Expected intramolecular reaction pathways of C6- and C5-substituted donor-acceptor 
bicyclo[3.1.0]hexanes. 
Despite the undeniable utility of a one-step ring-opening cyclization to bridged 
bicyclic scaffolds, donor-acceptor bicyclo[3.1.0]hexanes have been showcased almost 
exclusively in applications to prepare ring-expanded fused bicycles (for representative 
examples, see Chapter 5). In fact, there are only two literature examples employing a C5-
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substituted synthon. The first application was mentioned in Chapter 1 from Stork and 
Grieco (Scheme 4-2).2 They showcased an intramolecular Michael-type addition of an 
anisole moiety onto a C5-methyl-substituted bicyclo[3.1.0]hexane to form a tricyclic 
scaffold, albeit fused rather than the desired bridged structure described above. 
 
Scheme 4-2: Michael-type cyclizations of D-A cyclopropyl ketones.  
The second example is an intermolecular application from Jiang and co-workers.3 
They presented a simple methyl-substituted donor-acceptor bicyclo[3.1.0]hexane that 
undergoes SnCl4-catalyzed ring-opening, elimination, and acid-promoted isomerization to 
form an α,β-unsaturated cyclohexanone, which is further reacted in a Michael-type addition 
with 1,3,5-trimethoxybenzene (Scheme 4-3). This was the only example of this scaffold in 
the article, and this work was not probed further by the authors. 
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Scheme 4-3: (a) Jiang's example of SnCl4-mediated D-A bicyclo[3.1.0]hexane ring-opening. (b) 
Mechanism proposed by the authors.  
Nevertheless, these results do suggest that C5-substituted donor-acceptor 
bicyclo[3.1.0]hexanes may proceed by the polar ring-opening pathway described in 
Scheme 4-1. Whether a localized carbocation forms to be subsequently trapped, or a 
nucleophile is required to act as the driving force for ring-opening (as suggested by the 
example above), is a question that this study seeks to answer. 
4.2 Hypothesis 
With tronocarpine in mind, I hypothesized that the crucial bridged bicyclic moiety 
could be accessed through an intramolecular Friedel-Crafts-type ring-opening cyclization 
of heteroaromatic-tethered, C5-substituted donor-acceptor bicyclo[3.1.0]hexane. Using the 
N-acyl scaffold of tronocarpine as a model (as shown in Scheme 4-4), and following the 
previously established polar mechanism for intramolecular ring-opening cyclizations of N-
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acyl-tethered DACPs, the bridgehead bond would cleave in the presence of a Lewis acid 
to form a localized tertiary carbocation, which would be trapped by the pendant indole to 
afford the bridged bicyclic moiety and be subsequently rearomatized. It should be noted 
that this proposed mechanism does not violate Bredt’s rules, as it was shown by Wiseman 
and co-workers that a double bond is allowed at the bridgehead carbon in larger ring 
systems (i.e. 8+ atoms), which would allow for the enolate-type bicyclic intermediate.4 
This mechanism would be further applied to C2- and C3-tethered (benzo)furan and 
(benzo)thiophene scaffolds, as encompassed in Scheme 4-1. 
 
Scheme 4-4: Hypothesized intramolecular ring-opening cyclization to the tronocarpine core. 
4.3 Model Systems for the Intramolecular Ring-opening Cyclization 
From the outset of this research project, the plan was to establish the intramolecular 
ring-opening cyclization of an N-acyl indole-tethered D-A bicyclo[3.1.0]hexane, as a 
successfully developed method could subsequently be applied to the first total synthesis of 
tronocarpine. Thus, the first iterations of a proof-of-concept model all contain 3-
methylindole as the heterocyclic nucleophile. Additional parameters to survey include 
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different heterocyclic nucleophiles such as benzofuran and thiophene; different acceptor 
groups such as ketone, ester, and amide; different donor groups, including a β-silane for its 
synthetic utility in Fleming-Tamao oxidations; and different ring sizes to probe entropic 
and stereochemical effects (Figure 4-1). 
 
Figure 4-1: Envisioned substrate scope for C5-sub. D-A bicyclo[3.1.0]hexane template. 
4.3.1 First Indole-tethered Model System 
For the indole-tethered model, I initially envisioned a synthetic route that would 
install the indole moiety at the end of the synthesis. This approach would open the door to 
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synthesizing multiple bicyclo[3.1.0]hexane templates and pairing them with various 
heterocyclic nucleophiles to test the method’s robustness, ultimately making the method 
more convergent. The general retrosynthetic analysis (Scheme 4-5) demonstrates the ring-
opening cyclization adduct 49 that would arise from the N-acyl C5-substituted 
bicyclo[3.1.0]hexane 50, after N-acylation of the methyl ester 51. Intramolecular 
cyclopropanation would occur from the diazo alkene 52; the diazo transfer would be 
effected following a nucleophilic addition of commercially available methyl acetoacetate 
(53) and allylic electrophile 54, which may be prepared from allyl alcohol 55. 
 
Scheme 4-5: General retrosynthetic analysis of tronocarpine model system. 
The optimized synthetic route for the first indole-tethered model is shown below 
(Scheme 4-6) and will be discussed in the subsequent section. A silyl ether-protected β-
alcohol was selected as the donor group, in hopes that this substituent would be donating 
enough to effect ring-opening and facilitate later access to the lactam carbonyl via 
deprotection and oxidation. Employing 2-methylene-1,3-propanediol (56) as the starting 
material, tert-butyldiphenylsilyl chloride (TBDPSCl) was selected as the protecting agent 
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for its UV activity (leading to enhanced visualization) and its stability under most 
conditions other than fluoride (deemed essential for maintaining this protecting group 
throughout the total synthesis). Mono-protection of 56 with TBDPSCl thus proceeded 
smoothly to form 55a in 88% yield, with the remaining 12% constituting the di-protected 
adduct and unreacted starting material. 
 
Scheme 4-6: Optimized synthesis of first tronocarpine model system. 
Converting the second alcohol moiety to a suitable leaving group for nucleophilic 
attack required extensive optimization (Table 4-1). As a note, early experiments 
incorporated tert-butyldimethylsilane (TBS) as the alcohol protecting group due to its 
lower profile by proton NMR, as in entries 1-9, solely for the purpose of optimizations. 
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Leaving groups surveyed included tosyl (Ts), mesyl (Ms), bromide (Br), and iodide (I) for 
classic nucleophilic substitution chemistry, and acetate (Ac) for Tsuji-Trost chemistry.5 It 
was determined after early attempts that purification by silica flash chromatography would 
be impossible due to the tendency for allylic groups to eliminate in acidic medium, so 
efforts were redirected toward protocols that afforded sufficiently clean adducts to take 
forward crude. Ultimately, the best protocol turned out to be a two-step, one-pot conversion 
of the alcohol first to a mesylate, then to a bromide (entry 15, 78% crude yield). 
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Table 4-1: Optimization of alcohol conversion to various leaving groups. 
 
Entry R LG (equiv) Base (equiv) Additive (equiv) Yielda 
1 CH2OTBS TsCl (3) Et3N (4) N/A 18 mg 
2 CH2OTBS MsCl (3) Et3N (4) N/A trace 
3 CH2OTBS TsCl (3) Et3N (4) N/A trace 
4 CH2OTBS MsCl (1.5) Et3N (2) N/A trace 
5 CH2OTBS I2 (1.2) ImH (1.3) PPh3 (1.15) trace 
6 CH2OTBS I2 (1.2) ImH (1.3) PPh3 (1.15) trace 
7 CH2OTBS TsCl (1) Pyr (0.165M) N/A NR 
8 CH2OTBS Ac2O (1.2) Pyr (2.3M) N/A 31% 
9 CH2OTBS Ac2O (1.2) Pyr (1M) DMAP (0.1) 68% 
10 CH3 MsCl (1) Et3N (1.1) DMAP (0.1) 28% 
11 CH3 MsCl (1.5) Et3N (2) N/A ND 
12 CH3 MsCl (2) Et3N (2) LiBr (2.5) ND 
13 CH3 CBr4 (1.5) N/A PPh3 (1.2) 25% 
14 CH3 LiBr (1.5) Et3N (2) MsCl (1.5) ND 
15 H LiBr (4) Et3N (2) MsCl (1.5) 78% 
16 CH2OTBDPS LiBr (4) Et3N (2) MsCl (1.5) 65% 
17 CH3 PBr3 (1) N/A N/A NR 
a NR = No reaction, ND = Not determined (i.e. complex mixture). 
Next, conditions were evaluated to form the dienolate of methyl acetoacetate (53), 
which was essential to promote nucleophilic attack from the external (less acidic) ketone. 
Table 4-2 shows various attempts of nucleophilic attack onto commercially available 
electrophiles (benzyl bromide, allyl bromide, and methallyl bromide) promoted by various 
bases (sodium hydride, n-butyllithium, lithium hexamethyldisilazide, and lithium 
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diisopropylamide). Generally speaking, from these results, deprotonation required at least 
3 equiv of base, and a lithium base alone, even at this loading, was ineffective toward 
forming the dienolate. Sodium hydride in 1.2-1.7 equivalents in conjunction with a similar 
loading of lithium base worked most cooperatively (entries 6-7).6 












1 1 BnBr (1) NaH (1.1) n-BuLi (1.1) Complex mixture 
2 1 BnBr (1) NaH (1.1) n-BuLi (1.1) Complex mixture 
3 1 BnBr (1) LHMDS (2.2) N/A Complex mixture 
4 1 allyl Br (1) LHMDS (1.2) NaH (1.2) 26% 
5 1 allyl Br (1) LDA (2.2) N/A No reaction 
6 1.5 allyl Br (1) NaH (1.7) n-BuLi (1.6) 43% 
7 1.1 allyl Br (1) NaH (1.3) n-BuLi (1.2) 35% 








NaH (1.5) n-BuLi (1.5) Complex mixture 
Table 4-3 shows experiments in which the electrophile was first prepared and then 
subjected to nucleophilic conditions. (Tsuji-Trost protocols are included in this dataset, i.e. 
entries 1-2.) Among the combination protocols evaluated, it was determined that the 
optimal conditions were still the mesylation-bromination of the allylic alcohol starting 
material, then 1.5 equivalents of NaH followed by 1.5 equivalents of n-BuLi to form the 
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dienolate (Table 4-4, entry 13). These conditions greatly outperformed contrasting 
precedent for two full equivalents of a lithiate base such as LHMDS. This optimized 
protocol applied with 56a afforded the desired precursor 57a in 72% yield relative to 53. 
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1 1 NaH (1.5) n-BuLi (1.5) ND 
13 CH2OTBPDS 
1. MsCl, Et3N, 
THF, -42oC; 2. 
LiBr, THF, 
0oC 
2 1 NaH (1.5) n-BuLi (1.5) 72% 
14 CH2OTBPDS 
1. MsCl, Et3N, 
THF, -42oC; 2. 
LiBr, THF, 
0oC 
1.7 1 NaH (1.5) n-BuLi (1.5) 75% 
15 CH2OTBPDS 
1. MsCl, Et3N, 
THF, -42oC; 2. 
LiBr, THF, 
0oC 
1.7 1 NaH (1.5) n-BuLi (1.5) 55% 
a NR = No reaction, ND = Not determined (i.e. complex mixture). b Added Pd2(dba)3 and PPh3. 
In the process of optimizing the dienolate formation, it was hypothesized that a 
diazo transfer onto 53 could be performed before the nucleophilic addition step, thereby 
blocking the most acidic position and requiring only one equivalent of base to effect the 
transformation (Table 4-4). Unfortunately, every experiment led to either degradation of 
the diazo starting material or no reaction at all, so the synthesis was pushed forward with 
the optimized dienolate conditions. 
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Table 4-4: Test reactions for nucleophilic attack from a diazo precursor. 
 
Entry Bromide equiv Base (equiv) Result 
1 1 LHMDS (1.5) Complex mixture 
2 1 LHMDS (1.5) Degradation 
3 1 LDA (1.5) Degradation 
4 1 NaH (2) No reaction 
5 1 Et3N (2) No reaction 
6 1.5 Et3N (2) No reaction 
Diazo transfer from 52a proceeded without difficulty (95% yield), and the 
intramolecular cyclopropanation was similarly successful to afford 51a (89% yield). Next, 
to incorporate the indole moiety, several conditions were evaluated. Saponification to the 
acid 58a was feasible at 70% yield, but traditional preparations for the corresponding acid 
chloride were unsuccessful. Gratifyingly, N-acylation with 3-methylindole (59) was 
achievable in the presence of 2-chloro-1-methylpyridinium iodide (i.e. Mukaiyama’s 
reagent)7 to afford 50a in a modest 39% yield. 
Once the N-acylation was optimized and a suitable model for the eventual 
tryptamine-based system thus prepared, a short Lewis acid screen was conducted to test 
the intramolecular ring-opening cyclization (Scheme 4-7). Unfortunately, both In(OTf)3 
and Al(OTf)3 afforded predominantly TBDPSOH and a slew of degradation products rather 
than desired cyclization adduct 49a. These results were partially attributed to deprotection 
of the silyl group by the Lewis acid, despite the fact that TBDPS ought to have been 
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sufficiently stable,8 and the β-silanol was deemed unsuitable as a donating group for this 
ring-opening cyclization. 
 
Scheme 4-7: Unsuccessful intramolecular ring-opening cyclization of first model system. 
4.3.2 Second Indole-tethered Model System 
Applying lessons learned from the first model system, the second model selected 
for evaluation traded the β-silanol for a simple phenyl donor group. Phenyl has been shown 
to be an effectively good donor not solely for its electron richness but also its improved 
ability over alkyl donors to stabilize the intermediary carbocation.1a Due to the close 
similarities between this model system and the previous one, the optimized conditions were 
expected to facilitate a more expedient synthesis of the final target (Scheme 4-8). 
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Scheme 4-8: Optimized synthesis for second tronocarpine model system. 
To generate the allyl electrophile, propargyl alcohol (61) was treated with 
phenylmagnesium bromide and copper iodide in a Gilman reaction9 to afford the allyl 
alcohol 55b in 80% yield. After treatment with the same bromination conditions used 
previously to form 54b, and after preparing the dienolate of methyl acetoacetate, 
nucleophilic addition to 57b was readily achieved in 66% yield, followed by similar 
positive results for the diazo transfer to 52b, cyclopropanation to 51b, and saponification 
to 58b (94%, 89%, and 83%, respectively). 
At this stage of the model synthesis, however, it was quickly determined that 
bicyclo[3.1.0]hexane 58b was incredibly susceptible to irreversible ring-opening 
elimination. Simply exposing 58b to Mukaiyama’s reagent, as optimized for the previous 
model system, led to various elimination and decarboxylation by-products, without 
showing any productive reactivity toward 3-methylindole (59); treatment with oxalyl 
chloride (i.e. Swern conditions) gave the same result (Scheme 4-9). 
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Scheme 4-9: Attempted amidation for second model system. 
4.3.3 Third Indole-tethered Model System 
Though disheartening, the apparent sensitivity of the bicyclo[3.1.0]hexane model 
precursor to ring-open in acidic medium was promising toward the ultimate goal, and it 
was hypothesized that installing the indole moiety earlier in the synthesis would both 
circumvent this issue and afford a system primed for intramolecular ring-opening 
cyclization. Initial test reactions probed the viability of performing a simple N-acylation 
on 59 and building up the alkene-containing side chain gradually (Scheme 4-10). Though 
formation of 63 proceeded readily in the presence of acetyl chloride, test reactions to 
append an additional ketone yielded no desired product and instead resulted in recovery of 
3-methylindole. 
 
Scheme 4-10: Attempted model synthesis beginning with N-acylation of indole with acetyl chloride. 
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Then, a new model synthesis was envisioned in which the first step would be an 
addition of 59 and commercially available 2,2,6-trimethyl-4H-1,3-dioxin-4-one (65), 
essentially 53 masked as a ketal, to afford the N-acyl precursor. As shown in the new 
retrosynthetic analysis (Scheme 4-11), the key difference is that the bicyclo[3.1.0]hexane 
precursor would already be tethered to the indole nucleophile after the cyclopropanation 
step. 
 
Scheme 4-11: Retrosynthetic analysis for third tronocarpine model system. 
After a short optimization study, it was determined that the best conditions required 
stirring 59 and 65 overnight in refluxing toluene to afford β-ketoamide 67 (88% yield). The 
subsequent alkylation step to prepare 68, however, proved challenging (Table 4-5). 
Previously optimized conditions for preparing the dienolate of 53 were, disappointingly, 
incompatible with 67 (entry 1). With this setback, a literature source suggested that 
employing a lithium based in greater than two equivalents and in the -20 to -15°C range 
should produce the dienolate with sufficient persistence and reactivity to perform 
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nucleophilic addition.10 To evaluate these conditions, commercial methallyl bromide 54c 
was selected as the electrophile to avoid having to prepare the allyl bromide for each test. 
Several loadings of electrophile were surveyed in conjunction with LHMDS 
(entries 2-3). Despite increasing the concentration of 54c to prevent loss of 3-methylindole, 
the yield did not improve beyond ~60%. Also surprisingly, subjecting these conditions to 
the prepared 54b did not afford desired product (entry 4). After testing the effects of slow-
addition of the base (entry 5) and a different cation (Na, entry 6), it was decided that the 
lowest effective loading of 54c (1.5 equiv.) in conjunction with 2.5 equiv. LHMDS were 
the optimal conditions (entry 2, 59%). 
Table 4-5: Optimization of nucleophilic addition for third tronocarpine model system. 
 
Entry R (equiv) Base (equiv) Solvent (M, T) Result 
1 Ph (2) NaH (1.5), n-BuLi (1.5) THF (0.2M, 0°C) No desired product 
2 Me (1.5) LHMDS (2.5) THF (0.1M, -17°C) 59% 
3 Me (2) LHMDS (2.5) THF (0.1M, -17°C) 61% 
4 Me (4) LHMDS (2.5) THF (0.1M, -15°C) 59% 
5 Ph (2) LHMDS (2.5) THF (0.1M, -15°C) No desired product 
6 Me (1.5) LHMDS (2.5) THF (0.1M, -15°C) 33%a 
7 Me (1.5) NaHMDS (2.5) THF (0.1M, -15°C) No reaction 
a Slow-added LHMDS over 30 minutes. 
The diazo transfer and cyclopropanation steps proceeded as expected to prepare 
66a (96%) and 50c (87% yield), respectively. Therefore, the synthesis was completed in 
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four steps in 34% overall yield, a great improvement over previous model system syntheses 
(Scheme 4-12). 
 
Scheme 4-12: Optimized synthesis of third tronocarpine model system. 
Despite earlier lack of success with promoting nucleophilic attack from diazo 
compound 60, it was desirous to improve the yield of the nucleophilic addition step as 
much as possible to facilitate large-scale synthesis. Two separate strategies were employed. 
First, nucleophilic addition directly from 65 was attempted (Table 4-6). Unfortunately, 
lithium and amine bases, even in the presence of activating agents, failed to deliver addition 
adduct 69.  
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Table 4-6: Test reactions for direct nucleophilic addition of 2,2,6-trimethyl-4H-1,3-dioxin-4-one. 
 
Entry Allyl equiv Base (equiv) Additive (equiv) Result 
1 1.1 n-BuLi (1.1) N/A No desired product 
2 1.1 Et3N (1.1) TMSOTf (1.1) No desired producta 
3 1.5 Et3N (1.5) TMSOTf (1.5) No reaction 
4 1.5 LDA (1.2) N/A No reaction 
5 1.2 LDA (1.5) TBAI (0.03) No reaction 
a Used BnBr instead of methallyl bromide. 
Next, nucleophilic addition from 70, the diazo transfer product of 67, was 
endeavored (Table 4-7). A plethora of bases were employed, but in every case, there was 
either no desired product formed (entry 1), no reaction (entries 2-5), or degradation of 
starting material (entries 6-10). Activating agents attempted for adduct 70 also failed for 
this system (entries 11-12). 
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Table 4-7: Test reactions for direct nucleophilic addition of diazo precursor. 
 
Entry Allyl equiv Base (equiv) Result 
1 1.2 LHMDS (1.5) No desired product 
2 1.2 DIPEA (1.5) No reaction 
3 1.2 Et3N (1.5) No reaction 
4 1.2 ImH (1.5) No reaction 
5 1.2 2,6-lut. (1.5) No reaction 
6 1.2 LHMDS (1.5) Degradation 
7 1.2 DBU (1.5) Degradation 
8 1.2 KOtBu (1.5) Degradation 
9 1.2 NaH (1.5) Degradation 
10 1.5 LHMDS (2.5) Degradation 
11 1.5 Et3N (1.1) No reactiona,b 
12 1.5 Et3N (1.5) No reactionc 
a Used BnBr instead of methallyl bromide. b Added TMSOTf (1.1 equiv). c Added TMSOTf (1.5 equiv). 
With a route to model system 50c in hand, no further optimizations were pursued, 
and an extensive Lewis acid screen was conducted to test the intramolecular ring-opening 
cyclization to 49b (Table 4-8, pathway a). Interestingly, the choice of catalyst counteranion 
affected the preferred reaction pathway. For metal triflates and bistriflimides, the preferred 
pathway was a ring-opening elimination (pathway b); whereas for metal chlorides, the 
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preferred pathway was not a ring-opening elimination, but accurate structural elucidation 
has proven challenging despite extensive NMR studies (pathway d). In one case, the major 
product resulted from a hydride shift of the intermediary carbocation (pathway d), though 
this result has not been replicated. Brønsted acids, in contrast, were ineffective catalysts 
for this reaction. 
Table 4-8: Lewis acid screen for model intramolecular ring-opening cyclization. 
 
Entry Lewis acid Solvent Temp. Result/Notes 
1 In(OTf)3 DCM r.t. SM + 2.1mg c, messy reaction 
2 Sc(OTf)3 DCM r.t. Mostly a 
3 SnCl4 DCM r.t. Mostly d 
4 In(OTf)3 DCM reflux Complete after 1h, mostly b 
5 In(OTf)3 DCM r.t. Not complete after 22h, mostly b 
6 In(OTf)3 DCM 0°C No reaction after 22h 
7 Ca(NTf2)2/n-Bu4NPF6 DCM r.t. Mostly a 
8 Cu(OTf)2 DCM r.t. No reaction after 24 h 
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9 In(OTf)3 MeCN r.t. No reaction after 23h 
10 In(OTf)3 MeCN 50°C Mostly a, some degradation 
11 Al(OTf)3 DCM r.t. Complete after 4h, mostly b 
12 Ga(OTf)3 DCM r.t. Not complete after 21h, only SM + b 
13 Sc(OTf)3 DCM r.t. Not complete after 21h, only SM + b 
14 Yb(OTf)3 DCM r.t. No reaction after 21h 
15 Zn(OTf)2 DCM r.t. No reaction after 21h 
16 Mg(OTf)2 DCM r.t. No reaction after 21h 
17 Bi(OTf)3 DCM r.t. Mostly a 
18 SnCl4 DCM r.t. Mostly d 
19 TFA DCM r.t. No reaction after 48h 
20 TsOH DCM r.t. No reaction after 48h 
21 TfOH DCM r.t. Only b after 1h 
22 Tf2NH DCM r.t. Not complete after 17h, only SM + b 
23 InCl3 DCM r.t. Not complete after 22h, mostly d 
24 InCl3 DCM reflux Only degradation after 6h 
25 AgOTf DCM r.t. No reaction after 24h 
26 AgBF4 DCM r.t. No reaction after 24h 
27 Bi(OTf)3, TFA DCM r.t. After 19h, mostly b + degradation 
28 GaCl3 DCM 0°C-r.t. Complete in 30 min, mostly d 
Unfortunately, though the product outcomes support a ring-opening mechanism, 
none of the surveyed catalysts afforded the desired bridged bicyclic product 49b, and 
additional treatment with a Brønsted acid failed to reprotonate the elimination product to 
drive the reaction toward cyclization. 
4.3.4 Benzofuran-tethered Model System 
Hypothesizing that 3-methylindole might not be the optimal nucleophile for testing 
this transformation, and that a β-ketoester might have better chelating ability than a β-
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ketoamide (or a diketone, since the aromaticity of indole affords this amide more ketone-
like character), a benzofuran-tethered oxabicyclo[3.1.0]hexane model system was prepared 
in short order from commercially available benzofuran-2-carboxylic acid (71) (Scheme 
4-13). After converting 71 to its corresponding acid chloride, 2-phenylallyl acetate (72) 
was treated with LHMDS to promote nucleophilic attack onto the acid chloride, which 
afforded β-ketoester 73 in 65% yield. Next, diazo transfer to 74 was achieved with p-
acetamidobenzenesulfonyl azide (p-ABSA)11 in 95% yield, followed by intramolecular 
cyclopropanation to 75 at a modest 60% yield. 
 
Scheme 4-13: Synthesis and testing of benzofuran-tethered oxabicyclo[3.1.0]hexane model system. 
Subjecting this oxabicyclo[3.1.0]hexane model 75 to Ga(OTf)3 afforded the same 
result as before, only more definitively: complete consumption of starting material after 2 
hours to afford a single ring-opened elimination product 76’. This result further supported 
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that the mechanism was proceeding as expected, but unfortunately, the desired product was 
not favored. 
4.4 Troubleshooting the Intramolecular Ring-opening Cyclization 
The propensity for the D-A bicyclo[3.1.0]hexane synthon to ring-open in acidic 
medium was incidental confirmation that a carbocation intermediate was being generated. 
Unfortunately, elimination appeared to be kinetically favored over Friedel-Crafts-type 
cyclization, especially when an enol could easily form, as in the benzofuran-tethered case.  
With these limitations in mind, it was hypothesized that either the tertiary 
carbocation was too sterically hindered toward nucleophilic attack, or the carbonyl adjacent 
to the tethered heterocycle was making the system too rigid to access the carbocation. As 
the nature of the C5-subsituted donor-acceptor bicyclo[3.1.0]hexane scaffold necessitates 
formation of a tertiary carbocation, addressing the possible steric hindrance was 
functionally impossible. Thus, the rigidity of the system was targeted for alteration. 
4.4.1 Decarbonylated Model Systems 
Two syntheses were attempted to access model systems without the aforementioned 
carbonyl moiety. Beginning with the N-acyl system, 51b was subjected to a universal 
reduction, which was effected quantitatively to yield 77 (Scheme 4-14). The next step was 
the selective conversion of the resulting primary alcohol to a suitable leaving group for 
nucleophilic displacement by 59. Unfortunately, the mesylation-bromination conditions 




Scheme 4-14: Attempts toward an indole-tethered decarbonylated bicyclo[3.1.0]hexane model 
system. 
 Concurrently, efforts were directed toward the benzofuran-tethered system 
(Scheme 4-15). Acid 71 was first reduced to the alcohol 79 (51% yield), then converted to 
the bromide 80 in the presence of PBr3.
12 Unfortunately, 2-(bromomethyl)benzofuran was 
inseparable from unreacted starting material by silica flash chromatography. Optimistic 
that the alcohol would not drastically hinder the next synthetic step, however, the bromide 
mass was estimated by 1H NMR (93.7 mg out of 104.1 mg crude), and the mixture was 
carried forward. 
Next, LHMDS-mediated nucleophilic addition was attempted with acetate 72. 
Disappointingly, but perhaps due to the impure starting material, there was no evidence of 
desired product 81. At this time, this reaction has not been optimized, but there are plans 
to attempt the mesylation-bromination sequence that was effective for the synthesis of 
allylic bromides. If successful, subsequent steps would include a NaH-mediated diazo 
transfer followed by cyclopropanation to afford the proposed benzofuran-based 
decarbonylated model system 82. 
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Scheme 4-15: Attempts toward a benzofuran-tethered decarbonylated oxabicyclo[3.1.0]hexane model 
system. 
4.4.2 Ring-Expanded Model System 
Although ring size was a parameter intended to evaluate later in the methodology 
development process, it was suggested that a ring-expanded model system might bring the 
tertiary carbocation into closer proximity to the heterocyclic nucleophile and reduce steric 
crowding at the carbocation. An indole-tethered oxabicyclo[4.1.0]heptane was therefore 
envisioned, beginning with readily available starting materials: 3-methylindole (59), 
Meldrum’s acid (83),13 and 2-methyl-1-buten-4-ol (84). 
The initial reaction between 59 and 83 was tested in various solvents at their reflux 
temperatures (Table 4-9). It was quickly determined that stirring the two reagents in 
refluxing, anhydrous THF overnight provided acid 85 in the best yield (entry 1), as 
refluxing in higher-boiling solvents led to degradation of 83 (entries 2-3). Furthermore, 
increasing the loading of 59 added a driving force for the reaction (entry 4). 
  
 245 
Table 4-9: Optimization of 3-methylindole N-acylation with Meldrum's acid. 
 
Entry Meldrum’s equiv Indole equiv Solvent Yield 
1 1 1 THF 50% 
2 1 1 DCE Degradation 
3 1 1 MeCN Degradation 
4 1 1.5 THF 62% 
Next, several esterification protocols were evaluated (Table 4-10). It was desirous 
to use the synthesized acid 85 in lower equivalents relative to the commercially available 
alcohol 84. Unfortunately, these reaction attempts afforded no desired product (entries 1-
3). Literature suggested an excess of acid under standard DCC coupling conditions, and 
gratifyingly, the ester 86 was achieved at 66% yield relative to the alcohol (entry 4). 
Table 4-10: Optimization of 3-methyl-3-buten-1-ol esterification. 
 
Entry Acid equiv Alcohol equiv Conditions Result 
1 1 1.2 EDCI (1.3 equiv), DMAP (0.1 equiv) No reaction 
2 1 4 EtOC(O)Cl (1.3 equiv), Et3N (1.2 equiv) No desired product 
3 1 1.2 DCC (1.1 equiv), DMAP (0.2 equiv) No reaction 
4 2.4 1 DCC (2 equiv), DMAP (0.1 equiv) 66% 
 246 
Disappointingly, modest yields in these first two steps, coupled with requiring an 
excess 85 for the esterification, hampered preparation of sufficient quantities to push 
forward, and the proposed synthesis has yet to be completed (Scheme 4-16). 
 
Scheme 4-16: Attempted synthesis of ring-expanded indole-tethered bicyclo[4.1.0]heptane model 
system. 
4.4.3 An Intermolecular, Stepwise Incorporation of the Heteroarene 
Considering the challenges associated with the intramolecular ring-opening 
cyclization, a stepwise, intermolecular incorporation of indole under typical ring-opening 




Scheme 4-17: Kerr's intermolecular ring-opening cyclization toward indole-containing tricycles. 
A C5-phenyl-substituted donor-acceptor oxabicyclo[3.1.0]hexane model system 89 
was readily synthesized to probe this hypothesis (Scheme 4-18). This DACP was selected 
over its cyclic ketone analogue to promote more effective chelation of the Lewis acid and 
because the synthesis was more expedient. Alcohol 62 was subjected to nucleophilic 
addition with methyl malonyl chloride to afford β-ketoester 90 quantitatively. Subsequent 
diazo transfer and cyclopropanation effected the swift preparations of 91 (86%) and 92 
(75%), respectively. 
 
Scheme 4-18: Synthesis of oxabicyclo[3.1.0]hexane intermolecular cycloaddition model system. 
DACP 89 was then treated with a Lewis acid (Table 4-11) and, in separate 
instances, N-methylindole and 3-methylindole, in hopes of trapping the carbocation with 
an external nucleophile. The hypothesized adduct 92 would then be isolated and subjected 
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to amidation conditions to form bridged bicycle 93. This Friedel-Crafts-type alkylation was 
attempted with representative metal triflate Bi(OTf)3 (entries 1-2) and metal chloride InCl3 
(entries 3-4), since these catalysts had demonstrated excellent reactivity in the 
intramolecular ring-opening cyclization study. Consumption of starting material was 
observed; however, this reaction did not proceed as desired. 
Table 4-11: Attempted intermolecular Friedel-Crafts-type alkylation with indoles. 
 
Entry R, R’ Lewis acid Result 
1 H, Me Bi(OTf)3 No desired product 
2 Me, H Bi(OTf)3 No desired product 
3 H, Me InCl3 No desired product 
4 Me, H InCl3 No desired product 
This hypothesis was tested again with other electron-rich coupling partners (Table 
4-12). 2,5-Dimethylfuran showed no reactivity with the D-A bicyclo[3.1.0]hexane (entry 
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1), so the reaction was repeated with 2,5-dimethylthiophene (entries 2-3). Unfortunately, 
both InCl3 and In(OTf)3 led to no reaction. 
Table 4-12: Attempted intermolecular Friedel-Crafts-type alkylation with 2,5-dimethylfuran and -
thiophene. 
 
Entry X Lewis acid Result 
1 O InCl3 No reaction 
2 S InCl3 No reaction 
3 S In(OTf)3 No reaction 
4.5 Changing Tactics: An Intermolecular Formal [3+2] Cycloaddition 
Having exhausted most possibilities toward the hypothesized intramolecular route, 
and given the challenges with synthesizing alternative model systems (i.e. decarbonylated, 
ring-expanded), efforts were shifted to an intermolecular formal [3+2] cycloaddition of C5-
substituted donor-acceptor bicyclo[3.1.0]hexanes. The operational mindset was that proof 
of concept of the intramolecular transformation would be streamlined if the system’s 
preferences and limitations could be determined for an analogous polar reaction pathway. 
There is no literature precedent for any intermolecular formal cycloaddition from 
this exact template. However, as early as 1981, Reißig demonstrated sequential TiCl4-
catalyzed ring-opening cyclizations of siloxy-substituted DACPs onto ketones to form 
aldol condensation products, followed by hydroxyl cleavage to yield substituted 
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dihydrofurans (DHFs).15 This reaction class has since been broadly expanded with efforts 
from Johnson,16 Tomilov,17 and others.18 We were particularly inspired by Johnson’s 
method to prepare densely substituted tetrahydrofurans,16a which was seminal toward 
validating the polar ring-opening mechanism of donor-acceptor cyclopropanes. Through a 
series of competition experiments, Johnson ruled out the possibilities of both electrocyclic 
and radical mechanisms, and by so doing established a stepwise, polar mechanism for the 
intermolecular addition between 1,3-dipoles resulting from DACPs and appropriate 
dipolarophiles such as benzaldehydes (Scheme 4-19). 
 
Scheme 4-19: (a) Johnson’s intermolecular formal [3+2] cycloaddition of DACPs and aldehydes. (b) 
Validated polar mechanism. 
The first template evaluated in this formal [3+2] cycloaddition was 
bicyclo[3.1.0]hexane 50a, using Johnson’s preferred catalyst and benzaldehyde as a 
starting point (Table 4-13). Unfortunately, there was no trace of desired product in any of 
these reactions, and most of the reactions formed a complex, inseparable mixture of 
products. The lack of success was attributed to the ability of Lewis acids to deprotect silyl 
alcohols,8 as hypothesized for the intramolecular ring-opening cyclization employing the 
same donor group. 
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Table 4-13: Lewis acid screen for intermolecular ring-opening cyclization.  
 
Entry Lewis acid Time (h) Result 
1 Sn(OTf)2a 4 No reaction 
2 In(OTf)3 24 Complex mixture 
3 Zn(OTf)2 24 No reaction 
4 Sc(OTf)3 6 Complex mixture 
5 Yb(OTf)3 24 Not complete 
6 Sn(OTf)2 22.5 No desired product 
7 In(OTf)3 24 No desired product 
8 Ga(OTf)3 2 No desired product 
9 Al(OTf)3 22.5 No desired product 
10 Ca(NTf2)2/n-Bu4NPF6 24 Complex mixture 
a Used 5 mol% catalyst loading. 
Next, oxabicyclo[3.1.0]hexane 89 was evaluated. p-Anisaldehyde (96, 3 equiv) was 
selected as the cycloaddition coupling partner, as it was supposed that a more electron-
donating benzaldehyde would facilitate nucleophilic trapping of the tertiary carbocation. 
A Lewis acid screen was conducted, with a catalytic loading of 30 mol%, in DCM at a 0.5 
M concentration (Scheme 4-20).  
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Scheme 4-20: Model intermolecular reaction and proposed mechanism. 
Johnson’s preferred catalyst, Sn(OTf)2, was ineffective under these conditions, 
affording only recovered starting material after 3 hours at room temperature (Table 4-14, 
entries 3-4). Several other Lewis acids yielded the same results (entries 1-2, 6-9); however, 
slight reactivity was observed in the presence of Ga(OTf)3 (entry 5). 
Table 4-14: Conditions screen for model intermolecular reaction. 
Entry Lewis acid Temp, time Result 
1 In(OTf)3 r.t., 3 h No reactiona 
2 InCl3 r.t., 3 h No reactiona 
3 Sn(OTf)2 r.t., 3 h No reactiona 
4 Sn(OTf)2 r.t., 3 h No reactionb 
5 Ga(OTf)3 r.t., 3 h 12% isolated productb 
6 Sn(OTf)2 Δ, 4 h No reactionb 
7 Bi(OTf)3 r.t., 4 h No reactionb 
8 TsOH.H2O r.t., 16 h No reactionb 
9 Ca(NTf2)2/n-Bu4NPF6 r.t., 16 h No reactionb 
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10 Ga(OTf)3 r.t., 3 h N/Ac 
11 Ga(OTf)3 r.t., 24 h 26% (q-NMR)d 
12 Ga(OTf)3 Δ, 24 h 27% isolated productb 
13 SnCl4 r.t., 24 h No reaction (q-NMR)b,d 
14 Bi(OTf)3 Δ, 24 h No reaction (q-NMR)b,d 
15 Sc(OTf)3 Δ, 24 h 52% (q-NMR)b,d 
16 Ga(OTf)3 Δ, 24 h Degradationb,e 
17 Ga(OTf)3 Δ, 24 h Degradationb,f 
18 Ga(OTf)3 Δ, 24 h Degradationb,g 
19 Ga(OTf)3 Δ, 24 h 27% (q-NMR)b,d 
20 Sn(OTf)2 Δ, 24 h 12% (q-NMR)b,d 
21 In(OTf)3 Δ, 24 h 52% (q-NMR)b,d 
22 Ga(OTf)3 Δ, 24 h Complex mixtureh 
23 Ga(OTf)3 Δ, 24 h Complex mixturei 
24 Ga(OTf)3 Δ, 24 h No desired productb,j 
25 Ga(OTf)3 Δ, 24 h No desired productb,k 
26 Ga(OTf)3 Δ, 6 h 58%b,d,l 
27 Ga(OTf)3 Δ, 6 h No desired productm 
28 Ga(OTf)3 Δ, 24 h No desired productn 
29 InCl3 Δ, 24 h (Not yet performed) 
30 AlCl3 Δ, 24 h (Not yet performed) 
31 Al(OTf)3 Δ, 24 h (Not yet performed) 
32 Ca(NTf2)2/n-Bu4NPF6 Δ, 24 h (Not yet performed) 
33 SnCl4 Δ, 24 h (Not yet performed) 
34 FeCl3 Δ, 24 h (Not yet performed) 
a Filtered reaction mixture through silica for work-up. b Purified p-anisaldehyde from bottle before use. c 
Control reaction without starting material to observe p-anisaldehyde by-product. d Evaluated yield by q-
NMR. e Solvent: THF. f Solvent: DCE. g Solvent: PhMe. h Coupling partner: benzaldehyde. i Coupling 
partner: 2-naphthaldehyde. j Used 1 equiv aldehyde. k Used 0.8 equiv aldehyde. l Used 10 equiv aldehyde. m 
Coupling partner: p-methoxystyrene. n Coupling partner: N-phenylmaleimide. 
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A small amount of product 97 (12% yield) was isolated by preparatory TLC; and 
1H, 13C, and various 2D NMR results were promising. Key differences between the 
oxabicyclo[3.1.0]hexane starting material and the proposed product are the shifts in the 
two doublets representing C6 (1.7 & 2.6 ppm in the starting material, 2.8 & 3.4 ppm in the 
product) and the shifts in the two doublets representing C4 (a pair of doublets at 4.4 ppm 
in the starting material, independent doublets at 4.5 & 4.6 ppm in the product) (Figure 4-2). 
Gratifyingly, high-resolution accurate-mass mass spectrometry gave a molecular ion peak 
that matched the expected mass. 
 
Figure 4-2: 1H NMR overlay for p-anisaldehyde, oxabicyclo[3.1.0]hexane starting material, and 
proposed product. 
Eager to validate these results, the Ga(OTf)3 test reaction was replicated and 
allowed to stir for 24 hours (entry 11). The same product was observed but conversion 
remained low (26% by q-NMR). Raising the temperature to 40°C allowed for a 27% 
isolated yield (entry 12), so a short temperature screen was conducted. Unfortunately, 
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refluxing in higher-boiling solvents such as THF, 1,2-DCE, and toluene (entries 16-18) 
afforded mostly degradation products. 
Instead, the Lewis acid screen initially performed at room temperature for 3 hours 
was repeated at reflux temperature and allowed to stir for up to 24 hours. The best 
performing Lewis acids so far, surprisingly, do not include Ga(OTf)3. Rather, Sc(OTf)3 
and In(OTf)3 (entries 15 & 21) both yielded 52% of desired product based on quantitative 
NMR (dimethylterephthalate, DMTP, as the internal standard). 
 At this stage, several more Lewis acids need to be evaluated for a comprehensive 
screen (entries 29-34), including FeCl3 and AlCl3, which have been employed in donor-
acceptor bicyclo[3.1.0]hexane ring-opening reactions in the literature,19 and Ca(NTf2)2/n-
Bu4NPF6, which has proven efficacious for a variety of Lewis acid-mediated chemistries 
since its publication.20 Then, several additional parameters such as catalyst loading, 
solvent, temperature, and concentration must be tested. One series of test reactions that has 
been pursued altered the loading of p-anisaldehyde (entries 24-26); increasing it did not 
improve yields, and decreasing it was a detriment, so the loading will remain at 3 
equivalents. 
Additionally, given the success with p-anisaldehyde (96), different dipolarophiles 
were evaluated for the formal [3+2] cycloaddition. Two different aromatic aldehydes, 
benzaldehyde and 2-naphthaldehyde (entries 22-23) were subjected to the Ga(OTf)3 
conditions, but NMR results were inclusive. Then, analogous p-methoxystyrene was tested 
as a suitable dipolarophile (entry 27); unfortunately, no desired product was detected. 
Finally, common cycloaddition partner N-phenylmaleimide was evaluated (entry 28), with 
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similar lack of success. Since the final optimized conditions have yet to be concretely 
established, these dipolarophiles will likely be revisited. 
To round out the study, a crystal is being grown to confirm the novel compound by 
X-ray analysis. Identification of this substrate would represent a significant advance in the 
field of DACP polar cycloadditions and rapid access to bridged bicyclic scaffolds.  
4.6 Summary 
In summary, an intramolecular Friedel-Crafts-type ring-opening cyclization of 
donor-acceptor C5-substituted bicyclo[3.1.0]hexanes was endeavored for the first time. 
Targeting tronocarpine for inspiration, an indole-tethered model system was successfully 
synthesized for Lewis acid screening; however, the desired bridged bicyclic scaffold was 
never detected. Several additional model syntheses were explored, including benzofuran-
tethered, decarbonylated, and ring-expanded donor-acceptor systems, as well as an 
intermolecular Friedel-Crafts-type addition, with limited or no success. For future work, 
the syntheses described require optimization to both complete the ring-opening cyclization 
model systems and prepare sufficient quantities for experimentation. 
In addition, an intermolecular formal [3+2] cycloaddition of a donor-acceptor C5-
substituted oxabicyclo[3.1.0]hexane was explored for the first time (Section 4.4). Efforts 
toward this end were more successful: inspired by Johnson’s work, a model system was 
rapidly synthesized and subjected to Lewis acid screening. Ga(OTf)3 initially appeared to 
be the preferred catalyst, but Sc(OTf)3 and In(OTf)3 outperformed this catalyst according 
to q-NMR, and further screening of conditions is underway. X-ray analysis of the isolated 
compound will be accomplished for proof of concept, and lessons learned from this 
pathway may be applied toward developing the intramolecular methodology. 
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4.7 Experimental Details 
4.7.1 General Information 
Chromatographic purification was performed via flash chromatography with 
Silicycle SiliaFlash P60 silica gel (40-63 µm) or preparative thin-layer chromatography 
(prep-TLC) with Analtech silica gel F254 (1000 µm) plates and solvents indicated as eluent 
with 0.1-0.5 bar pressure. For quantitative flash chromatography, technical grades solvents 
were utilized. Analytical thin-layer chromatography (TLC) was also used to separate and 
purify reaction products using Silicycle SiliaPlate TLC silica gel F254 (250 µm) TLC glass 
plates. Products on the TLC plates were visualized under UV light (254 nm).  
Proton, and carbon nuclear magnetic resonance spectra (1H NMR and 13C NMR, 
respectively) were recorded on a Bruker 500 MHz spectrometer. The solvent resonances 
were used the internal standards (1H NMR: CDCl3 at 7.26 ppm, DMSO-d6 at 3.50 ppm; 
13C NMR: CDCl3 at 77.0 ppm, DMSO-d6 at 39.5 ppm; 
19F NMR: locked to CDCl3 or 
DMSO-d6). MestReNova (v. 11.0) was used to analyze NMR spectra. 
1H NMR data are 
reported as follows: chemical shift (ppm), multiplicity (s = singlet, d = doublet, dd = 
doublet of doublets, dt = doublet of triplets, ddd = doublet of doublet of doublets, t = triplet, 
m = multiplet, br = broad), coupling constants (Hz), and integration. High-resolution 
accurate mass-mass spectrometry (HRAM-MS) was performed using a MicroMass 
Autospec M, run in EI mode at a mass resolution of 10,000 using perfluorokerosene (PFK) 
as an internal calibrant. 
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4.7.2 General Procedures 
General Mesylation-Bromination Procedure: In a flame-dried flask under N2, the 
alcohol (1 equiv) was dissolved in anhydrous THF (0.5 M) and cooled to -42°C. MsCl (1.5 
equiv) was added, followed by Et3N (2 equiv) over 5 minutes. The reaction mixture was 
allowed to stir for 30 minutes. In a separate flame-dried flask under N2, LiBr (4 equiv) was 
suspended in anhydrous THF (1 M) then slow-added to the mesylate solution via syringe 
pump over 15 minutes. The resulting slurry was stirred overnight and allowed to warm to 
room temperature. When complete, the slurry was poured into H2O, the aqueous layer was 
extracted with Et2O, and the combined organic extracts were washed with saturated 
aqeuous NaHCO3, dried over anhydrous Na2SO4, filtered through celite under reduced 
pressure, and concentrated by rotary evaporation. 
General Acetoacetate Addition Procedure: In a flame-dried flask under N2, NaH 
(1.5 equiv, 60% dispersion in mineral oil) was suspended in half the requisite volume of 
anhydrous THF (0.2 M) and cooled to 0°C. The acetoacetate (1 equiv) was added, the 
reaction was stirred for 15 minutes, then n-BuLi (1.5 equiv, 2.5 M/hexanes) was added 
slowly. After stirring for 15 minutes, the allyllic bromide (2 equiv) was dissolved in the 
remaining anhydrous THF and added via syringe to the reaction mixture over 10 minutes. 
After stirring for 1.5 hours, the reaction was quenched with saturated aqueous NH4Cl, the 
aqueous layer was extracted with Et2O, and the combined organic extracts were washed 
with H2O and brine, dried over anhydrous Na2SO4, filtered through celite under reduced 
pressure, and concentrated by rotary evaporation. The product was purified by silica flash 
chromatography. 
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General TsN3 Diazo Transfer Procedure: In a flame-dried flask under N2, the β-
ketoester (1 equiv) was dissolved in anhydrous MeCN (0.1 M). Et3N (1.5 equiv) was added, 
followed by TsN3 (1.2 equiv), and the reaction was allowed to stir overnight. The solution 
was concentrated by rotary evaporation directly onto silica and purified by flash 
chromatography. 
General Intramolecular Cyclopropanation Procedure: Rh2(esp)2 (0.5 mol%) was 
charged to a flame-dried flask under N2, suspended in half the requisite volume of 
anhydrous DCM (0.02 M), then the suspension was cooled to 0°C. In a separate flame-
dried flask under N2, the α-diazo-β-ketoester (1 equiv) was dissolved in the remaining 
anhydrous DCM and transferred to the Rh flask via syringe in one shot with stirring. After 
10 minutes, the solution was allowed to warm to room temperature. After 30 minutes, the 
reaction was quenched with saturated aqueous thiourea and stirred for an additional 30 
minutes. Then, the aqueous layer was extracted with DCM and the combined organic layers 
were washed with brine, dried over anhydrous Na2SO4, filtered through celite under 
reduced pressure, and concentrated by rotary evaporation. The product was purified by 
silica flash chromatography. 
General Saponification Procedure: The ester (1 equiv) was dissolved in MeOH (1 
M) with stirring, then the solution was warmed to 50°C. NaOH (1.2 equiv, 1.7 M/H2O) 
was added and the reaction mixture was stirred for 2 hours. Then, the reaction was allowed 
to cool to room temperature, and 1 M HCl was used to adjust the pH to 3. The aqueous 
layer was extracted with EtOAc and the combined organic extracts were dried over 
anhydrous Na2SO4, filtered through celite under reduced pressure, and concentrated by 
rotary evaporation. The product was purified by silica flash chromatography. 
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General Intramolecular Ring-Opening Cyclization Procedure: The Lewis acid (30 
mol%) was charged to a flame-dried flask under N2, then the bicyclo[3.1.0]hexane (1 
equiv) was added as a solution in anhydrous DCM (0.1 M). When complete by TLC or 
after 24 hours, the reaction mixture was quenched with H2O, the aqueous layer was 
extracted with DCM, and the combined organic extracts were dried over anhydrous 
MgSO4, filtered through celite under reduced pressure, and concentrated by rotary 
evaporation. The product was purified by silica flash chromatography or prep-TLC. 
General Intermolecular Formal [3+2] Cycloaddition Procedure: The Lewis acid 
(30 mol%) was charged to a flame-dried flask under N2, followed by p-anisaldehyde (3 
equiv). Then, the oxabicyclo[3.1.0]hexane (1 equiv) was added as a solution in anhydrous 
DCM (0.5 M). The reaction mixture was stirred at reflux for 24 h. After cooling to room 
temperature, the reaction mixture was quenched with H2O, the aqueous layer was extracted 
with DCM, and the combined organic extracts were dried over anhydrous MgSO4, filtered 
through celite under reduced pressure, and concentrated by rotary evaporation. Conversion 
was determined by quantitative NMR using DMTP as the internal standard, or the product 
was isolated by silica prep-TLC. 
General Reduction Procedure: LiAlH4 (3 or 4 equiv) was charged to a flame-dried 
flask under N2, then the carbonyl-containing starting material (1 equiv) was added in 
anhydrous THF (0.1 M). After stirring overnight, the reaction mixture was quenched with 
1 M HCl, the aqueous layer was extracted with Et2O, and the combined organic extracts 
were washed with saturated aqueous NaHCO3, dried over anhydrous Na2SO4, filtered 
through celite under reduced pressure, and concentrated by rotary evaporation. 
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4.7.3 Experimental Procedures 
4.7.3.1 Procedures for the First Indole-tethered Model System 
2-(((tert-Butyldiphenylsilyl)oxy)methyl)prop-2-en-1-ol (55a). Following the 
published procedure:21 In a flame-dried flask under N2, NaH (228 mg, 5.67 mmol, 60% 
dispersion in mineral oil) was suspended in 68 mL of anhydrous THF and cooled to 0°C. 
2-Methylene-1,3-propanediol (500 mg, 5.67 mmol) was added dropwise, then the solution 
was allowed to warm to room temperature and stirred for 45 minutes. TBDPSCl (1.568 g, 
5.67 mmol) was added and the mixture stirred for an additional hour. The reaction was 
quenched with H2O, the aqueous layer extracted with EtOAc, and the combined organic 
extracts washed with brine, dried over anhydrous MgSO4, filtered through celite under 
reduced pressure, and concentrated by rotary evaporation. After purification by silica flash 
chromatography (25% EtOAc/hexanes, Rf = 0.46), compound 55a was afforded as a thick, 
colorless oil (1.550 g, 84% yield). NMR data were consistent with previously reported 
results. 
Methyl 6-(((tert-Butyldiphenylsilyl)oxy)methyl)-3-oxohept-6-enoate (57a). The 
general mesylation-bromination and general acetoacetate addition procedures were 
followed using 55a (1.123 g, 3.44 mmol), MsCl (0.4 mL, 5.16 mmol), and Et3N (1 mL, 
6.88 mmol) in 7 mL of anhydrous THF, LiBr (1.195 g, 13.76 mmol) in 14 mL of anhydrous 
THF, then methyl acetoacetate (200 mg, 1.72 mmol), NaH (103 mg, 2.58 mmol), and n-
BuLi (1.2 mL, 2.58 mmol, 2.5 M/hexanes) in 9 mL of anhydrous THF. After purification 
by silica flash chromatography (25% EtOAc/hexanes, Rf = 0.57), compound 57a was 
afforded as a viscous, light yellow oil (445.4 mg, 71% yield). 1H NMR (300 MHz, CDCl3) 
δ 7.71 (dd, J = 7.7, 1.8 Hz, 4H), 7.49 – 7.37 (m, 6H), 5.21 (s, 1H), 4.88 (d, J = 1.3 Hz, 1H), 
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4.14 (s, 2H), 3.73 (d, J = 0.5 Hz, 3H), 3.44 (s, 2H), 2.72 – 2.65 (m, 2H), 2.33 (t, J = 7.4 Hz, 
2H), 1.10 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 201.71, 167.41, 146.32, 135.41, 133.34, 
129.62, 129.60, 127.64, 127.61, 109.45, 66.36, 52.22, 48.83, 41.14, 26.72, 26.09, 19.16. 
Methyl 2-Diazo-3-Oxobutanoate (60). The general TsN3 diazo transfer procedure 
was followed using methyl acetoacetate (1 g, 8.61 mmol), TsN3 (1.5 mL, 10.33 mmol), and 
Et3N (1.8 mL, 12.9 mmol) in 48 mL of anhydrous MeCN. After purification by silica flash 
chromatography (25% EtOAc/hexanes), compound 60 was afforded as a yellow solid 
(945.3 mg, 77% yield). NMR data were consistent with previously reported results.22 
Methyl 6-(((tert-Butyldiphenylsilyl)oxy)methyl)-2-diazo-3-oxohept-6-enoate (52a). 
The general TsN3 diazo transfer procedure was followed using 57a (2.183 g, 6.04 mmol), 
TsN3 (1.1 mL, 7.24 mmol), and Et3N (1.3 mL, 9.06 mmol) in 60 mL of anhydrous MeCN. 
After purification by silica flash chromatography (25% EtOAc/hexanes, Rf = 0.64), 
compound 52a was afforded as a viscous, light yellow oil (2.226 g, 95% yield). 1H NMR 
(300 MHz, CDCl3) δ 7.73 – 7.66 (m, 4H), 7.44 – 7.35 (m, 6H), 5.21 (s, 1H), 4.92 (s, 1H), 
4.15 (s, 2H), 3.83 (s, 3H), 3.05 – 2.97 (m, 2H), 2.36 (t, J = 7.6 Hz, 2H), 1.08 (s, 9H). 13C 
NMR (75 MHz, cdcl3) δ 191.86, 161.64, 146.67, 135.47, 133.51, 129.58, 127.64, 127.61, 
127.57, 109.22, 66.39, 52.12, 38.38, 26.76, 19.23. 
Methyl 5-(((tert-Butyldiphenylsilyl)oxy)methyl)-2-oxobicyclo[3.1.0]hexane-1-
carboxylate (51a). The general intramolecular cyclopropanation procedure was followed 
using 52a (2.226 g, 5.74 mmol) and Rh2(esp)2 (21.8 mg, 0.0287 mmol) in 287 mL of 
anhydrous DCM. After purification by silica flash chromatography (25% EtOAc/hexanes, 
Rf = 0.43), compound 51a was afforded as an off-white solid (1.844 g, 89% yield). 
1H 
NMR (300 MHz, CDCl3) δ 7.66 – 7.57 (m, 4H), 7.47 – 7.35 (m, 6H), 3.95 (d, J = 11.4 Hz, 
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1H), 3.74 (s, 3H), 3.73 (d, 1H), 2.45 (dd, J = 21.5, 10.2 Hz, 1H), 2.35 – 2.15 (m, 2H), 2.05 
– 1.90 (m, 2H), 1.43 (d, J = 5.2 Hz, 1H), 1.03 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 207.68, 
167.82, 135.54, 135.49, 133.15, 133.01, 129.80, 129.79, 127.74, 127.72, 63.67, 52.52, 
46.29, 42.43, 33.99, 26.69, 23.77, 23.37, 19.30. 
5-(((tert-Butyldiphenylsilyl)oxy)methyl)-2-oxobicyclo[3.1.0]hexane-1-carboxylic 
Acid (58a). The general saponification procedure was followed using 51a (500 mg, 1.39 
mmol) and NaOH (1 mL, 1.67 mmol, 1.7 M/H2O) in 1.4 mL of MeOH. After purification 
by silica flash chromatography (10% MeOH/DCM, Rf = 0.65), compound 58a was 
afforded as a white solid (333.9 mg, 70% yield). 1H NMR (500 MHz, CDCl3) δ 7.67 – 7.61 
(m, 4H), 7.46 – 7.37 (m, 6H), 4.13 (d, J = 11.4 Hz, 1H), 4.05 (d, J = 11.4 Hz, 1H), 2.54 – 
2.31 (m, 3H), 2.20 (d, J = 4.7 Hz, 1H), 2.09 (ddd, J = 12.4, 8.0, 2.0 Hz, 1H), 1.83 (d, J = 
4.7 Hz, 1H), 1.04 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 215.57, 167.76, 135.64, 135.55, 
133.32, 132.78, 129.83, 129.79, 127.74, 62.68, 49.89, 40.53, 32.61, 29.90, 26.77, 23.42, 
19.32. 
5-(((tert-Butyldiphenylsilyl)oxy)methyl)-1-(3-methyl-1H-indole-1-
carbonyl)bicyclo[3.1.0]hexan-2-one (50a). Following the published procedure:23 In a 
flame-dried flask under N2, 58a (50 mg, 0.145 mmol) was dissolved in 0.8 mL of 
andrydrous DCM. Mukaiyama’s reagent (44.5 mg, 0.174 mmol) and 3-methylindole 
(104.7 mg, 0.789 mmol) were subsequently added, then the reaction mixture was stirred at 
reflux for 1 hour. After cooling the mixture to room temperature, Et3N (0.04 mL, 0.305 
mmol) was added and the mixture stirred at reflux overnight. Then, the mixture was cooled 
to room temperature and poured into H2O. The aqueous layer was extracted with DCM, 
then the combined organic layers were dried over anhydrous Na2SO4, filtered through celite 
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under reduced pressure, and concentrated by rotary evaporation. After purification by silica 
flash chromatography (25% EtOAc/hexanes, Rf = 0.46), compound 50a was afforded as a 
yellow, foamy solid (26.2 mg, 39% yield). 1H NMR (500 MHz, CD2Cl2) δ 8.43 (d, J = 8.0 
Hz, 1H), 7.52 (ddd, J = 7.4, 1.4, 0.7 Hz, 1H), 7.42 – 7.28 (m, 8H), 7.22 (t, J = 7.6 Hz, 2H), 
7.13 – 7.08 (m, 2H), 6.93 (s, 1H), 4.01 (d, J = 11.7 Hz, 1H), 3.64 (d, J = 11.7 Hz, 1H), 2.58 
– 2.40 (m, 3H), 2.20 (d, J = 1.3 Hz, 3H), 2.18 – 2.11 (m, 2H), 1.56 (d, J = 5.2 Hz, 1H), 
0.87 (s, 9H). 13C NMR (126 MHz, CD2Cl2) δ 209.37, 165.11, 136.40, 136.04, 135.86, 
133.08, 132.98, 132.24, 130.28, 130.18, 128.20, 128.15, 125.57, 124.24, 123.48, 119.35, 
118.91, 117.15, 63.82, 47.74, 45.31, 33.89, 26.90, 24.09, 20.78, 19.39, 10.09. 
4.7.3.2 Procedures for the Second Indole-tethered Model System 
2-Phenylprop-2-en-1-ol (55b). Following the published Gilman procedure:9 In a 
flame-dried flask under N2, propargyl alcohol (500 mg, 8.92 mmol) and CuI (850 mg, 4.46 
mmol) were suspended in 12 mL of anhydrous toluene. After cooling the suspension to -
78°C, PhMgBr (27 mL, 26.8 mmol, 1 M/THF) was added dropwise via syringe pump. The 
reaction mixture was allowed to warm slowly to room temperature and stirred overnight. 
After checking progress of reaction by TLC, the reaction mixture was cooled to 0°C and 
quenched with saturated aqueous NH4Cl. The aqueous layer was extracted with Et2O, then 
the combined organic extracts were dried over anhydrous Na2SO4, filtered through celite 
under reduced pressure, and concentrated by rotary evaporation. After purification by silica 
flash chromatography (25% EtOAc/hexanes, Rf = 0.38), compound 55b was afforded as a 
thick colorless oil (957.5 mg, 80% yield). NMR data were consistent with previously 
reported results. 
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Methyl 3-Oxo-6-phenylhept-6-enoate (57b). The general mesylation-bromination 
and general acetoacetate addition procedures were followed using 55b (756.5 mg, 5.64 
mmol), MsCl (0.65 mL, 8.46 mmol), and Et3N (1.6 mL, 11.3 mmol) in 11 mL of anhydrous 
THF, LiBr (1.958 g, 22.6 mmol) in 23 mL of anhydrous THF, then methyl acetoacetate 
(327 mg, 2.82 mmol), NaH (169.1 mg, 4.23 mmol), and n-BuLi (1.7 mL, 4.23 mmol, 2.5 
M/hexanes) in 14 mL of anhydrous THF. After purification by silica flash chromatography 
(25% EtOAc/hexanes, Rf = 0.48), compound 57b was afforded as a thin yellow oil (655.1 
mg, 69% yield). 1H NMR (500 MHz, CDCl3) δ 7.41 – 7.36 (m, 1H), 7.36 – 7.31 (m, 1H), 
7.30 – 7.26 (m, 1H), 3.72 (s, 1H), 3.42 (s, 1H), 2.85 – 2.80 (m, 1H), 2.70 (dd, J = 8.4, 6.4 
Hz, 1H). 
 Methyl 2-Diazo-3-oxo-6-phenylhept-6-enoate (52b). The general TsN3 diazo 
transfer procedure was followed using 57b (1.098 g, 4.73 mmol), TsN3 (0.9 mL, 5.67 
mmol), and Et3N (1.0 mL, 7.09 mmol) in 48 mL of anhydrous MeCN. After purification 
by silica flash chromatography (25% EtOAc/hexanes, Rf = 0.55), compound 52b was 
afforded as an off-white, chalky solid (1.187 g, 97% yield). 1H NMR (500 MHz, CDCl3) δ 
7.43 – 7.40 (m, 2H), 7.35 – 7.30 (m, 2H), 7.29 – 7.26 (m, 1H), 5.32 (s, 1H), 5.11 (s, 1H), 
3.80 (s, 3H), 3.06 – 3.00 (m, 2H), 2.89 – 2.83 (m, 2H). 
Methyl 2-Oxo-5-phenylbicyclo[3.1.0]hexane-1-carboxylate (51b). The general 
intramolecular cyclopropanation procedure was followed using 52b (100 mg, 0.387 mmol) 
and Rh2(esp)2 (1.5 mg, 1.94 μmol) in 19 mL of anhydrous DCM. After purification by 
silica flash chromatography (25% EtOAc/hexanes, Rf = 0.75), compound 52b was afforded 
as an off-white solid (70.4 mg, 89% yield). 1H NMR (500 MHz, CD2Cl2) δ 7.35 (d, J = 4.2 
Hz, 4H), 7.33 – 7.28 (m, 1H), 3.47 (s, 3H), 2.50 (d, J = 5.2 Hz, 1H), 2.42 – 2.33 (m, 4H), 
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1.75 (d, J = 5.2 Hz, 1H). 13C NMR (126 MHz, CD2Cl2) δ 206.80, 166.72, 138.65, 128.79, 
128.57, 127.92, 51.99, 48.19, 45.77, 34.49, 30.44, 23.27. 
2-Oxo-5-phenylbicyclo[3.1.0]hexane-1-carboxylic Acid (58b). The general 
saponification procedure was followed using 51b (456 mg, 1.98 mmol) and NaOH (1.4 
mL, 2.38 mmol, 1.7 M/H2O) in 2 mL of MeOH. After purification by silica flash 
chromatography (10% MeOH/DCM, Rf = 0.35), compound 58b was afforded as an off-
white foam (428.2 mg, 96% yield). 1H NMR (500 MHz, CDCl3) δ 7.39 – 7.29 (m, 5H), 
2.79 (d, J = 4.6 Hz, 1H), 2.57 – 2.49 (m, 2H), 2.45 (dd, J = 10.6, 4.0 Hz, 2H), 2.15 (d, J = 
4.6 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 214.58, 166.24, 136.84, 128.97, 128.76, 
128.50, 52.56, 43.72, 33.40, 30.34, 29.41. 
4.7.3.3 Procedures for the Third Indole-tethered Model System 
1-(3-Methyl-1H-indol-1-yl)ethan-1-one (63). In a flame-dried flask under N2, 3-
methylindole (100 mg, 0.762 mmol) and n-Bu4NHSO4 (25.9 mg, 0.0762 mmol) were 
dissolved in 1.9 mL of anhydrous DCM. Powdered NaOH (76.2 mg, 1.91 mmol) was 
added, then acetyl chloride (0.08 mL, 1.14 mmol) was added as a solution in 1.2 mL of 
anhydrous DCM. After 2.5 hours, the reaction mixture was concentrated by rotary 
evaporation directly onto silica. After purification by silica flash chromatography (25% 
EtOAc/hexanes), compound 63 was afforded (116.4 mg, 88% yield). NMR data were 
consistent with previously reported results.24 
1-(3-Methyl-1H-indol-1-yl)butane-1,3-dione (67). In a flame-dried flask under N2, 
2,2,6-trimethyl-4H-1,3-dioxin-4-one (2 g, 14.1 mmol) and 3-methylindole (1.846 g, 14.1 
mmol) were dissolved in 56 mL of anhydrous toluene and the solution heated to reflux 
overnight. Then, after cooling to room temperature, the reaction mixture was concentrated 
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by rotary evaporation directly onto silica. After purification by silica flash chromatography 
(25% EtOAc/hexanes, Rf = 0.46), compound 67 was afforded in a 1.5:1 keto-enol mixture 
as a viscous orange oil (3.029 g, 88% yield). 1H NMR (500 MHz, CDCl3) δ 14.05 (s, 1H), 
8.45 (d, J = 8.2 Hz, 2H), 7.50 (d, J = 7.7 Hz, 3H), 7.40 – 7.27 (m, 5H), 7.22 – 7.19 (m, 
1H), 7.09 (s, 1H), 5.66 (s, 1H), 3.99 (s, 3H), 2.37 (s, 4H), 2.28 (dd, J = 7.5, 1.3 Hz, 8H), 
2.11 (s, 3H). 
6-Methyl-1-(3-methyl-1H-indol-1-yl)hept-6-ene-1,3-dione (68). In a flame-dried 
flask under N2, 67 (100 mg, 0.465 mmol) and methallyl bromide (0.07 mL, 0.698 mmol) 
were dissolved in 4.7 mL of anhydrous THF. After cooling the solution to -15°C (with an 
ethylene glycol/dry ice bath), LHMDS (1.2 mL, 1.16 mmol, 1 M/THF) was slow-added 
via syringe pump over 10 minutes. After 6 hours, the reaction mixture was quenched with 
saturated aqueous NH4Cl and allowed to warm to room temperature. The aqueous layer 
was extracted with Et2O, then the combined organic extracts were washed with H2O and 
brine, dried over anhydrous Na2SO4, filtered through celite under reduced pressure, and 
concentrated by rotary evaporation. After purification by silica flash chromatography (25% 
Et2O/hexanes, Rf = 0.48), compound 68 was afforded in an 8:1 keto-enol mixture as a light 
orange oil (73.8 mg, 59% yield). 1H NMR (500 MHz, CDCl3) δ 8.44 (d, J = 8.1 Hz, 1H), 
7.50 (ddd, J = 7.6, 1.3, 0.7 Hz, 1H), 7.37 (td, J = 8.3, 7.9, 1.3 Hz, 1H), 7.32 (td, J = 7.5, 
1.1 Hz, 1H), 7.11 (s, 1H), 4.74 (s, 1H), 4.67 (s, 1H), 4.01 (s, 2H), 2.84 – 2.79 (m, 2H), 2.35 
(t, J = 7.5 Hz, 2H), 2.27 (d, J = 1.3 Hz, 3H), 1.73 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 
202.36, 164.34, 143.85, 125.46, 123.96, 121.76, 119.57, 118.93, 116.70, 110.57, 51.76, 
41.15, 31.11, 22.61, 9.73. 
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2-Diazo-1-(3-methyl-1H-indol-1-yl)butane-1,3-dione (70). The general TsN3 diazo 
transfer procedure was followed using 67 (670 mg, 2.78 mmol), TsN3 (0.51 mL, 3.33 
mmol), and Et3N (0.58 mL, 4.16 mmol) in 28 mL of anhydrous MeCN. After purification 
by silica flash chromatography (25% EtOAc/hexanes), compound 70 was afforded (741.8 
mg, 99% yield). 1H NMR (500 MHz, CDCl3) δ 8.06 (d, J = 8.2 Hz, 1H), 7.54 (d, J = 7.8 
Hz, 1H), 7.41 – 7.36 (m, 1H), 7.32 (td, J = 7.5, 1.1 Hz, 1H), 7.10 (d, J = 1.3 Hz, 1H), 2.52 
(s, 3H), 2.30 (d, J = 1.3 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 190.06, 158.15, 135.59, 
131.49, 125.33, 123.82, 121.42, 119.33, 119.12, 115.12, 28.18, 9.73. 
 2-Diazo-6-methyl-1-(3-methyl-1H-indol-1-yl)hept-6-ene-1,3-dione (66a). The 
general TsN3 diazo transfer procedure was followed using 68 (70.5 mg, 0.262 mmol), TsN3 
(0.05 mL, 0.314 mmol), and Et3N (0.05 mL, 0.393 mmol) in 2.6 mL of anhydrous MeCN. 
After purification by silica flash chromatography (25% EtOAc/hexanes, Rf = 0.65), 
compound 66a was afforded as an orange solid (74.6 mg, 96% yield). 1H NMR (500 MHz, 
CDCl3) δ 8.05 (d, J = 8.2 Hz, 1H), 7.54 (d, J = 8.1 Hz, 1H), 7.38 (td, J = 8.3, 7.8, 1.2 Hz, 
1H), 7.32 (td, J = 7.5, 1.1 Hz, 1H), 7.09 (q, J = 1.3 Hz, 1H), 4.75 (d, J = 20.0 Hz, 2H), 3.04 
– 2.98 (m, 2H), 2.42 (t, J = 7.6 Hz, 2H), 2.30 (s, 3H), 1.76 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 192.33, 158.10, 144.02, 135.58, 131.50, 125.32, 123.80, 121.42, 119.34, 119.09, 
115.12, 110.72, 38.51, 32.13, 22.55, 9.74. 
5-Methyl-1-(3-methyl-1H-indole-1-carbonyl)bicyclo[3.1.0]hexan-2-one (50c). 
The general intramolecular cyclopropanation procedure was followed using 66a (300 mg, 
1.02 mmol) and Rh2(esp)2 (3.9 mg, 5.08 μmol) in 51 mL of anhydrous DCM. After 
purification by silica flash chromatography (25% EtOAc/hexanes, Rf = 0.29), compound 
50c was afforded as a light orange solid (255.8 mg, 94% yield). 1H NMR (500 MHz, 
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CDCl3) δ 8.43 (d, J = 8.1 Hz, 1H), 7.49 (ddd, J = 7.6, 1.2, 0.7 Hz, 1H), 7.36 (td, J = 8.3, 
7.8, 1.3 Hz, 1H), 7.31 (td, J = 7.5, 1.1 Hz, 1H), 6.80 (s, 1H), 2.38 (td, J = 9.5, 8.8, 2.0 Hz, 
2H), 2.27 (d, J = 1.3 Hz, 4H), 2.25 – 2.19 (m, 1H), 1.93 (d, J = 5.1 Hz, 1H), 1.63 (d, J = 
5.2 Hz, 1H), 1.40 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 208.92, 164.69, 135.80, 131.53, 
125.15, 123.72, 121.99, 118.75, 118.73, 116.58, 48.00, 38.78, 33.66, 28.66, 24.59, 19.09, 
9.80. 
4.7.3.4 Procedures for the Benzofuran-tethered Model System 
2-Phenylallyl Acetate (72). Following the published procedure:25 In a flame-dried 
flask under N2, 55b (500 mg, 3.73 mmol) was dissolved in 19 mL of anhydrous DCM. The 
solution was cooled to 0°C, then DIPEA (0.8 mL, 4.47 mmol), DMAP (45.5 mg, 0.373 
mmol), and Ac2O (0.42 mL, 4.47 mmol) were added in sequence. After stirring for 30 
minutes, the reaction mixture was quenched with 1% HCl, the aqueous layers were 
extracted with DCM, and the combined organic extracts were washed with brine, dried 
over anhydrous Na2SO4, filtered through celite under reduced pressure, and concentrated 
by rotary evaporation. Compound 72 was afforded without further purification (25% 
EtOAc/hexanes, Rf = 0.69) as a slightly viscous light yellow liquid (586.4 mg, 89% yield). 
NMR data were consistent with previously reported results. 
2-Phenylallyl 3-(Benzofuran-2-yl)-3-oxopropanoate (73). In a flame-dried flask 
under N2, benzofuran-2-carboxylic acid (503.6 mg, 3.11 mmol) was dissolved in 6.2 mL 
of anhydrous DCM, then the solution was cooled to 0°C. Anhydrous DMF (4 drops) was 
added, then the flask was equipped with an empty N2-flushed balloon to vent any HCl 
vapors. (COCl)2 (0.32 mL, 3.73 mmol) was added slowly. After 15 minutes, the reaction 
mixture was allowed to warm to room temperature and stirred for 3 hours. The resulting 
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clear solution was then concentrated by rotary evaporation. Then, in a separate flame-dried 
flask under N2, 72 (574.6 mg, 3.26 mmol) was dissolved in 1.6 mL of anhydrous THF. The 
solution was cooled to -78°C, then LHMDS (6.5 mL, 6.52 mmol, 1M/THF) was added 
dropwise and the solution stirred for 45 minutes. The prepared benzofuran-2-carboxylic 
acid chloride was dissolved in 1.7 mL of anhydrous THF and added via syringe to the 
acetate solution, which was stirred for an additional 30 minutes. The reaction mixture was 
quenched with saturated aqueous NH4Cl, the aqueous layers extracted with EtOAc, and the 
combined organic extracts dried over anhydrous Na2SO4, filtered through celite under 
reduced pressure, and concentrated by rotary evaporation. After purification by silica flash 
chromatography (5% EtOAc/hexanes, Rf = 0.26), compound 73 was afforded in a 10:1 
enol-keto mixture as an off-white solid (644.3 mg, 65% yield). 1H NMR (500 MHz, CDCl3) 
δ 11.99 (s, 1H), 7.64 (d, J = 7.8 Hz, 1H), 7.50 – 7.45 (m, 3H), 7.38 (td, J = 7.4, 1.5 Hz, 
3H), 7.35 – 7.32 (m, 1H), 7.31 (d, J = 3.7 Hz, 1H), 7.29 – 7.26 (m, 1H), 5.91 (s, 1H), 5.60 
(s, 1H), 5.45 – 5.41 (m, 1H), 5.16 – 5.12 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 162.06, 
155.41, 142.27, 128.54, 128.14, 126.62, 126.00, 123.53, 122.23, 115.50, 111.59, 108.90, 
88.43, 65.69. 
2-Phenylallyl 3-(Benzofuran-2-yl)-2-diazo-3-oxopropanoate (74). In a flame-dried 
flask under N2, 73 (639.7 mg, 2.00 mmol) was dissolved in 4 mL of anhydrous MeCN, 
then Et3N (0.33 mL, 2.40 mmol) was added. After cooling the solution to 0°C, p-ABSA 
(2.20 mmol) was added. The reaction mixture was allowed to warm to room temperature 
and stirred overnight. Then, the reaction mixture was filtered through celite under reduced 
pressure and concentrated by rotary evaporation directly onto silica. After purification by 
silica flash chromatography (25% EtOAc/hexanes, Rf = 0.52), compound 74 was afforded 
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as a yellow solid (660.9 mg, 95% yield). 1H NMR (500 MHz, CDCl3) δ 7.81 (s, 1H), 7.70 
(d, J = 7.9 Hz, 1H), 7.55 (d, J = 9.1 Hz, 1H), 7.50 – 7.45 (m, 1H), 7.43 (dd, J = 8.2, 1.4 Hz, 
2H), 7.39 – 7.29 (m, 4H), 5.60 (s, 1H), 5.43 (s, 1H), 5.21 (s, 2H). 
1-(Benzofuran-2-carbonyl)-5-phenyl-3-oxabicyclo[3.1.0]hexan-2-one (75). The 
general intramolecular cyclopropanation procedure was followed using 74 (655.2 mg, 1.89 
mmol) and Rh2(esp)2 (7.2 mg, 9.45 μmol) in 94 mL of anhydrous DCM. After purification 
by silica flash chromatography (25% EtOAc/hexanes, Rf = 0.35), compound 75 was 
afforded as a yellow solid (363.0 mg, 60% yield). 1H NMR (500 MHz, CDCl3) δ 7.71 (d, 
J = 7.9 Hz, 1H), 7.63 (d, J = 9.3 Hz, 1H), 7.55 – 7.50 (m, 2H), 7.36 – 7.31 (m, 1H), 7.28 
(dd, J = 7.2, 2.5 Hz, 2H), 7.23 (dd, J = 5.1, 2.0 Hz, 3H), 4.83 (d, J = 10.5 Hz, 1H), 4.59 (d, 
J = 9.8 Hz, 1H), 2.91 (d, J = 5.2 Hz, 1H), 1.74 (d, J = 5.1 Hz, 1H). 13C NMR (126 MHz, 
CDCl3) δ 179.55, 172.58, 155.62, 151.97, 132.18, 129.18, 129.03, 129.00, 128.72, 126.94, 
124.18, 123.59, 114.29, 112.58, 73.75, 45.72, 42.40, 20.12. 
(Z)-3-(Benzofuran-2-yl(hydroxy)methylene)-5-phenyl-3,6-dihydro-2H-pyran-2-
one (76’). The general intramolecular ring-opening cyclization procedure was followed 
using Ga(OTf)3 (36.6 mg, 0.0708 mmol) and 1-(benzofuran-2-carbonyl)-5-phenyl-3-
oxabicyclo[3.1.0]hexan-2-one (75 mg, 0.236 mmol) in 1.2 mL of anhydrous DCM. After 
work-up, the product was afforded without further purification (25% EtOAc/hexanes, Rf = 
0.63) as an orange solid (61.3 mg, 81% yield). 1H NMR (500 MHz, CDCl3) δ 13.38 (s, 
1H), 7.80 (t, J = 1.4 Hz, 1H), 7.71 – 7.68 (m, 1H), 7.60 – 7.57 (m, 1H), 7.50 (d, J = 0.9 Hz, 
1H), 7.42 (q, J = 3.1 Hz, 5H), 7.37 – 7.31 (m, 2H), 5.46 (d, J = 1.5 Hz, 2H). 
  
 272 
4.7.3.5 Procedures for the Decarbonylated Model Systems 
1-(Hydroxymethyl)-5-phenylbicyclo[3.1.0]hexan-2-ol (77). The general reduction 
procedure was followed using 51b (500 mg, 2.17 mmol) and LiAlH4 (329.6 mg, 8.68 
mmol) in 22 mL of anhydrous THF. Compound 77 was afforded without further 
purification (10% MeOH/DCM, Rf = 0.42) in a 3:1 mixture of diastereomers as a white 
solid (276.2 mg, 62% yield). 1H NMR (500 MHz, CDCl3) δ 7.35 – 7.28 (m, 2H), 7.27 (d, 
J = 1.8 Hz, 1H), 7.25 (t, J = 1.5 Hz, 1H), 7.24 – 7.19 (m, 1H), 4.84 – 4.76 (m, 1H), 3.72 
(dd, J = 11.5, 4.0 Hz, 1H), 3.32 (dd, J = 11.5, 5.3 Hz, 1H), 2.17 (d, J = 4.1 Hz, 1H), 2.14 – 
1.99 (m, 3H), 1.63 (t, J = 5.1 Hz, 1H), 1.34 – 1.21 (m, 2H), 1.00 (d, J = 5.3 Hz, 1H). 13C 
NMR (126 MHz, CDCl3) δ 141.17, 129.23, 128.93, 128.49, 128.44, 126.68, 66.08, 39.27, 
37.42, 33.27, 29.26, 13.48. 
Benzofuran-2-ylmethanol (79). The general reduction procedure was followed 
using benzofuran-2-carboxylic acid (500 mg, 3.08 mmol) and LiAlH4 (351.1 mg, 9.25 
mmol) in 31 mL of anhydrous THF. After purification by silica flash chromatography (25% 
EtOAc/hexanes), compound 79 was afforded as a white solid (235.8 mg, 51% yield). NMR 
data were consistent with previously reported results.26 
2-(Bromomethyl)benzofuran (80). Following the published procedure:27 In a flame-
dried flask under N2, 79 (100 mg, 0.675 mmol) was dissolved in 2.7 mL of anhydrous THF. 
The solution was cooled to 0°C, then PBr3 (0.27 mL, 0.270 mmol, 1 M/DCM) was added 
dropwise. After stirring for 1 hour, the reaction was quenched with H2O, the aqueous layer 
extracted with DCM, and the combined organic extracts dried over anhydrous Na2SO4, 
filtered through celite under reduced pressure, and concentrated by rotary evaporation. 
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After purification by silica flash chromatography (25% EtOAc/hexanes, Rf = 0.77), 
compound 80 was afforded as an inseparable mixture with unreacted 79. 
4.7.3.6 Procedures for the Ring-Expanded Model System 
3-(3-Methyl-1H-indol-1-yl)-3-oxopropanoic Acid (85). In a flame-dried flask under 
N2, Meldrum’s acid (1 g, 6.94 mmol) and 3-methylindole (1.366 g, 10.4 mmol) were 
dissolved in 28 mL of anhydrous THF. The solution was stirred at reflux overnight. Then, 
after cooling to room temperature, the reaction mixture was concentrated by rotary 
evaporation directly onto silica. After purification by silica flash chromatography (10% 
MeOH/DCM, Rf = 0.18), compound 85 was afforded as an orange solid (938.3 mg, 62% 
yield). 1H NMR (500 MHz, CDCl3) δ 8.42 (s, 1H), 7.53 – 7.49 (m, 1H), 7.42 – 7.32 (m, 
2H), 7.10 (s, 1H), 3.98 (s, 2H), 3.49 (s, 1H), 2.29 (d, J = 1.4 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) δ 168.68, 165.28, 125.90, 124.48, 120.89, 120.70, 119.15, 50.83, 40.91, 9.76. 
3-Methylbut-3-en-1-yl 3-(3-Methyl-1H-indol-1-yl)-3-oxopropanoate (86). In a 
flame-dried flask under N2, 85 (100 mg, 0.460 mmol), 3-methyl-3-buten-1-ol (16.5 mg, 
0.192 mmol), and DMAP (2.3 mg, 0.0192 mmol) were dissolved in 1.3 mL of anhydrous 
DCM. Then, DCC (79.2 mg, 0.384 mmol) was added, and the reaction mixture was stirred 
at reflux for 90 minutes. The reaction mixture was allowed to cool to room temperature 
then filtered through a pad of celite under reduced pressure, using Et2O as the eluent. The 
filtrate was partitioned between Et2O and H2O, the aqueous layer was extracted with Et2O, 
and the combined organic extracts were washed with H2O and brine, dried over anhydrous 
MgSO4, filtered through celite under reduced pressure, and concentrated by rotary 
evaporation. After purification by silica flash chromatography (25% EtOAc/hexanes, Rf = 
0.52), compound 86 was afforded as an orange oil (36.2 mg, 66% yield). 1H NMR (500 
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MHz, CDCl3) δ 8.43 (s, 1H), 7.50 (d, J = 7.6 Hz, 1H), 7.39 – 7.28 (m, 3H), 7.14 (d, J = 
32.1 Hz, 1H), 4.71 (d, J = 24.8 Hz, 2H), 4.31 (t, J = 6.8 Hz, 2H), 3.91 (s, 2H), 2.59 (s, 1H), 
2.35 (t, J = 6.8 Hz, 2H), 2.28 (dd, J = 3.7, 1.3 Hz, 4H), 1.71 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 168.23, 166.30, 163.35, 141.05, 135.93, 131.45, 125.41, 125.09, 123.84, 123.31, 
122.15, 121.48, 119.40, 118.83, 118.75, 118.31, 116.67, 112.51, 63.88, 43.78, 36.44, 
22.25, 9.67, 9.64. 
4.7.3.7 Procedures for the Intermolecular Formal [3+2] Cycloaddition  
Methyl (2-Phenylallyl) Malonate (90). In a flame-dried flask under N2, 62 (1 g, 7.45 
mmol) was dissolved in 7.5 mL of anhydrous DCM. After cooling the solution to 0°C, 
Et3N (1.2 mL, 8.94 mmol) was added and the reaction was stirred for 15 minutes. Then, 
methyl malonyl chloride (1 mL, 8.94 mmol) was added slowly. The reaction mixture was 
allowed to warm to room temperature and stirred for an additional 30 minutes, then 
quenched with saturated aqueous NaHCO3. The aqueous layers were extracted with DCM 
and the combined organic extracts were washed with saturated aqueous NaHCO3 and brine, 
dried over anhydrous Na2SO4, filtered through celite under reduced pressure, and 
concentrated by rotary evaporation. Compound 90 was afforded without further 
purification (25% EtOAc/hexanes, Rf = 0.52) as a slightly viscous orange liquid (1.822 g, 
quant.). 1H NMR (500 MHz, CDCl3) δ 7.44 – 7.40 (m, 2H), 7.38 – 7.29 (m, 3H), 5.58 – 
5.56 (m, 1H), 5.39 (d, J = 0.9 Hz, 1H), 5.07 – 5.04 (m, 2H), 3.68 (s, 3H), 3.41 (s, 2H). 13C 
NMR (126 MHz, CDCl3) δ 166.73, 166.14, 141.84, 137.72, 128.47, 128.11, 125.93, 
115.79, 66.68, 52.46, 41.32. 
1-Methyl 3-(2-Phenylallyl) 2-Diazomalonate (91). The general TsN3 diazo transfer 
procedure was followed using 90 (200 mg, 0.757 mmol), TsN3 (0.14 mL, 0.908 mmol), 
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and Et3N (0.16 mL, 1.14 mmol) in 7.6 mL of anhydrous MeCN. After purification by silica 
flash chromatography (25% Et2O/hexanes, Rf = 0.22), compound 91 was afforded as a 
yellow solid (203.4 mg, 92% yield). 1H NMR (300 MHz, CDCl3) δ 7.45 – 7.40 (m, 2H), 
7.39 – 7.30 (m, 3H), 5.57 (d, J = 0.7 Hz, 1H), 5.41 (q, J = 1.3 Hz, 1H), 5.14 (dd, J = 1.3, 
0.6 Hz, 2H), 3.83 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 161.44, 160.55, 141.90, 137.70, 
128.51, 128.14, 125.95, 115.61, 66.44, 52.56. 
Methyl 2-Oxo-5-phenyl-3-oxabicyclo[3.1.0]hexane-1-carboxylate (89). The 
general intramolecular cyclopropanation procedure was followed using 91 (1.657 g, 5.67 
mmol) and Rh2(esp)2 (21.5 mg, 0.0284 mmol) in 113 mL of anhydrous DCM. After 
purification by silica flash chromatography (25% EtOAc/hexanes, Rf = 0.27), compound 
89 was afforded as a white solid (1.160 g, 77% yield). 1H NMR (500 MHz, CDCl3) δ 7.40 
– 7.32 (m, 5H), 4.47 (dd, J = 9.7, 0.8 Hz, 1H), 4.42 (d, J = 9.7 Hz, 1H), 3.60 (s, 3H), 2.61 
(d, J = 5.0 Hz, 1H), 1.72 (d, J = 5.1 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 170.94, 164.89, 
133.02, 129.23, 129.04, 73.21, 52.81, 43.85, 36.53, 22.59. 
Methyl (1R,5S)-7-(4-Methoxyphenyl)-2-oxo-5-phenyl-3,6-
dioxabicyclo[3.2.1]octane-1-carboxylate (97). The general intermolecular formal [3+2] 
cycloaddition procedure was followed using 89 (75 mg, 0.323 mmol), p-anisaldehyde (0.12 
mL, 0.969 mmol), and Ga(OTf)3 (50.1 mg, 0.0969 mmol) in 0.6 mL of anhydrous DCM. 
After purification by silica prep-TLC (25% EtOAc/hexanes, Rf = 0.15), compound 97 was 
afforded as a white solid (9.5 mg, 12% yield). 1H NMR (500 MHz, CDCl3) δ 7.55 (d, J = 
8.5 Hz, 2H), 7.50 (dd, J = 8.3, 1.4 Hz, 2H), 7.40 (dt, J = 20.4, 6.7 Hz, 3H), 6.91 (d, J = 8.9 
Hz, 2H), 4.58 (dd, J = 11.7, 1.8 Hz, 1H), 4.50 (d, J = 11.6 Hz, 1H), 3.88 (s, 1H), 3.81 (d, J 
= 5.1 Hz, 6H), 3.18 (d, J = 11.9 Hz, 1H), 2.82 (dd, J = 11.9, 2.1 Hz, 1H). 13C NMR (126 
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MHz, CDCl3) δ 167.60, 165.57, 159.88, 137.48, 132.31, 128.81, 128.74, 128.04, 127.84, 
125.33, 113.76, 113.74, 84.23, 81.30, 79.89, 63.22, 55.20, 52.91, 41.07. HRAM-MS (EI) 
m/z [M+Na]+ Calcd for C21H20O6 391.1152; Found 391.1143. 
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CHAPTER 5. STEREOCHEMICAL IMPLICATIONS OF THE 
INTRAMOLECULAR FRIEDEL-CRAFTS-TYPE RING-
OPENING CYCLIZATION OF DONOR-ACCEPTOR C6-
SUBSTITUTED BICYCLO[3.1.0]HEXANES 
5.1 Recent Advances in C6-Substituted D-A Bicyclo[3.1.0]hexane Ring-opening 
Reactions 
Of the two classes of D-A bicyclo[3.1.0]hexanes described in Chapter 4, C6-
substituted bicyclo[3.1.0]hexanes are more prevalent in the synthetic methodology 
literature.1 Primary applications of this template and analogous scaffolds have been formal 
[3+2] cycloadditions with dipolarophiles (especially aldehydes), intramolecular ring 
expansions, and intermolecular ring-opening reactions to γ-butyrolactones. 
5.1.1 Formal [3+2] Cycloadditions 
Johnson presented one of the earliest examples of a formal [3+2] cycloaddition in 
this class, employing an analogous D-A bicyclo[4.1.0]heptanone and isobutyraldeyde as 
the dipolarophile (Scheme 5-1a).2 This study was shortly followed by the total synthesis of 
(+)-polyanthellin A, featuring this cycloaddition as the first key step (Scheme 5-1b).3 
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Scheme 5-1: (a) Johnson’s formal [3+2] cycladdition of a C6-substituted D-A 
bicyclo[4.1.0]heptanone. (b) Application in the total synthesis of (+)-polyanthellin A. 
In 2011, Johnson further showcased three examples of a D-A bicyclo[3.1.0]hexane 
formal [3+2] cycloaddition in the presence of catalytic Sn(OTf)2 (5 mol%) or SnCl4 (10 
mol%) (Scheme 5-2a).1a In the same year, Zhang published one example of this 
transformation with a C6-phenyl-substituted template, with high stereoselectivity (Scheme 
5-2b).1b Much more recently, in 2018, Yang reported a formal [3+2] cycloaddition of D-A 
bicyclo[3.1.0]hexanes with isothiocyanates and carbodiimides, which represent the first 
examples of employing coupling partners other than aldehydes in (Scheme 5-2c).1f This 
seminal work also represents one of the most efficient methods to date for this type of 
transformation, as they achieved 53 examples (92-99% yield) with inexpensive FeCl3 (2 
equiv) in room-temperature 1,2-DCE. 
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Scheme 5-2: (a) Johnson's formal [3+2] between C6-sub. D-A oxabicyclo[3.1.0]hexanes and 
aldehydes. (b) Zhang's formal [3+2] between a C6-sub. D-A oxabicyclo[3.1.0]hexane and 
benzaldehyde. (c) Yang’s formal [3+2] between D-A C6-sub. oxabicyclo[3.1.0]hexanes and 
isothiocyantes or carbodiimides. 
 It should be noted that Zhang and Yang both observed an inversion of 
stereochemistry at the donor site with the formal cycloaddition. This result supports a polar 
mechanism, which is consistent with Johnson’s earlier mechanistic findings.1a 
5.1.2 Intramolecular Ring-Expansions 
In 2013, Corey performed a narrow but in-depth study of DACPs contained within 
highly condensed, polycyclic frameworks and their corresponding intramolecular ring 
expansions in the presence of TMSOTf and H2O.
4 Of the small scope, two substrates 
explicitly examined the influence of a C6-donor on the ring expansions of 
(oxa)bicyclo[3.1.0]hexanes (Scheme 5-3). Significantly, the second example represents the 




Scheme 5-3: Corey’s TMSOTf-promoted ring-expansion of C6-sub. D-A (oxa)bicyclo[3.1.0]hexanes. 
5.1.3 Nishii’s Manipulations of the D-A Bicyclo[3.1.0]hexane Scaffold 
By 2016, studies toward the behavior of this DACP scaffold were beginning to take 
off, with Nishii leading the charge. Nishii first examined the Lewis acid-mediated oxy-
homo-Michael addition of alkyl and aryl alcohols onto enantioenriched D-A 
bicyclo[3.1.0]hexane templates to form γ-butyrolactones (Scheme 5-4a).5a Across 14 
examples, he observed exclusive preference for inversion of stereochemistry at the site of 
addition and a trans orientation of the α and β hydrogens on the resulting γ-butyrolactone, 
as well as excellent retention of enantiopurity. This work was quickly followed by the 
application of this nucleophilic addition to the total synthesis of tupichilignan A5b 
(effecting the key step in 83% yield with 95% ee), as well as the syntheses of several 7-
benzyloxy dibenzyl lignans lactones.5c Next, Nishii expanded the scope by testing Grignard 
additions onto this scaffold (Scheme 5-4b); across 10 examples (up to 94% yield), the same 
stereochemical outcomes were favored.5d Finally, he explored the effect of hydrogenolysis 
(Scheme 5-4c); across 7 examples (up to 97% yield), he again observed a trans-α,β 
orientation of the γ-butyrolactone.5e 
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Scheme 5-4: Nishii's synthetic studies toward C6-sub. oxabicyclo[3.1.0]hexane ring-opening 
reactions. (a) Nucleophilic addition by alcohols. (b) Grignard addition. (c) Hydrogenolysis. 
5.2 Opportunity for an Intramolecular Friedel-Crafts-type Ring-opening 
Cyclization of C6-Substituted D-A Bicyclo[3.1.0]hexanes 
Despite recent advances in ring-opening chemistries for this scaffold, 
intramolecular transformations, such Friedel-Crafts-type ring-opening cyclizations, have 
not been demonstrated from these synthetic precursors (for the proposed pathway, see 
Chapter 4). Unlike their C5-substituted analogues, C6-substituted D-A 
bicyclo[3.1.0]hexanes may be reasonably expected to undergo much more expedient 
intramolecular ring-opening cyclizations due to more sterically accessible secondary 
carbocation intermediates and increased flexibility in the resulting fused bicyclic scaffolds. 
In 2016, Shenje and France envisioned a synthetic strategy for the total synthesis 
of propolisbenzofuran B that employed benzofuran-tethered, C6-substituted D-A 
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oxabicyclo[3.1.0]hexane 98 (Scheme 5-5).6 As shown from the abbreviated retrosynthetic 
analysis of truncated model 99, this DACP would enable a ring-opening cyclization to 
install the desired tetracycle 100 with trans diastereoselectivity, and subsequent 
functionalizations would open the lactone and afford the final target. 
 
Scheme 5-5: Abbreviated retrosynthetic analysis to truncated model of propolisbenzofuran B. 
5.2.1 Previous Literature Regarding Diastereoselectivity 
Although this ring-opening cyclization chemistry has not been previously studied, 
literature for traditional (i.e. non-tethered) DACPs strongly suggests that the intramolecular 
ring-opening cyclization adduct of a 1,2-disubstituted DACP will possess a trans 
configuration. Waser’s seminal report on the catalytic homo-Nazarov cyclization of 
cyclopropyl vinyl ketones supported a polar, stepwise mechanism in which the rate-
limiting step was the ring-opening of the cyclopropane, generating a carbocation that could 
subsequently be trapped.7 (This is in harmony with Johnson’s mechanistic studies for 
intermolecular formal [3+2] cycloadditions of DACPs, which reached the same 
conclusion.) The implications of this mechanism are significant, as any stereochemical 
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information built into the template would be lost with the formation of the carbocation, and 
the thermodynamic product, most likely trans, would be favored. A pericyclic mechanism, 
in contrast, would be expected to retain stereochemistry. 
To date, the only two literature examples of an intramolecular ring-opening 
cyclization resulting in a cis-substituted adduct are from the France group. First, in 2011, 
thiophene-tethered DACP 101 containing a 1,2-indanyl donor group successfully 
underwent a Friedel-Crafts-type ring-opening cyclization to afford the 1,2-cis adduct 102 
as a single diastereomer in 87% yield (Scheme 5-6a).8 Then, in 2016, cyclopropyl carbinol 
103 (also containing a 1,2-indanyl donor) was evaluated, to also afford the 1,2-cis adduct 
104 (Scheme 5-6b).9 The stereochemical outcome is not at odds with Waser’s findings: 
although carbocation formation scrambles previous stereoinduction, in this case, the trans 
isomer would cause unwanted strain on the system, therefore the cis isomer is preferred. 
 
Scheme 5-6: Literature precedent for cis diastereoselectivity. (a) France’s 1,2-indanyl DACP 
intramolecular ring-opening cylization. (b) France’s 1,2-indanyl cyclopropyl carbinol intramolecular 
ring-opening cyclization. 
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Since Shenje’s original hypothesis, further studies by Nishii have supported the 
formation of a trans-1,2-disubstituted ring-opening cyclization adduct regardless of the 
stereochemistry of the DACP precursor. In his 2017 article,10 Nishii synthesized a variety 
of enantioenriched and racemic 1,2-cis- and -trans-disubstituted DACPs, then observed the 
stereochemical outcomes of the corresponding intramolecular ring-opening cyclizations 
(Scheme 5-7). (A parallel study was conducted on analogous cyclopropyl carbinols.)5c In 
every case, the trans adduct formed preferentially relative to the stereochemistry of the 2-
subsituent, which is unaffected by the adjacent carbocation formation. These results led 
Nishii to conclude that the polar, stepwise, Friedel-Crafts-type mechanism was in fact the 
mode of action for this transformation. 
 
Scheme 5-7: Nishii's ring-opening cyclization of enantioenriched and racemic DACPs to trans 
adducts. 
5.2.2 Shenje’s Observed Stereochemical Outcome 
Surprisingly, and contrary to the proposed retrosynthetic analysis, preliminary 
results exhibited formation of a single diastereomer in a cis configuration at the point of 
ring fusion (epi-100, Scheme 5-8).6 Though this outcome would render the synthesis of 
propolisbenzofuran B inviable by this route, this stereochemistry has not been observed in 
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previous DACP ring-opening cyclizations and would thus serve as a complementary 
methodology. Additionally, it could open the door to mechanistic studies to better 
understand and predict the stereochemical outcome of intramolecular ring-opening 
cyclizations outside the influence of chiral Lewis acid catalysts. 
 
Scheme 5-8: Observed stereochemical outcome of model ring-opening cyclization. 
5.3 Further Examination of the cis-Exclusive Model Adduct 
5.3.1 Optimization of the Ring-opening Cyclization 
Desirous to probe this unique transformation further, my first objective was to 
prepare the model 98 and expand the Lewis acid screen (Table 5-1). Shenje surveyed 
several catalysts commonly employed for ring-opening cyclizations of DACPs (entries 1-
8) and found that 10 mol% Ca(NTf2)2/n-Bu4NPF6
11 gave the best yield at 63%. A short but 
thorough solvent and concentration screen confirmed that his initial conditions of 
anhydrous DCM at 0.2 M concentration were optimal. Under these parameters, I set about 
surveying additional catalysts (entries 9-13). Surprisingly, three of the five Lewis acids 
added to this screen outperformed the Ca(NTf2)2 catalyst system, including Sn(OTf)2 
(Johnson’s preferred catalyst,2 entry 10) and In(OTf)3 (entry 13), which had previously 
been less successful. It is possible, based on the rapid reaction time for this transformation, 
that prolonged exposure to In(OTf)3 (i.e. longer than 2-3 hours) led to degradation of the 
 348 
ring-opening cyclization adduct after it formed (entry 2). Regardless, Ga(OTf)3 was the 
best-performing catalyst based on this screen (entry 9, 83% yield). 
Table 5-1: Lewis acid screen for ring-opening cyclization of 98. 
 
Entry Lewis acid X (mol%) Time (h) Yield (%) 
1a In(OTf)3 5 3 49 
2a In(OTf)3 10 4 No desired product 
3a Sc(OTf)3 10 4 49 
4a Al(OTf)3 10 24 No desired product 
5a Hf(OTf)4 10 3 No desired product 
6a Ca(NTf2)2/n-Bu4NPF6 10 3 63 
7a Ca(NTf2)2/n-Bu4NPF6 5 13 No desired product 
8a Cu(OTf)2 10 24 No desired product 
9b Ga(OTf)3 10 2 83 
10b Sn(OTf)2 10 18 72 
11b SnCl4 10 21 No desired product 
12b Yb(OTf)3 10 21 No desired product 
13b In(OTf)3 10 2 70 
a Reactions performed by Shenje. b Reactions performed by myself. 
5.3.2 Derivatization of the Model Adduct for Further Characterization 
Next, inspired by Nishii’s recent work, model adduct epi-100 was capped as enol 
triflate 105 to simplify characterization, since the model ring-opening cyclization adduct 
exists as a keto-enol mixture and may epimerize at the α carbon to yield multiple 
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diastereomers. After a short conditions screen (Table 5-2), trifluoromethanesulfonic 
(triflic) anhydride (Tf2O) was deemed the optimal reagent for this transformation (entries 
3 & 4), despite literature precedent for softer triflating agents such as N-phenyl-
bis(triflimide) (entry 1) and Comins’s reagent [N-(5-Chloro-2-pyridyl)bis(triflimide)] 
(entry 2).12 
Table 5-2: Optimization of enol triflate formation. 
 
Entry “Tf” Result 
1 PhNTf2 No desired product 
2 Comins’s No desired product 
3 Tf2O 20% desired product + 64% SMa 
4 Tf2O 40% desired product + 39% SM 
a Used crude starting material. 
Then, 105 was subjected to rigorous NMR studies. Gratifyingly, this capped adduct 
was pristine by 1H NMR (Figure 5-1), and the coupling constants were readily deducible 
in the aliphatic region (4.5-4.0 ppm). Proton A (9 Hz, 1H) is a triplet that overlaps just 
slightly with the doublet representing proton B (18 Hz, 1H). Proton C (9 Hz, 1H) is also a 
triplet, and proton D (18 Hz, 9 Hz, 1H) is a doublet of triplets. COSY analysis shows a 
proton B correlating only to proton D, whereas protons A, C, and D all correlate with each 
other. Finally, HSQC confirms that protons A and C are situated on the same carbon. These 
results support the assignments shown below, and the J-values strongly suggest cis 
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orientation among protons B and D, but an X-ray structure would unequivocally confirm 
this stereochemistry. 
 
Figure 5-1: 1H NMR results for model enol triflate 105. 
5.4 Novel Methodology Substrate Scope 
5.4.1 Identifying the Desired Targets 
As with any synthetic methodology development, several substrates were proposed 
to test the robustness of the Friedel-Crafts-type ring-opening cyclization (Figure 5-2). 
Keeping in mind privileged scaffolds of medicinal compounds, various tethered aryl and 
heteroaryl nucleophiles, including indole, furan, and thiophene were targeted; as the effects 
of substituent electronics on aryl rings are well-established for Friedel-Crafts substitutions, 
substrates were intentionally limited to more electron-donating arenes. Then, cyclopropane 
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donor groups were selected, including diversely substituted arenes, heteroarenes, and β-
silylalkanes. Finally, we envisioned three representative substrates to probe the effects of 
different acceptor groups and ring sizes incorporated into the bicyclo[3.1.0]hexane 
precursor. 
 
Figure 5-2: Proposed substrate scope. 
5.4.2 Progress Toward the Synthesis of the Substrate Scope 
To prepare the model adduct, synthesis began with acetylation of cinnamyl alcohol 
(106), which proceeded quantitatively (Scheme 5-9a). Then, the acid chloride of 
benzofuran-2-carboxylic acid (71) was achieved under typical Swern conditions, followed 
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by α-substitution of cinnamyl acetate (107) via LHMDS deprotonation to afford the desired 
β-ketoester 108 in 60% yield (Scheme 5-9b). For the diazo transfer, Shenje applied tosyl 
azide (TsN3), as it is readily and inexpensively synthesized on large scale. However, recent 
literature has highlighted p-acetamidobenzenesulfonyl azide (p-ABSA)13 as an 
exceptionally useful diazo transfer agent due to the facile separation of product from both 
excess p-ABSA and sulfonamide by-product, which is more challenging with TsN3. 
Therefore, I attempted this transformation with p-ABSA and achieved the β-keto-α-
diazoester 109 in 90% yield, an improvement over 80% yield with TsN3. Subsequent 
intramolecular cyclopropanation by catalytic Rh2(esp)2 was effected to afford 98 in 88% 
yield. 
 
Scheme 5-9: (a) Preparation of cinnamyl acetate. (b) Synthesis of propolisbenzofuran B 
oxabicyclo[3.1.0]hexane model precursor. 
Next, I began synthesizing precursors that varied the tethered arene, as these targets 
were readily achievable from the route above (Scheme 5-10). Two of the proposed 
substrates have been prepared through the diazo transfer, while a third (113b) has been 
carried forward to the cyclopropanation, diazo precursor 112b having been prepared 
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previously by Sandridge.14 For 111a, the LHMDS-mediated addition was effected from 
commercially available benzoyl chloride. 
 
Scheme 5-10: Progress toward synthesis of various aryl-tethered bicyclo[3.1.0]hexanes. 
 Once the heteroarene precursor syntheses were well underway, synthesis of the 
precursors with variable donor groups was pursued. As these allyl acetates are not 
commercially available, a scheme was developed from the corresponding aldehydes 
(Scheme 5-11). First, a Horner-Wadsworth-Emmons (HWE) reaction was conducted with 
an α-ester phosphonate, followed by global reduction by diisobutylaluminum hydride 
(DIBAL-H) and finally acetylation by the conditions previously described. This synthetic 
route was both high-yielding and practically efficient, as every product (except for 116d) 
was pure after work-up. 
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Scheme 5-11: Synthesis of various acetate precursors. 
 Then, acetates 117a-c were subjected to LHMDS-mediated addition with 
benzofuran-2-carboxylic acid chloride (Scheme 5-12). Unfortunately, the p-nitrophenyl 
precursor 118c did not tolerate the LHMDS conditions, as only degradation products were 
observed by NMR. Remaining steps include diazo transfer to 119 and cyclopropanation to 
120. 
 




In summary, an intramolecular Friedel-Crafts-type ring-opening cyclization of a C6-
substituted oxabicyclo[3.1.0]hexane was pursued as the key step in a new total synthesis 
of propolisbenzofuran B. Preliminary results pointed to an unexpected stereochemical 
outcome, an exclusively cis diastereomer when the trans isomer was anticipated. Further 
studies validated the stereochemistry of this ring-opening cyclization adduct. Synthesis of 
an expanded substrate scope is underway to probe the selectivity of this novel outcome. 
5.6 Experimental Details 
5.6.1 General Information 
Chromatographic purification was performed via flash chromatography with 
Silicycle SiliaFlash P60 silica gel (40-63 µm) or preparative thin-layer chromatography 
(prep-TLC) with Analtech silica gel F254 (1000 µm) plates and solvents indicated as eluent 
with 0.1-0.5 bar pressure. For quantitative flash chromatography, technical grades solvents 
were utilized. Analytical thin-layer chromatography (TLC) was also used to separate and 
purify reaction products using Silicycle SiliaPlate TLC silica gel F254 (250 µm) TLC glass 
plates. Products on the TLC plates were visualized under UV light (254 nm).  
Proton, and carbon nuclear magnetic resonance spectra (1H NMR and 13C NMR, 
respectively) were recorded on a Bruker 500 MHz spectrometer. The solvent resonances 
were used the internal standards (1H NMR: CDCl3 at 7.26 ppm, DMSO-d6 at 3.50 ppm; 
13C NMR: CDCl3 at 77.0 ppm, DMSO-d6 at 39.5 ppm; 
19F NMR: locked to CDCl3 or 
DMSO-d6). MestReNova (v. 11.0) was used to analyze NMR spectra. 
1H NMR data are 
reported as follows: chemical shift (ppm), multiplicity (s = singlet, d = doublet, dd = 
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doublet of doublets, dt = doublet of triplets, ddd = doublet of doublet of doublets, t = triplet, 
m = multiplet, br = broad), coupling constants (Hz), and integration. High-resolution 
accurate mass-mass spectrometry (HRAM-MS) was performed using a MicroMass 
Autospec M, run in EI mode at a mass resolution of 10,000 using perfluorokerosene (PFK) 
as an internal calibrant. 
5.6.2 General Procedures 
General Horner-Wadsworth-Emmons Procedure: In a flame-dried flask under N2, 
NaH (1.2 equiv, 60% dispersion in mineral oil) was suspended in anhydrous THF (0.2 
M/NaH), then the suspension was cooled to 0°C. Methyl 2-(diethoxyphosphoryl)acetate 
(1.1 equiv) was added and the solution stirred for 15 minutes, during which time the 
solution turned clear. Next, the aryl aldehyde (1 equiv) was added in anhydrous THF (3.5 
M), and the reaction mixture stirred overnight, warming gradually to room temperature. 
The reaction mixture was quenched with saturated aqueous NH4Cl, the aqueous layer was 
extracted with EtOAc, and the combined organic extracts were washed with brine, dried 
over anhydrous Na2SO4, filtered through celite under reduced pressure, and concentrated 
by rotary evaporation. 
General DIBAL-H Reduction Procedure:14 In a flame-dried flask under N2, the 
methyl acrylate (1 equiv) was dissolved in anhydrous DCM (0.4 M). The solution was 
cooled to -78°C, then DIBAL-H (3 equiv, 1 M/DCM) was added dropwise. After stirring 
for 1 hour, the reaction mixture was quenched with saturated aqueous Na2SO4, the aqueous 
layer was extracted with DCM, and the combined organic extracts were washed with 
saturated aqueous NH4Cl, dried over anhydrous Na2SO4, filtered through celite under 
reduced pressure, and concentrated by rotary evaporation. 
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General Acetylation Procedure: In a flame-dried flask under N2, the alcohol (1 
equiv) was dissolved in anhydrous DCM (0.5 M). The solution was cooled to 0°C, then 
DIPEA (1.2 equiv), DMAP (0.1 equiv), and Ac2O (1.2 equiv) were added in sequence. 
After stirring for 30 minutes, the reaction mixture was quenched with 1% HCl, the aqueous 
layers were extracted with DCM, and the combined organic extracts were washed with 
brine, dried over anhydrous Na2SO4, filtered through celite under reduced pressure, and 
concentrated by rotary evaporation. The product was afforded without further purification. 
General Acid Chloride Procedure: In a flame-dried flask under N2, the carboxylic 
acid (1 equiv) was dissolved in anhydrous DCM (0.5 M), then the solution was cooled to 
0°C. Anhydrous DMF (cat.) was added, then the flask was equipped with an empty N2-
flushed balloon to vent any HCl vapors. (COCl)2 (1.05 equiv) was added slowly. After 15 
minutes, the reaction mixture was allowed to warm to room temperature and stirred for 3 
hours. The resulting clear solution was then concentrated by rotary evaporation. 
General LHMDS-mediated Addition Procedure: In a flame-dried flask under N2, 
the allyl acetate (1.05 equiv) was dissolved in half the requisite volume of anhydrous THF 
(1 M). The solution was cooled to -78°C, then LHMDS (2.1 equiv, 1M/THF) was added 
dropwise and the solution stirred for 45 minutes. The acid chloride (1 equiv) was dissolved 
in the remaining anhydrous THF and added via syringe to the acetate solution, which was 
stirred for an additional 30 minutes. The reaction mixture was quenched with saturated 
aqueous NH4Cl, the aqueous layers extracted with EtOAc, and the combined organic 
extracts dried over anhydrous Na2SO4, filtered through celite under reduced pressure, and 
concentrated by rotary evaporation. 
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General p-ABSA Diazo Transfer Procedure: In a flame-dried flask under N2, the β-
ketoester (1 equiv) was dissolved in anhydrous MeCN (0.5 M), then Et3N (1.1 equiv) was 
added. After cooling the solution to 0°C, p-ABSA (1.05 equiv) was added. The reaction 
mixture was allowed to warm to room temperature and stirred overnight. Then, the reaction 
mixture was filtered through celite under reduced pressure and concentrated by rotary 
evaporation directly onto silica.  
General Intramolecular Cyclopropanation Procedure for the Synthesis of C6-
Substituted Bicyclo[3.1.0]hexanes: Rh2
(esp)2 (0.5 mol%) was charged to a flame-dried 
flask under N2, suspended in half the requisite volume of anhydrous DCM (0.02 M), then 
the suspension was cooled to 0°C. In a separate flame-dried flask under N2, the α-diazo-β-
ketoester (1 equiv) was dissolved in the remaining anhydrous DCM and transferred to the 
Rh flask via syringe in one shot with stirring. After 10 minutes, the solution was allowed 
to warm to room temperature. After 30 minutes, the reaction was quenched with saturated 
aqueous thiourea and stirred for an additional 30 minutes. Then, the aqueous layer was 
extracted with DCM and the combined organic layers were washed with brine, dried over 
anhydrous Na2SO4, filtered through celite under reduced pressure, and concentrated by 
rotary evaporation. Purification was achieved by silica flash chromatography. 
General Intramolecular Ring-opening Cyclization Procedure: The Lewis acid (10 
mol%) was charged to a flame-dried flask under N2, then the oxabicyclo[3.1.0]hexane (1 
equiv) was added as a solution in anhydrous DCM (0.2 M). After stirring for 3 hours, the 
reaction mixture was quenched with H2O, the aqueous layer was extracted with DCM, and 
the combined organic layers were washed with brine, dried over anhydrous MgSO4, filtered 
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through celite under reduced pressure, and concentrated. Purification was achieved by 
silica flash chromatography. 
General Enol Triflation Procedure:9 In a flame-dried flask under N2, NaH (2 equiv, 
60% dispersion in mineral oil) was suspended in anhydrous DCM (0.1 M/NaH) and the 
suspension cooled to 0°C. The β-ketoester (1 equiv) was added as a solution in anhydrous 
DCM (0.1 M/β-ketoester), then the reaction mixture was stirred for 1 hour. Tf2O (2 equiv) 
was added, then the reaction was stirred for an additional 30 minutes. The reaction mixture 
was quenched with saturated aqueous NaHCO3, the aqueous layers extracted with EtOAc, 
and the combined organic extracts washed with brine, dried over anhydrous Na2SO4, 
filtered through celite under reduced pressure, and concentrated by rotary evaporation. 
Purification was achieved by silica flash chromatography. 
5.6.3 Experimental Procedures 
Cinnamyl Acetate (107). The general acetylation procedure was following using 
cinnamyl alcohol (2 g, 14.9 mmol), DIPEA (3.1 mL, 17.9 mmol), DMAP (182.2 mg, 1.49 
mmol), and Ac2O (1.7 mL, 17.9 mmol) in 30 mL of anhydrous DCM. Compound 107 was 
afforded without further purification (25% EtOAc/hexanes, Rf = 0.6) as a yellow oil (2.593 
g, 99% yield). NMR data were consistent with previously reported results.16  
Cinnamyl 3-(Benzofuran-2-yl)-3-oxopropanoate (108). The general acid chloride 
and LHMDS-mediated addition procedures were followed using benzofuran-2-carboxylic 
acid (500 mg, 3.08 mmol), DMF (4 drops), and (COCl)2 (0.31 mL, 3.70 mmol) in 6.2 mL 
of anhydrous DCM, then 107 (570.6 mg, 3.24 mmol) and LHMDS (6.5 mL, 6.48 mmol, 
1M/THF) in 3.2 mL of anhydrous THF. After purification by silica flash chromatography 
(25% EtOAc/hexanes, Rf = 0.81), compound 108 was afforded in a 3.3:1 keto-enol mixture 
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(599.9 mg, 61% yield). 1H NMR (500 MHz, CDCl3) δ 7.71 (d, J = 7.9 Hz, 1H), 7.61 (s, 
1H), 7.56 (d, J = 8.4 Hz, 1H), 7.52 – 7.46 (m, 2H), 7.42 (d, J = 7.4 Hz, 1H), 7.35 – 7.29 
(m, 5H), 6.63 (d, J = 15.9 Hz, 1H), 6.25 (dt, J = 15.9, 6.4 Hz, 1H), 4.89 (dd, J = 6.3, 1.2 
Hz, 1H), 4.83 (dd, J = 6.4, 1.1 Hz, 2H), 4.03 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 182.85, 
166.61, 155.80, 151.69, 135.98, 134.72, 134.36, 128.73, 128.61, 128.56, 128.13, 126.95, 
126.64, 126.62, 126.59, 124.13, 123.52, 123.51, 122.85, 122.35, 122.22, 114.11, 112.53, 
111.62, 108.86, 88.42, 66.09, 65.03, 45.83. 
Cinnamyl 3-(Benzofuran-2-yl)-2-diazo-3-oxopropanoate (109). The general p-
ABSA diazo transfer procedure was followed using 108 (200 mg, 0.624 mmol), Et3N (0.10 
mL, 0.686 mmol), and p-ABSA (157.4 mg, 0.655 mmol) in 1.2 mL of anhydrous MeCN. 
After purification by silica flash chromatography (25% EtOAc/hexanes, Rf = 0.43), 
compound 109 was afforded as an off-white, chalky solid (193.2 mg, 89% yield). 1H NMR 
(500 MHz, CDCl3) δ 7.85 (d, J = 0.8 Hz, 1H), 7.72 (d, J = 7.9 Hz, 1H), 7.58 – 7.54 (m, 
1H), 7.47 (ddd, J = 8.4, 7.2, 1.2 Hz, 1H), 7.42 – 7.38 (m, 2H), 7.37 – 7.27 (m, 4H), 6.72 
(d, J = 15.9 Hz, 1H), 6.33 (dt, J = 15.9, 6.6 Hz, 1H), 4.96 (dd, J = 6.6, 1.2 Hz, 2H). 13C 
NMR (126 MHz, CDCl3) δ 172.30, 160.81, 155.11, 150.61, 135.86, 135.41, 128.65, 
128.35, 128.29, 126.92, 126.72, 123.99, 123.41, 122.16, 115.13, 112.29, 66.33.  
1-(Benzofuran-2-carbonyl)-6-phenyl-3-oxabicyclo[3.1.0]hexan-2-one (98). The 
general intramolecular cyclopropanation procedure was followed using 109 (857 mg, 2.47 
mmol) and Rh2(esp)2 (9.4 mg, 0.0124 mmol) in 120 mL of anhydrous DCM. After 
purification by silica flash chromatography (25% EtOAc/hexanes, Rf = 0.24), the product 
was afforded as a white solid (501.4 mg, 63% yield). 1H NMR (500 MHz, CDCl3) δ 7.77 
(s, 1H), 7.69 (d, J = 7.9 Hz, 1H), 7.49 (d, J = 8.4 Hz, 1H), 7.44 (t, J = 7.7 Hz, 1H), 7.28 (d, 
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J = 7.8 Hz, 1H), 7.19 – 7.07 (m, 5H), 4.64 (dd, J = 9.4, 4.9 Hz, 1H), 4.50 (d, J = 9.4 Hz, 
1H), 3.52 (t, J = 5.1 Hz, 1H), 3.05 (d, J = 5.3 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 
178.19, 170.73, 155.76, 151.34, 131.52, 128.89, 128.58, 128.08, 127.61, 126.83, 123.81, 
123.79, 118.57, 112.39, 68.17, 44.45, 38.09, 26.25. 
epi-100. The general ring-opening cyclization procedure was followed using 
Ga(OTf)3 (12.2 mg, 0.0236 mmol) and 98 (75 mg, 0.236 mmol) in 1.2 mL of anhydrous 
DCM. After purification by silica flash chromatography (25% EtOAc/hexanes, Rf = 0.14), 
compound epi-100 was afforded as a yellow foam (62.4 mg, 83% yield). 1H NMR (500 
MHz, CDCl3) δ 7.55 (d, J = 8.5 Hz, 1H), 7.45 – 7.40 (m, 3H), 7.33 (dd, J = 7.4, 2.0 Hz, 
2H), 7.19 – 7.12 (m, 1H), 7.07 – 7.02 (m, 1H), 6.59 (d, J = 8.0 Hz, 1H), 4.38 – 4.32 (m, 
3H), 3.86 (d, J = 7.4 Hz, 1H), 3.57 – 3.49 (m, 1H). 13C NMR (126 MHz, CDCl3) δ 176.47, 
171.13, 169.72, 156.84, 146.32, 138.99, 135.14, 129.87, 129.46, 129.35, 129.12, 129.01, 
128.92, 128.88, 128.70, 128.48, 127.41, 125.93, 125.34, 124.13, 123.94, 123.57, 122.94, 
112.88, 112.39, 69.51, 60.35, 51.82, 47.43, 41.30, 21.01, 14.15. 
epi-100 using Ca(NTf2)2/n-Bu4NPF6. The general ring-opening cyclization 
procedure was followed, with a slight change. Ca(NTf2)2 (18.9 mg, 0.0314 mmol) was 
charged to the flask, then n-Bu4NPF6 (12.2 mg, 0.0314 mmol) was added. The two reagents 
were suspended in 0.8 mL of anhydrous DCM and stirred for 5 minutes. Then, 98 (100 mg, 
0.314 mmol) was added as a solution in 0.8 mL of anhydrous DCM. After purification by 
silica flash chromatography (25% EtOAc/hexanes, Rf = 0.14), compound epi-100 was 
afforded as a yellow foam (64.1 mg, 64% yield). 
105. The general enol triflation procedure was followed using epi-100 (78.8 mg, 
0.248 mmol), NaH (19.8 mg, 0.496 mmol, 60% dispersion in mineral oil), and Tf2O (0.08 
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mL, 0.496 mmol) in 1.2 mL of anhydrous DCM. After purification by silica flash 
chromatography (25% EtOAc/hexanes, Rf = 0.44), compound 105 was afforded as a yellow 
solid (32.1 mg, 28% yield), and unreacted epi-100 was recovered (31.0 mg, 39%). 1H NMR 
(500 MHz, CDCl3) δ 7.55 (d, J = 8.5 Hz, 1H), 7.50 – 7.33 (m, 6H), 7.09 – 7.03 (m, 1H), 
6.49 (d, J = 7.9 Hz, 1H), 4.45 – 4.35 (m, 2H), 4.23 (t, J = 8.9 Hz, 1H), 4.07 (dt, J = 17.6, 
8.7 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 164.50, 156.97, 144.82, 138.15, 137.83, 
129.54, 128.66, 127.49, 125.97, 125.56, 124.09, 121.69, 114.66, 112.39, 70.38, 46.70, 
45.41. 
Cinnamyl 3-Oxo-3-phenylpropanoate (111a). The LHMDS-mediated addition 
procedure was followed using benzoyl choride (250 mg, 1.78 mmol), 107 (329.5 mg, 1.87 
mmol), and LHMDS (3.7 mL, 3.74 mmol, 1M/THF) in 1.8 mL of anhydrous THF. After 
purification by silica flash chromatography (25% EtOAc/hexanes, Rf = 0.24), compound 
111a was afforded in a 2.5:1 keto-enol mixture (312.5 mg, 63% yield). 1H NMR (500 MHz, 
CDCl3) δ 7.98 – 7.94 (m, 2H), 7.81 – 7.77 (m, 1H), 7.62 – 7.57 (m, 1H), 7.51 – 7.45 (m, 
2H), 7.45 – 7.40 (m, 1H), 7.38 – 7.34 (m, 2H), 7.32 (ddd, J = 7.7, 6.7, 1.4 Hz, 2H), 7.29 – 
7.23 (m, 2H), 6.63 (d, J = 15.9 Hz, 1H), 6.25 (dt, J = 15.9, 6.4 Hz, 1H), 4.88 (dd, J = 6.4, 
1.3 Hz, 1H), 4.82 (dd, J = 6.4, 1.3 Hz, 2H), 4.05 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 
192.30, 171.79, 167.28, 136.06, 135.96, 134.60, 134.37, 133.78, 131.33, 128.80, 128.61, 
128.57, 128.55, 128.52, 128.12, 126.64, 126.09, 123.00, 122.48, 87.17, 65.98, 64.88, 
45.94. 
Cinnamyl 3-(3,4-Dimethoxyphenyl)-3-oxopropanoate (111c). The general acid 
chloride and LHMDS-mediated addition procedures were followed using 3,4-
dimethoxybenzoic acid (250 mg, 1.37 mmol), DMF (2 drops), and (COCl)2 (0.14 mL, 1.64 
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mmol) in 2.7 mL of anhydrous DCM, then 107 (253.8 mg, 1.44 mmol) and LHMDS (2.9 
mL, 2.88 mmol, 1M/THF) in 1.4 mL of anhydrous THF. After purification by silica flash 
chromatography (25% EtOAc/hexanes, Rf = 0.21), compound 111c was afforded in a 5:1 
keto-enol mixture (218.6 mg, 47% yield). 1H NMR (500 MHz, CDCl3) δ 7.57 – 7.53 (m, 
2H), 7.37 – 7.29 (m, 4H), 6.87 (d, J = 8.2 Hz, 1H), 6.62 (d, J = 15.9 Hz, 1H), 6.25 (dt, J = 
15.9, 6.4 Hz, 1H), 4.81 (d, J = 7.7 Hz, 2H), 4.01 (s, 2H), 3.93 (d, J = 1.1 Hz, 6H). 13C NMR 
(126 MHz, CDCl3) δ 190.78, 167.49, 153.87, 149.21, 136.06, 134.61, 129.22, 128.58, 
128.12, 126.62, 123.59, 122.53, 110.31, 110.04, 65.91, 56.10, 56.00, 45.74. 
Cinnamyl 2-Diazo-3-oxo-3-phenylpropanoate (112a). The general p-ABSA diazo 
transfer procedure was followed using 111a (308.6 mg, 1.10 mmol), Et3N (0.17 mL, 1.21 
mmol), and p-ABSA (277.5 mg, 1.16 mmol) in 2.2 mL of anhydrous MeCN. After 
purification by silica flash chromatography (25% EtOAc/hexanes), compound 112a was 
afforded (283.0 mg, 84% yield). 1H NMR (500 MHz, CDCl3) δ 7.64 (dd, J = 8.1, 1.1 Hz, 
2H), 7.53 (tt, J = 7.0, 1.3 Hz, 1H), 7.43 (t, J = 7.6 Hz, 2H), 7.39 – 7.31 (m, 4H), 7.28 (dt, J 
= 8.1, 2.0 Hz, 1H), 6.61 (d, J = 15.9 Hz, 1H), 6.24 (dt, J = 15.9, 6.5 Hz, 1H), 4.84 (dd, J = 
6.5, 1.2 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 160.85, 137.02, 135.87, 135.14, 132.34, 
128.65, 128.38, 128.32, 127.92, 126.66, 122.14, 66.02. 
Cinnamyl 2-Diazo-3-(3,4-dimethoxyphenyl)-3-oxopropanoate (112c). The general 
p-ABSA diazo transfer procedure was followed using 111c (214.7 mg, 0.631 mmol), Et3N 
(0.10 mL, 0.694 mmol), and p-ABSA (159.1 mg, 0.662 mmol) in 1.3 mL of anhydrous 
MeCN. After purification by silica flash chromatography (25% EtOAc/hexanes), 
compound 112c was afforded (232.3 mg, quant.). 1H NMR (500 MHz, CDCl3) δ 7.39 – 
7.31 (m, 5H), 7.30 – 7.26 (m, 2H), 6.87 (d, J = 8.4 Hz, 1H), 6.64 (d, J = 15.9 Hz, 1H), 6.27 
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(dt, J = 15.9, 6.5 Hz, 1H), 4.86 (dd, J = 6.5, 1.3 Hz, 2H), 3.91 (d, J = 7.4 Hz, 6H). 13C NMR 
(126 MHz, CDCl3) δ 185.04, 152.87, 148.55, 135.87, 135.16, 129.24, 128.66, 128.33, 
126.65, 123.41, 122.22, 111.44, 109.59, 65.98, 55.99. 
1-(3,4,5-Trimethoxybenzoyl)-6-phenyl-3-oxabicyclo[3.1.0]hexan-2-one (113b). 
The general intramolecular cyclopropanation procedure was followed using 112b (250 mg, 
0.631 mmol) and Rh2(esp)2 (2.4 mg, 3.16 μmol) in 6.3 mL of anhydrous DCM. After 
purification by silica prep-TLC (25% EtOAc/hexanes, Rf = 0.14), compound 113b was 
afforded as a white solid (94.6 mg, 41% yield). 1H NMR (500 MHz, CDCl3) δ 7.20 – 7.14 
(m, 5H), 7.05 (dd, J = 8.0, 1.4 Hz, 2H), 4.61 (dd, J = 9.4, 4.9 Hz, 1H), 4.48 (d, J = 9.5 Hz, 
1H), 3.86 (d, J = 15.2 Hz, 9H), 3.42 (t, J = 4.8 Hz, 1H), 3.00 (d, J = 5.2 Hz, 1H). 13C NMR 
(126 MHz, CDCl3) δ 188.25, 171.18, 152.53, 143.21, 132.10, 130.50, 128.67, 128.09, 
127.31, 107.79, 68.10, 60.88, 56.17, 44.49, 38.01, 26.34. 
Methyl (E)-3-(4-Bromophenyl)acrylate (115a). The general Horner-Wadsworth-
Emmons procedure was followed using NaH (130 mg, 3.24 mmol, 60% dispersion in 
mineral oil) and methyl 2-(diethoxyphosphoryl)acetate (0.43 mL, 2.97 mmol) in 17 mL of 
anhydrous THF, then p-bromobenzaldehyde (500 mg, 2.70 mmol) in 0.8 mL of anhydrous 
THF. Compound 115a was afforded without further purification (580.1 mg, 89% yield). 
NMR data were consistent with previously reported results.17 
Methyl (E)-3-(4-Methoxyphenyl)acrylate (115b). The general Horner-Wadsworth-
Emmons procedure was followed using NaH (176 mg, 4.41 mmol, 60% dispersion in 
mineral oil) and methyl 2-(diethoxyphosphoryl)acetate (0.59 mL, 4.04 mmol) in 22 mL of 
anhydrous THF, then p-anisaldehyde (500 mg, 3.67 mmol) in 1 mL of anhydrous THF. 
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Compound 115b was afforded without further purification (25% EtOAc/hexanes, Rf = 
0.47) (705.8 mg, quant.). NMR data were consistent with previously reported results.17 
Methyl (E)-3-(4-Nitrophenyl)acrylate (115c). The general Horner-Wadsworth-
Emmons procedure was followed using NaH (159 mg, 3.97 mmol, 60% dispersion in 
mineral oil) and methyl 2-(diethoxyphosphoryl)acetate (0.53 mL, 3.64 mmol) in 20 mL of 
anhydrous THF, then p-nitrobenzaldehyde (500 mg, 3.31 mmol) in 1 mL of anhydrous 
THF. Compound 115c was afforded without further purification (25% EtOAc/hexanes, Rf 
= 0.41) (466.3 mg, 68% yield). NMR data were consistent with previously reported 
results.18 
Methyl (E)-3-(Furan-2-yl)acrylate (115d). The general Horner-Wadsworth-
Emmons procedure was followed using NaH (300 mg, 6.25 mmol, 60% dispersion in 
mineral oil) and methyl 2-(diethoxyphosphoryl)acetate (0.83 mL, 5.72 mmol) in 31 mL of 
anhydrous THF, then 2-furaldehyde (500 mg, 5.20 mmol) in 2 mL of anhydrous THF. 
Compound 115d was afforded without further purification (25% EtOAc/hexanes, Rf = 
0.59) (628.1 mg, 78% yield). NMR data were consistent with previously reported results.19 
(E)-3-(4-Bromophenyl)prop-2-en-1-ol (116a). The general DIBAL-H reduction 
procedure was followed using 115a (500 mg, 2.07 mmol), DIBAL-H (6.2 mL, 6.21 mmol, 
1 M/DCM) in 5.2 mL of anhydrous DCM. Compound 116a was afforded without further 
purification (25% EtOAc/hexanes, Rf = 0.17) as a white solid (363.6 mg, 82% yield).
 NMR 
data were consistent with previously reported results.20 
(E)-3-(4-Methoxyphenyl)prop-2-en-1-ol (116b). The general DIBAL-H reduction 
procedure was followed using 115b (500 mg, 2.60 mmol), DIBAL-H (7.8 mL, 7.80 mmol, 
1 M/DCM) in 6.5 mL of anhydrous DCM. Compound 116b was afforded without further 
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purification (25% EtOAc/hexanes, Rf = 0.17) as a white solid (420.3 mg, 98% yield). NMR 
data were consistent with previously reported results.21 
(E)-3-(4-Nitrophenyl)prop-2-en-1-ol (116c). The general DIBAL-H reduction 
procedure was followed using 115c (400 mg, 1.93 mmol), DIBAL-H (5.8 mL, 5.79 mmol, 
1 M/DCM) in 4.8 mL of anhydrous DCM. Compound 116c was afforded without further 
purification (25% EtOAc/hexanes, Rf = 0.10) as a white solid (305.7 mg, 88% yield). NMR 
data were consistent with previously reported results.21 
(E)-3-(Furan-2-yl)prop-2-en-1-ol (116d). The general DIBAL-H reduction 
procedure was followed using 115d (400 mg, 2.63 mmol), DIBAL-H (7.9 mL, 7.89 mmol, 
1 M/DCM) in 6.5 mL of anhydrous DCM. Compound 116d was afforded without further 
purification (25% EtOAc/hexanes, Rf = 0.28) as a white solid (303.7 mg, 93% yield). NMR 
data were consistent with previously reported results.22 
(E)-3-(4-Bromophenyl)allyl Acetate (117a). The general acetylation procedure was 
following using 116a (250 mg, 1.17 mmol), DIPEA (0.25 mL, 1.41 mmol), DMAP (28.7 
mg, 0.235 mmol), and Ac2O (0.13 mL, 1.41 mmol) in 12 mL of anhydrous DCM. 
Compound 117a was afforded without further purification (235.9 mg, 79% yield). NMR 
data were consistent with previously reported results.16 
(E)-3-(4-Methoxyphenyl)allyl Acetate (117b). The general acetylation procedure 
was following using 116b (250 mg, 1.52 mmol), DIPEA (0.32 mL, 1.83 mmol), DMAP 
(37.3 mg, 0.305 mmol), and Ac2O (0.17 mL, 1.52 mmol) in 15 mL of anhydrous DCM. 
Compound 117b was afforded without further purification (253.6 mg, 81% yield). NMR 
data were consistent with previously reported results.20 
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(E)-3-(4-Nitrophenyl)allyl Acetate (117c). The general acetylation procedure was 
following using 116c (250 mg, 1.40 mmol), DIPEA (0.29 mL, 1.67 mmol), DMAP (34.1 
mg, 0.279 mmol), and Ac2O (0.16 mL, 1.67 mmol) in 14 mL of anhydrous DCM. 
Compound 116c was afforded without further purification (25% EtOAc/hexanes, Rf = 
0.38) (235.3 mg, 76% yield). NMR data were consistent with previously reported results.23 
(E)-3-(Furan-2-yl)allyl Acetate (117d). The general acetylation procedure was 
following using 116d (250 mg, 2.01 mmol), DIPEA (0.42 mL, 2.42 mmol), DMAP (49.2 
mg, 0.403 mmol), and Ac2O (0.23 mL, 2.42 mmol) in 20 mL of anhydrous DCM. After 
purification by alumina flash chromatography (25% EtOAc/hexanes, Rf = 0.70), compound 
117d was afforded (34.1 mg, 10% yield). NMR data were consistent with previously 
reported results.24 
(E)-3-(4-Bromophenyl)allyl 3-(Benzofuran-2-yl)-3-oxopropanoate (118a). The 
general acid chloride and LHMDS-mediated addition procedures were followed using 
benzofuran-2-carboxylic acid (125 mg, 0.771 mmol), DMF (1 drop), and (COCl)2 (0.08 
mL, 0.925 mmol) in 1.5 mL of anhydrous DCM, then 117a (206.6 mg, 0.810 mmol) and 
LHMDS (1.6 mL, 1.62 mmol, 1M/THF) in 0.8 mL of anhydrous THF. After purification 
by silica flash chromatography (25% EtOAc/hexanes), compound 118a was afforded in a 
2.2:1 enol-keto mixture as an off-white, chalky solid (209.1 mg, 68% yield). 1H NMR (500 
MHz, CDCl3) δ 12.00 (s, 1H), 7.65 (d, J = 7.8 Hz, 1H), 7.50 (d, J = 8.9 Hz, 1H), 7.46 (d, J 
= 6.7 Hz, 2H), 7.44 – 7.36 (m, 2H), 7.31 (s, 1H), 7.28 (dd, J = 8.2, 2.1 Hz, 2H), 6.65 (d, J 
= 15.9 Hz, 1H), 6.34 (dt, J = 15.9, 6.2 Hz, 1H), 5.92 (s, 1H), 4.88 (dd, J = 6.2, 1.2 Hz, 2H), 
4.81 (dd, J = 6.3, 1.2 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 162.13, 135.08, 132.97, 
131.76, 128.15, 127.78, 126.65, 123.74, 123.56, 122.25, 111.63, 108.96, 88.31, 64.75. 
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(E)-3-(4-Methoxyphenyl)allyl 3-(Benzofuran-2-yl)-3-oxopropanoate (118b). The 
general acid chloride and LHMDS-mediated addition procedures were followed using 
benzofuran-2-carboxylic acid (125 mg, 0.771 mmol), DMF (1 drop), and (COCl)2 (0.08 
mL, 0.925 mmol) in 1.5 mL of anhydrous DCM, then 118a (167.1 mg, 0.810 mmol) and 
LHMDS (1.6 mL, 1.62 mmol, 1M/THF) in 0.8 mL of anhydrous THF. After purification 
by silica flash chromatography (25% EtOAc/hexanes), the product was afforded in a 1.8:1 
keto-enol mixture as a yellow-green oil (194.8 mg, 72% yield). 1H NMR (500 MHz, 
CDCl3) δ 7.71 (d, J = 7.9 Hz, 1H), 7.60 (d, J = 0.9 Hz, 1H), 7.58 – 7.54 (m, 1H), 7.52 – 
7.46 (m, 1H), 7.36 (d, J = 8.8 Hz, 1H), 7.31 (d, J = 8.1 Hz, 1H), 7.29 – 7.26 (m, 1H), 6.89 
– 6.85 (m, 1H), 6.85 – 6.81 (m, 2H), 6.67 (d, J = 15.8 Hz, 1H), 6.58 (d, J = 15.8 Hz, 1H), 
6.21 (dt, J = 15.8, 6.5 Hz, 1H), 6.11 (dt, J = 15.8, 6.6 Hz, 1H), 4.87 (dd, J = 6.6, 1.2 Hz, 
1H), 4.80 (dd, J = 6.6, 1.2 Hz, 2H), 4.02 (s, 2H), 3.81 (d, J = 4.3 Hz, 3H). 
(E)-3-(4-Nitrophenyl)allyl 3-(Benzofuran-2-yl)-3-oxopropanoate (118c). The 
general acid chloride and LHMDS-mediated addition procedures were followed using 
benzofuran-2-carboxylic acid (160 mg, 0.987 mmol), DMF (2 drops), and (COCl)2 (0.10 
mL, 1.18 mmol) in 2 mL of anhydrous DCM, then 117c (229.2 mg, 0.810 mmol) and 
LHMDS (2.1 mL, 2.07 mmol, 1M/THF) in 1 mL of anhydrous THF. Only degradation 
products were detected. 
(E)-3-(4-Bromophenyl)allyl 3-(Benzofuran-2-yl)-2-diazo-3-oxopropanoate (119a). 
The general p-ABSA diazo transfer procedure was followed using 118a (207.1 mg, 0.519 
mmol), Et3N (0.08 mL, 0.571 mmol), and p-ABSA (130.9 mg, 0.545 mmol) in 1.5 mL of 
anhydrous MeCN. After purification by silica flash chromatography (25% 
EtOAc/hexanes), compound 119a was afforded as a yellow solid (222 mg, quant.). 1H 
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NMR (500 MHz, CDCl3) δ 7.83 (s, 1H), 7.71 (d, J = 7.9 Hz, 1H), 7.57 – 7.52 (m, 1H), 7.50 
– 7.43 (m, 3H), 7.35 – 7.29 (m, 1H), 7.28 – 7.23 (m, 2H), 6.65 (d, J = 15.9 Hz, 1H), 6.31 
(dt, J = 15.9, 6.5 Hz, 1H), 4.94 (dd, J = 6.5, 1.2 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 
172.16, 160.83, 155.08, 150.62, 134.80, 133.97, 131.77, 128.31, 128.19, 126.87, 124.01, 
123.38, 123.01, 122.20, 115.04, 112.26, 66.04. 
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CHAPTER 6. EFFORTS TOWARD THE TOTAL SYNTHESES 
OF RHAZINICINE AND TRONOCARPINE 
6.1 Efforts Toward Rhazinicine 
As mentioned in Chapter 4, rhazinicine is an anti-tumor natural product that has 
inspired several total syntheses and tetrahydroindolizine (THI) methodology studies. In 
2016, Cavitt and France published a method analogous to the Friedel-Crafts-type ring-
opening cyclization of N-acyl indole DACPs, whereby N-acyl pyrrole DACP 121 ring-
opens in the presence of catalytic Al(OTf)3 to form THI scaffold 122 diastereoselectively 
(Scheme 6-1).1 This process is significantly milder and greener than previously published 
conditions. It also represents the culmination of a generalized method to form fused, 
polycyclic nitrogen-containing heterocycles from N-acyl DACPs. 
 
Scheme 6-1: Diastereoselective ring-opening cyclization of N-acyl pyrrole DACPs to THIs. 
6.1.1 First Synthetic Approach to Rhazinicine 
Cavitt’s retrosynthetic analysis of rhazicinine is shown in Scheme 6-2.2 The final 
step would be a Suzuki cross-coupling to form the 9-membered lactam. 2-Iodoacetanilide 
precursor 123 would arise from a Krapcho decarboxylation and amidation of the methyl 
ester moiety in THI 124, which would be prepared through the ring-opening cyclization of 
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pyrrole-tethered N-acyl DACP 125. This DACP 125 would be prepared through the 
cyclopropanation of N-acyl diazo precursor 126 and 1,1-disubstituted terminal alkene 127 
containing the requisite ethyl and pendant methyl ester functional groups. 
 
Scheme 6-2: Cavitt's retrosynthetic analysis of rhazinicine. 
Early work in the synthesis was promising. Literature protocols furnished efficient 
routes to both 126 and 127.3 Then, the cyclopropanation was extensively optimized by 
Cavitt to afford 125 in 52% yield, and the subsequent ring-opening cyclization under the 
published Al(OTf)3 catalysis yielded the desired adduct 124 in 63% yield. The Krapcho 
decarboxylation to intermediate 128 was achieved at an excellent 90% yield.2 
6.1.2 Optimizations for First Synthetic Approach to Rhazinicine 
Then, I pursued several routes for the subsequent amidation with 2-iodoaniline. 
First, hydroxy bases were screened for a saponification to acid precursor 129 (Table 6-1). 
Sodium hydroxide was ultimately selected as the optimal base, despite a modest 61% yield 
(entries 1, 7). 
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Table 6-1: Optimization of rhazinicine saponification. 
 
Entry Base (equiv) Solvent (conc.) T (°C) Result 
1 NaOH (1.2)a MeOH (1 M) 50 61% 
2 KOH (3)b THF (30%/H2O) r.t. No reaction 
3 NaOH (1.5)a MeOH (1 M) 50 Low conversion 
4 LiOH.H2O (8)c MeOH (0.25 M), THF (0.25 M) r.t. Low conversion 
5 NaOH (1.2)a IPA (1 M) 50 Low conversion 
6 TMSI (5) CHCl3 (0.3 M) 80 Degradation 
7 NaOH (1.5)a MeOH (1 M) 50 57% 
a 1.7 M in H2O. b 85% in H2O. c 2 M in H2O. 
Then, the amidation of acid 129 with 2-iodoaniline (130) was attempted (Table 6-
2). EDC, a traditional peptide coupling agent, did not afford any desired product (entries 
1, 2); however, Mukaiyama’s reagent performed well here, and the 2-iodoacetanilide 123 
was prepared in 35% yield (entry 3). 
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Table 6-2: Optimization of rhazinicine amidation. 
 
Entry Aniline equiv CA (equiv) Base (equiv) Result 
1 2 EDCI (1.5) DMAP (0.1) No reaction 
2 2 EDCI.HCl (1.5) DMAP (0.1) No reaction 
3 5.5 Mukaiyama (1.2) Et3N (2.1) 35% 
Given the modest yields of the stepwise approach, a direct amidation of methyl 
ester 128 was attempted (Table 6-3). Unfortunately, Weinreb conditions did not afford any 
desired amide (entries 1-3), and a literature protocol employing potassium tert-butoxide (t-
BuOK) was similarly ineffective (entry 4).4 
Table 6-3: Attempts at direct amidation of methyl ester precursor. 
 
Entry Aniline equiv CA (equiv) Solvent (conc, T) Result 
1 1 Me3Al (1.2) PhMe (0.9 M, reflux) No desired product 
2 1 Me3Al (1.2) PhMe (0.9 M, reflux) No desired producta 
3 1.6 Me3Al (1.6) DCE (0.25 M, r.t. to reflux) Complex mixture 
4 1 t-BuOK (2) THF (0.08 M, r.t.) No desired product 
a Used a fresh bottle of Me3Al. 
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Finally, as it was expected that protection of acetanilide 123 would be necessary to 
facilitate the final coupling step, several protection protocols employing methoxymethyl 
chloride (MOMCl, entries 1-3) and benzyl bromide (BnBr, entries 4-6) were attempted 
with 130 (Table 6-4). All of these, unfortunately, were unsuccessful, which prevented a 
shorter synthetic route. 
Table 6-4: Attempts at 2-iodoaniline protection. 
 
Entry R-X (equiv) Base (equiv) Result 
1 MOMCl (1.5) KH (1.2)a Complex mixture 
2 MOMCl (1.1) DIPEA (6.5) Complex mixture 
3 MOMCl (4) NaH (4) Complex mixture 
4 BnBr (1.1) Et3N (1.2) No reaction 
5 BnBr (1.1) NaH (1.1) No reaction 
6 BnBr (1.5) NaH (3) No reaction 
a Added TMEDA (1.2 equiv). 
At this stage, it was necessary to prepare gram-scale quantities of DACP precursor 
125 to push the synthesis to the final coupling step (Table 6-3). Unfortunately, the 
cyclopropanation yield suddenly plummeted from 50% to 5%. This was initially attributed 
to difficulties purifying alkene precursor 127, so sequential distillations were performed to 
make the alkene as clean as possible. Despite 1H NMR validation that there were no 
residual impurities in 127, and despite careful monitoring and purification of the reaction 
in subsequent attempts, the cyclopropanation remained low-yielding. 
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Scheme 6-3: Abbreviated progress toward first synthetic approach to rhazinicine. 
6.1.3 Optimizing the Alkene Precursor 
Desirous to both improve cyclopropanation yields and avoid any future challenges 
from the alkene, two different alkene precursors were synthesized. First, a benzyl-protected 
2-iodoanilide substrate 132 was evaluated since early incorporation of the aniline moiety 
would both contribute mass and make the total synthesis more convergent (Scheme 6-4a). 
Cavitt had previously prepared 132 via a two-step route.5 First, acid precursor 133 was 
converted to an acid chloride under Swern conditions, followed by a triethylamine-
promoted amidation with 130 to prepare intermediate 134 (75% yield). Then, treatment 
with benzyl bromide furnished 132 (79% yield). Afterwards, I subjected 126 and 132 to 
typical intermolecular cyclopropanation conditions (Scheme 6-4b), but the resulting 
reaction mixture was complex and showed no evidence of desired product 135 by NMR. 
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Scheme 6-4: (a) Synthesis of 2-iodoanilide alkene precursor. (b) Failed cyclopropanation. 
Next, a benzyl ester precursor 136 was prepared in short order via a mixed 
anhydride synthesis followed by displacement with benzyl alcohol (Scheme 6-5). Initial 
results were promising, as the esterification was efficient and the product 136, much more 
shelf-stable than methyl ester 125. 
 
Scheme 6-5: Synthesis of benzyl ester alkene precursor. 
Despite extensive optimizations, however, the cyclopropanation yield for DACP 
137 was modest (Table 6-5). Temperature displayed prominent influence on the reaction 
outcome, as reactivity was slow at 0°C but quickly funneled 133 to degradation products 
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at room temperature (entries 1-3). The first noticeable increase occurred with an increase 
in loading of 136 (entry 4); slow addition of 133 did not make a positive difference (entry 
5). Increasing the loading of 136 continued to drive the yield up (entries 6-8). Finally, it 
was found that 5 equiv. was a sufficient concentration of 136 to hinder degradation of 133, 
and allowing the reaction to stir for 3 hours at room temperature provided the best yield at 
39%. Moreover, the stability of 136 on silica column enabled facile recovery of the excess 
during reaction purification. 
Table 6-5: Optimization of rhazinicine cyclopropanation with benzyl ester-functionalized alkene. 
 
Entry Alkene equiv Temp./Time Yield 
1 1.3 0°C 10 min, then r.t. 30 min 9% 
2 1.3 0°C 10 min, then r.t. 15 min 13% 
3 1.3 0°C 3 h, then r.t. 3 h 10% 
4 2 0°C 4 h, then r.t. 30 min 21% 
5 1.3 0°C 30 mina 11% 
6 2 0°C 30 min, r.t. 30 min 19% 
7 5 0°C 30 min, r.t. 30 min 33% 
8 5 0°C 60 min, r.t. 30 min 33% 
9 5 0°C 10 min, r.t. 3 h 39% 
a Slow-added diazo over 10 min. 
Though this cyclopropanation yield was low compared to the original 52% with 
DACP 125, the acquired cyclopropane was carried forward to the ring-opening cyclization, 
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which unfortunately fared little better (Table 6-6). Adduct 138 was ultimately prepared at 
37% optimal yield, a far cry from the previously achievable 63%. 
Table 6-6: Optimization of rhazinicine ring-opening cyclization from benzyl precursor. 
 
Entry Lewis acid (X mol%) Result 
1 In(OTf)3 (30) 37% 
2 Al(OTf)3 (20) 29%a 
3 In(OTf)3 (30) No reactionb 
4 Sc(OTf)3 (30) No reactionb 
5 In(OTf)3 (30) 31% 
6 In(OTf)3 (20) 37% 
7 In(OTf)3 (10) No reaction 
8 Bi(OTf)3 (20) 7% 
9 Sc(OTf)3 (20) 28% 
10 Al(OTf)3 (20) No reaction 
11 InCl3 (20) No reaction 
12 Ca(NTf2)2/n-Bu4NPF6 (20) No reaction 
a Reaction performed in MeCN. b Reaction performed at r.t. 
As a last-ditch effort, two additional alkenes and one ketone precursor were 
hypothesized. t-Butyl ester 139 was initially selected for its greater mass relative to 127 
and for its lower steric profile and potentially simpler saponification compared to 133 
(Scheme 6-6a). Traditional esterification conditions, however, did not afford the desired 
product. Next, perfluorophenyl ester 140 was considered, as recent literature has 
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showcased its highly electrophilic character, resulting facile cleavage to the acid, and low 
profile by 1H NMR, but esterification with perfluorophenol (141) failed, as well (Scheme 
6-6b). Finally, it was envisioned that the geminal di-substituted cyclopropane moiety could 
be introduced in a stepwise fashion by converting the alkene precursor to a ketone, 
performing a Knoevenagel condensation, and subsequently preparing the cyclopropane 
through Simmons-Smith conditions. Unfortunately, oxidative cleavage of 127 to ketone 
precursor 142 was unsuccessful (Scheme 6-6c). 
 
Scheme 6-6: Additional attempted syntheses of cyclopropane precursors. (a) t-Butyl ester. (b) 
Perfluorophenyl ester. (c) Knoevenagel precursor. 
6.2 Efforts Toward Tronocarpine 
Additional efforts were expended toward a targeted synthesis of tronocarpine that 
would build the bicyclic moiety incrementally through a key ring-opening cyclization 
method previously studied by France lab. This is in contrast to the desired pathway that 
would install the bicylic moiety during the ring-opening cyclization step, but was believed 
to be workable due to earlier success with Friedel-Crafts-type ring-opening cyclizations of 
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N-acyl indole-tethered DACPs.3,6 Two distinct approaches were pursued: first, an 
intermolecular cyclopropanation with an alkene containing the appropriate functional 
handles for further annulations; and second, the nucleophilic addition of a 3-substituted 
indole onto the lactone moiety of a C5-substituted D-A oxabicyclo[3.1.0]hexane. Both 
approaches would be followed by a Lewis acid-catalyzed ring-opening cyclization to form 
the hydropyrido[1,2-a]indole core of tronocarpine. 
6.2.1 Intermolecular Cyclopropanation Approach 
 The retrosynthetic analysis for the first approach is shown in Scheme 6-7. 
Tronocarpine would be prepared from a lactamization after deprotecting precursor 143. 
Base-mediated annulation would occur from advanced intermediate 144, which would 
arise from a Horner-Wadsworth-Emmons (HWE) reaction of aldehyde 145. The aldehyde 
would be formed from a deprotection and oxidation of 146, the Krapcho decarboxylation 
product of 147. This adduct would be prepared via a ring-opening cyclization of DACP 
148, and cyclopropanation of diazo 149 and alkene 150 would afford the cyclopropane. 
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Scheme 6-7: Proposed retrosynthetic analysis for tronocarpine. 
 To model this process, 3-methylindole (59) was selected for the N-acyl-tethered 
nucleophile. Synthesis of malonate 151 was high-yielding (98%), and the diazo transfer to 
152 had excellent yield as expected (93%). Then, two different mono-silyl protections of 
commercially available 2-methylene-1,3-propanediol (56) were effected: TBDPS (55a, 
89%) and TBS (153, 80%). The subsequent acetate protections proceeded in quantitative 
yield for both (TBDPS: 150a; TBS: 150b).  
Several cyclopropanation conditions were explored, starting with 152 and 150a 
(Table 6-7). Standard conditions afforded a complex mixture of inseparable products, 
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including diazo starting material (entries 1-2), and it was found early on that increases in 
temperature decreased the overall reaction time but unfortunately did not clean up the 
resulting reaction mixture or appreciably generate more desired product (entries 3-5). 
Hypothesizing that the TBDPS protecting group could be sterically hindering the 
intermolecular interaction, alkene 150b was tested under standard conditions (entry 6). 
Although the reaction mixture remained complex, 6% of desired product 154b was 
successfully isolated by silica preparatory TLC. 
Table 6-7: Test conditions for intermolecular cyclopropanation. 
 
Entry SiR3 Solv (conc, T) Result 
1 TBDPS DCM (0.5 M, 0°C – r.t.) Complex mixture 
2 TBDPS DCM (0.5 M, 0°C – r.t.) Complex mixturea 
3 TBDPS MeCN (0.2 M, r.t.) Complete in 24 h, complex mixture 
4 TBDPS MeCN (0.2 M, 50°C) Complete in 2 h, complex mixture 
5 TBDPS MeCN (0.2 M, Δ) Complete in 1 h, complex mixture 
6 TBS DCM (0.5 M, 0°C – r.t.) 6% isolated yield 
7 TBS DCM (0.5 M, 0°C – r.t.) Complex mixtureb 
8 TBS DCM (0.5 M, 0°C – r.t.) 1% isolated yieldc 
a Slow-added solution of diazo starting material. b Took forward crude to ring-opening cyclization. c Scaled 
up from 50 mg to 200 mg diazo starting material. 
Hoping that perhaps a one-pot method could be feasible for this transformation 
(since a tandem cyclopropanation/ring-opening cyclization has been demonstrated by 
France and co-workers),7 the reaction was duplicated (entry 7) and 154b taken forward 
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crude to the ring-opening cyclization step (Scheme 6-8). Unfortunately, no desired 
cyclization adduct 155b was detected. Then, the cyclopropanation attempted at a slightly 
larger scale to attain sufficient product to begin optimizing the ring-opening cyclization 
(entry 8), but the yield plummeted to trace amounts. 
 
Scheme 6-8: Test ring-opening cyclization from crude DACP. 
6.2.2 Synthetic Attempts Toward a β-Silane Donor Group 
 At this stage of the tronocarpine study, results from D-A bicyclo[3.1.0]hexane 
methodology study suggested that the β-silanol donor group proposed for the total 
synthesis of tronocarpine might not tolerate the Lewis acid-mediated ring-opening 
cyclization. Thus, the observed poor results from the ring-opening cyclization above could 
be attributed to this effect. With that possibility in mind, two syntheses toward an allyl β-
silane were attempted, as a β-silyl donor group may be converted later in the synthesis to 
the desired carbonyl functionality through a Fleming-Tamao oxidation to the 
corresponding alcohol.8 
 First, alcohol 55a was subjected to the optimized mesylate formation conditions 
and further treated with lithium chloride (Scheme 6-9). It was envisioned that this allyl 
chloride could be subsequently converted to a Grignard reagent then add nucleophilically 
to dimethylphenylsilyl chloride to form the desired allyl β-silane 156. Unfortunately, this 
method proved ineffective. 
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Scheme 6-9: First attempt toward allyl β-silane precursor. 
 Next, efforts were redirected to a literature Grignard protocol between commercial 
starting materials (2-(chloromethyl)allyl)dimethyl(phenyl)silane (157) and 2-chloroprop-
2-en-1-ol (158) (Scheme 6-10).9 This method employed a nickel(II) catalyst to facilitate 
the cross-coupling, with a reported literature yield of 70% for this product. Unfortunately, 
this method proved challenging to replicate, and the synthesis was not pursued further. 
 
Scheme 6-10: Second attempt toward β-silyl alkene precursor. 
6.2.3 Oxabicyclo[3.1.0]hexane Lactone Ring-opening Approach 
With the unexpected difficulties encountered in the intermolecular 
cyclopropanation approach, attention shifted almost exclusively to the second approach. 
There was hope that this route would be more fruitful given the literature precedent for 
nucleophilic ring-opening of five-membered lactones and my own previous successes with 
intramolecular cyclopropanations to prepare oxabicyclo[3.1.0]hexanes (see Chapter 4). 
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Selecting model 89 as the DACP template and 59 as the nucleophile, various 
temperatures and loadings of NaH were evaluated to promote nucleophilic addition at the 
lactone to form DACP 160 (Table 6-8). Unfortunately, almost all conditions led to either 
no reaction or complete decomposition of 89. Using excess 89 and 2 equiv. of NaH, a 
complex mixture resulted, both at high and low temperature (entries 1-2). Decreasing the 
loading of 89, removing the base, and promoting the reaction through reflux, however, 
showed no consumption of starting material (entries 3-5). Reintroducing the NaH and 
increasing the loading of 59, unfortunately, also led to degradation of 89 (entry 6). 
Table 6-8: Test nucleophilic addition of 3-methylindole onto oxabicyclo[3.1.0]hexane model. 
 
Entry DACP:Indole NaH equiv Solvent (conc, temp) Result 
1 2:1 2 PhMe (0.1 M, 0°C – reflux) Complex mixture 
2 2:1 2a THF (0.1 M, 0°C) Complex mixture 
3 1:1 0 DCE (0.25 M, r.t. – Δ) No reaction 
4 1:1 0 PhMe (0.25 M, r.t. – Δ) No reaction 
5 1:1 0 DMF (0.25 M, Δ) No reaction 
6 1:2 2 THF (0.2 M, 0°C) Degradation 
a Added 15-crown-5 (0.2 equiv). b NMR showed evidence of cyclopropane or ring-opening cyclization 
adduct. 
 One surprising result was detected in the presence of trimethylaluminum (Me3Al) 
(Scheme 6-11). It has been demonstrated that various amines, including anilines, may be 
treated with Me3Al to form a Weinreb nucleophile that is significantly more reactive in 
amidation reactions with esters.10 There was no literature precedent to suggest that indoles 
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could complex with Me3Al in this manner, but a test reaction under the classical Weinreb 
conditions afforded a single isolated product in 22% yield. 
 
Scheme 6-11: Test Weinreb amidation and proposed products. 
Extensive NMR studies and mass analysis were indicative of one of two adducts: 
the anticipated cyclopropane 160, or the ring-opening cyclization product 161. (Both 
adducts have the same molecular weight). 1H NMR accounts for the methyl ester and 
methyl peaks, and a broad singlet at 3.49 ppm is highly indicative of an alcohol O-H. 
However, the aromatic region features only nine aromatic protons: the five from the phenyl 
substituent, and four from the indole moiety. This result strongly supports ring-opening 
cyclization adduct 161, otherwise a fifth proton from indole would be present. 
The aliphatic region is even more challenging to decipher, in large part due to the 
chemical shifts that are more downfield than expected and the presence of one additional 
proton (Table 6-9). Offering tentative assignments, protons G and K correlate only to each 
other and are in the appropriate region to be adjacent to an alcohol. That leaves protons J, 
H, M, and N to assign. By COSY, protons J and H correlate, and protons M and N correlate, 
with no additional overlap. Moreover, by HSQC, protons J and H share the same carbon, 
as do protons M and N, and by DEPT, there are two CH2 moieties, which is consistent with 
both proposed structures. 
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(Multiplicity, J-Value, Integration) 
Correlations 
J 4.54 (dd, J = 11.1, 2.4 Hz, 1H) H 
K 4.51 (d, J = 3.8 Hz, 1H) G 
G 4.45 (d, J = 4.0 Hz, 1H); K 
H 4.14 (d, J = 11.1 Hz, 1H) J 
M 3.03 (dd, J = 12.4, 2.5 Hz, 1H) N 
N 2.57 (d, J = 12.4 Hz, 1H) M 
Crystallization is underway to perform X-ray analysis, hopes of solving this 
mystery. If either of these products is detected, further efforts toward the total synthesis of 




In summary, the total synthesis of rhazinicine was endeavored via a novel ring-
opening cyclization of an N-acyl pyrrole-tethered DACP. Despite precedent for this 
Friedel-Crafts-type reaction as well as early success toward the natural product synthesis, 
the alkene precursor proved unreliable with scale-up. 2-Iodoanilide and benzyl ester 
alkenes were successfully prepared and evaluated, without notable improvement in yield. 
Ultimately, the total synthesis of rhazinicine was abandoned because the proposed 
synthetic route did not improve upon previous published approaches. 
Additionally, the first total synthesis of tronocarpine was attempted but ultimately 
not accomplished by the avenues pursued in this chapter. The primary limitations from the 
first approach were the failed synthesis of an adequate alkene precursor for the 
intermolecular cyclopropanation, as well as difficulties effecting the cyclopropanation in 
sufficiently high yields to move forward in the synthesis. The second approach of 
introducing the indole moiety through nucleophilic attack onto an oxabicyclo[3.1.0]hexane 
was more promising, and further work must be done to validate the product’s structure. 
This approach could also open the door to a new methodology study, as Weinreb-type 
amidations with indole precursors are unprecedented in synthetic literature. 
6.4 Experimental Details 
6.4.1 General Information 
Chromatographic purification was performed via flash chromatography with 
Silicycle SiliaFlash P60 silica gel (40-63 µm) or preparative thin-layer chromatography 
(prep-TLC) with Analtech silica gel F254 (1000 µm) plates and solvents indicated as eluent 
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with 0.1-0.5 bar pressure. For quantitative flash chromatography, technical grades solvents 
were utilized. Analytical thin-layer chromatography (TLC) was also used to separate and 
purify reaction products using Silicycle SiliaPlate TLC silica gel F254 (250 µm) TLC glass 
plates. Products on the TLC plates were visualized under UV light (254 nm).  
Proton, and carbon nuclear magnetic resonance spectra (1H NMR and 13C NMR, 
respectively) were recorded on a Bruker 500 MHz spectrometer. The solvent resonances 
were used the internal standards (1H NMR: CDCl3 at 7.26 ppm, DMSO-d6 at 3.50 ppm; 
13C NMR: CDCl3 at 77.0 ppm, DMSO-d6 at 39.5 ppm; 
19F NMR: locked to CDCl3 or 
DMSO-d6). MestReNova (v. 11.0) was used to analyze NMR spectra. 
1H NMR data are 
reported as follows: chemical shift (ppm), multiplicity (s = singlet, d = doublet, dd = 
doublet of doublets, dt = doublet of triplets, ddd = doublet of doublet of doublets, t = triplet, 
m = multiplet, br = broad), coupling constants (Hz), and integration. High-resolution 
accurate mass-mass spectrometry (HRAM-MS) was performed using a MicroMass 
Autospec M, run in EI mode at a mass resolution of 10,000 using perfluorokerosene (PFK) 
as an internal calibrant. 
6.4.2 General Procedures 
General Intermolecular Cyclopropanation Procedure:11 Rh2(esp)2 (0.1 mol%) was 
charged to a flame-dried flask under N2, suspended in half the requisite volume of 
anhydrous DCM (0.5 M), then the suspension was cooled to 0°C. The alkene (1.3 equiv) 
was added to the Rh flask and stirred. In a separate flame-dried flask under N2, the α-diazo-
β-amidoester (1 equiv) was dissolved in the remaining anhydrous DCM and transferred to 
the Rh flask via syringe in one shot with stirring. After 10 minutes, the solution was allowed 
to warm to room temperature. After 30 minutes, the reaction was quenched with saturated 
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aqueous thiourea and stirred for an additional 30 minutes. Then, the aqueous layer was 
extracted with DCM and the combined organic layers were washed with brine, dried over 
anhydrous Na2SO4, filtered through celite under reduced pressure, and concentrated by 
rotary evaporation. The product was purified by silica flash chromatography. 
General Intramolecular Ring-Opening Cyclization Procedure: The Lewis acid (20 
mol%) was charged to a flame-dried flask under N2, then the cyclopropane (1 equiv) was 
added as a solution in anhydrous DCM or MeCN (0.1 M). When complete by TLC or after 
24 hours, the reaction mixture was quenched with H2O, the aqueous layer was extracted 
with DCM, and the combined organic extracts were dried over anhydrous MgSO4, filtered 
through celite under reduced pressure, and concentrated by rotary evaporation. The product 
was purified by silica flash chromatography or prep-TLC. 
General Krapcho Decarboxylation Procedure:2 In a flask equipped with a reflux 
condenser, the indolizine (1 equiv), LiCl (2.338 equiv), and H2O (cat.) were dissolved in 
anhydrous DMSO (0.2 M). The reaction was stirred at 150°C under N2 for 2 h. After 
cooling to room temperature, the reaction was poured into H2O, the aqueous layer extracted 
with Et2O, and the combined organic extracts dried over anhydrous Na2SO4, filtered 
through celite under reduced pressure, and concentrated by rotary evaporation. 
General Saponification Procedure: The ester (1 equiv) was dissolved in MeOH (1 
M) with stirring, then the solution was warmed to 50°C. NaOH (1.5 equiv, 1.7 M/H2O) 
was added and the reaction mixture was stirred for 2 hours. Then, the reaction was allowed 
to cool to room temperature, and 1 M HCl was used to adjust the pH to 3. The aqueous 
layer was extracted with EtOAc and the combined organic extracts were dried over 
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anhydrous Na2SO4, filtered through celite under reduced pressure, and concentrated by 
rotary evaporation. The product was purified by silica flash chromatography. 
General N-Acylation Procedure: In a flame-dried flask under N2, the indole (1 
equiv) was dissolved in anhydrous 1,2-DCE (1 M). Methyl malonyl chloride (1.5 equiv) 
was added, then the reaction was stirred at reflux. After 3 hours, the reaction mixture was 
concentrated by rotary evaporation directly onto silica and purified by silica flash 
chromatography. 
General TsN3 Diazo Transfer Procedure:
12 In a flame-dried flask under N2, the β-
amidoester (1 equiv) was dissolved in anhydrous MeCN (0.1 M). Et3N (1.5 equiv) was 
added, followed by TsN3 (1.2 equiv), and the reaction was allowed to stir overnight. The 
solution was concentrated by rotary evaporation directly onto silica and purified by flash 
chromatography. 
General Mono-Silylation Procedure: Following the published procedure:13 In a 
flame-dried flask under N2, NaH (1.2 equiv, 60% dispersion in mineral oil) was suspended 
in anhydrous THF (0.5 M) and cooled to 0°C. 2-Methylene-1,3-propanediol (1 equiv) was 
added dropwise, then the solution was allowed to warm to room temperature and stirred 
for 45 minutes. R3SiCl (1 equiv) was added and the mixture stirred for an additional hour. 
The reaction was quenched with H2O, the aqueous layer extracted with EtOAc, and the 
combined organic extracts washed with brine, dried over anhydrous MgSO4, filtered 
through celite under reduced pressure, and concentrated by rotary evaporation. 
General Acetylation Procedure: In a flame-dried flask under N2, the alcohol (1 
equiv) was dissolved in anhydrous DCM (0.5 M). The solution was cooled to 0°C, then 
DIPEA (1.2 equiv), DMAP (0.2 equiv), and Ac2O (1.2 equiv) were added in sequence. 
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After stirring for 30 minutes, the reaction mixture was quenched with 1% HCl, the aqueous 
layers were extracted with DCM, and the combined organic extracts were washed with 
brine, dried over anhydrous Na2SO4, filtered through celite under reduced pressure, and 
concentrated by rotary evaporation. The product was afforded without further purification. 
6.4.3 Experimental Procedures 
6.4.3.1 Procedures for the Original Synthesis of Rhazinicine 
Methyl 2-Ethyl-2-(3-methoxy-3-oxopropyl)-1-(1H-pyrrole-1-
carbonyl)cyclopropane-1-carboxylate (125). The general intermolecular cyclopropanation 
procedure was followed using 126 (400 mg, 2.07 mmol) in 7 mL of anhydrous DCM (slow-
added over 4 hours), and 127 (956.6 mg, 6.73 mmol) and Rh2(esp)2 (5.8 mg, 7.66 μmol) in 
8 mL of anhydrous DCM. After purification by silica flash chromatography, compound 
125 was afforded as a yellow oil (331.5 mg, 52% yield). NMR data were consistent with 
previously reported results.2 
Methyl 8-Ethyl-8-(3-methoxy-3-oxopropyl)-5-oxo-5,6,7,8-tetrahydroindolizine-6-
carboxylate (124). The general intramolecular ring-opening cyclization procedure was 
followed using 125 (327 mg, 1.06 mmol) and In(OTf)3 (179.2 mg, 0.319 mmol) in 11 mL 
of anhydrous DCM (0.1 M). After purification by silica flash chromatography, compound 
124 was afforded as a brown oil (193.3 mg, 63% yield). NMR data were consistent with 
previously reported results.2 
Methyl 3-(8-Ethyl-5-oxo-5,6,7,8-tetrahydroindolizin-8-yl)propanoate (128). The 
general Krapcho decarboxylation procedure was followed using 124 (263.3 mg, 0.857 
mmol), LiCl (85.0 mg, 2.00 mmol), and H2O (2 drops) in 4.3 mL of anhydrous DMSO. 
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Compound 128 was afforded without further purification (193.4 mg, 90% yield). NMR 
data were consistent with previously reported results.2 
3-(8-Ethyl-5-oxo-5,6,7,8-tetrahydroindolizin-8-yl)propanoic Acid (129). The 
general saponification procedure was followed using 128 (189 mg, 0.757 mmol) and NaOH 
(0.67 mL, 1.14 mmol, 1.7 M/H2O) in 0.8 mL of MeOH. After purification by silica flash 
chromatography (10% MeOH/DCM), compound 129 was afforded as a white solid (100.9 
mg, 57% yield). 1H NMR (500 MHz, MeOD) δ 7.34 (dd, J = 3.4, 1.5 Hz, 1H), 6.28 (t, J = 
3.3 Hz, 1H), 6.07 (dd, J = 3.3, 1.5 Hz, 1H), 2.84 (ddd, J = 6.9, 6.1, 1.6 Hz, 2H), 2.40 – 2.21 
(m, 2H), 2.08 – 1.90 (m, 4H), 1.81 – 1.65 (m, 2H), 0.93 (t, J = 7.5 Hz, 3H). 13C NMR (126 
MHz, MeOD) δ 177.74, 170.23, 139.90, 117.59, 113.80, 110.82, 38.42, 32.91, 31.86, 
31.27, 30.57, 30.21, 8.66. 
3-(8-Ethyl-5-oxo-5,6,7,8-tetrahydroindolizin-8-yl)-N-(2-iodophenyl)propanamide 
(123). Following the published procedure:13 In a flame-dried flask under N2, 129 (50 mg, 
0.213 mmol) was dissolved in 1.1 mL of andrydrous DCM. Mukaiyama’s reagent (65.4 
mg, 0.256 mmol) and 3-methylindole (256.3 mg, 1.17 mmol) were subsequently added, 
then the reaction mixture was stirred at reflux for 1 hour. After cooling the mixture to room 
temperature, Et3N (0.08 mL, 0.538 mmol) was added and the mixture stirred at reflux 
overnight. Then, the mixture was cooled to room temperature and poured into H2O. The 
aqueous layer was extracted with DCM, then the combined organic layers were dried over 
anhydrous Na2SO4, filtered through celite under reduced pressure, and concentrated by 
rotary evaporation. After purification by silica flash chromatography (25% 
EtOAc/hexanes), compound 123 was afforded (32.2 mg, 35% yield). 1H NMR (500 MHz, 
CDCl3) δ 8.17 (d, J = 7.7 Hz, 1H), 7.77 (d, J = 7.9 Hz, 1H), 7.40 – 7.30 (m, 3H), 6.84 (t, J 
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= 7.2 Hz, 1H), 6.23 (t, J = 3.3 Hz, 1H), 6.03 (s, 1H), 2.82 (td, J = 6.6, 3.3 Hz, 2H), 2.39 
(ddd, J = 28.1, 10.1, 5.6 Hz, 2H), 2.18 – 2.03 (m, 2H), 1.98 (t, J = 7.1 Hz, 2H), 1.80 – 1.62 
(m, 2H), 0.92 (t, J = 7.5 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 167.74, 138.74, 137.97, 
137.69, 129.29, 126.01, 122.01, 116.74, 112.41, 109.39, 36.98, 31.72, 30.63, 30.38, 29.48, 
8.10. 
6.4.3.2 Procedures for Rhazinicine Synthesis Optimizations 
Benzyl 4-Methylenehexanoate (136). In a flame-dried flask under N2, 133 (100 mg, 
0.780 mmol) was dissolved in 0.8 mL of anhydrous DCM then cooled to 0°C. Et3N (0.13 
mL, 0.936 mmol) was added slowly, then ethyl chloroformate (0.12 mL, 1.01 mmol) was 
added slowly. After stirring for 30 minutes, BnOH (0.32 mL, 3.12 mmol) was added, and 
the reaction was allowed to warm to room temperature. After 15 hours, the reaction was 
quenched with cold H2O, the aqueous layer extracted with DCM, and the combined organic 
extracts washed with brine, dried over anhydrous Na2SO4, filtered through celite under 
reduced pressure, and concentrated by rotary evaporation. After purification by silica flash 
chromatography (25% EtOAc/hexanes, Rf = 0.70), compound 136 was afforded as a 
colorless liquid (139.0 mg, 82% yield). 1H NMR (500 MHz, CDCl3) δ 7.40 – 7.31 (m, 5H), 
5.13 (s, 2H), 4.77 – 4.69 (m, 2H), 2.52 (dd, J = 9.1, 6.5 Hz, 2H), 2.41 – 2.35 (m, 2H), 2.04 
(q, J = 7.4 Hz, 2H), 1.03 (t, J = 7.4 Hz, 3H). 
Methyl 2-(3-(Benzyloxy)-3-oxopropyl)-2-ethyl-1-(1H-pyrrole-1-
carbonyl)cyclopropane-1-carboxylate (137). The general intermolecular cyclopropanation 
procedure was followed using 126 (500 mg, 2.59 mmol), 136 (2.826 g, 12.9 mmol), and 
Rh2(esp)2 (2.0 mg, 2.59 μmol) in 5.2 mL of anhydrous DCM. After purification by silica 
flash chromatography (25% EtOAc/hexanes, Rf = 0.33), compound 137 was afforded in a 
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1.5:1 mixture of diastereomers (410.5 mg, 41% yield). 1H NMR (500 MHz, CDCl3) δ 7.40 
– 7.28 (m, 11H), 6.27 (dt, J = 3.6, 2.5 Hz, 3H), 5.13 (d, J = 1.4 Hz, 1H), 5.08 (s, 2H), 3.66 
(d, J = 5.1 Hz, 5H), 2.62 – 2.51 (m, 2H), 2.45 – 2.34 (m, 2H), 2.34 – 2.25 (m, 1H), 2.19 – 
2.06 (m, 2H), 1.79 (q, J = 7.5 Hz, 2H), 1.67 (ddd, J = 13.0, 4.9, 1.2 Hz, 2H), 1.54 (dd, J = 
15.5, 5.0 Hz, 2H), 1.32 (ddd, J = 14.5, 9.8, 6.4 Hz, 1H), 0.96 (dt, J = 20.7, 7.0 Hz, 6H). 13C 
NMR (126 MHz, CDCl3) δ 172.63, 172.52, 169.21, 169.12, 165.02, 164.90, 135.78, 
135.73, 128.57, 128.54, 128.31, 128.25, 128.22, 119.78, 119.75, 113.15, 66.47, 66.36, 
52.93, 40.37, 39.97, 37.75, 37.65, 31.38, 31.31, 28.39, 27.16, 27.02, 26.68, 23.99, 21.91, 
10.60, 10.57. 
Methyl 8-(3-(Benzyloxy)-3-oxopropyl)-8-ethyl-5-oxo-5,6,7,8-tetrahydroindolizine-
6-carboxylate (138). The general intramolecular ring-opening cyclization procedure was 
followed using methyl 137 (50 mg, 0.13 mmol) and In(OTf)3 (21.9 mg, 0.0390 mmol) in 
1.3 mL of anhydrous DCM, heated to reflux. After purification by silica flash 
chromatography (25% EtOAc/hexanes, Rf = 0.13), compound 138 was afforded in a 1.3:1 
mixture of diastereomers (18.5 mg, 37% yield). 1H NMR (500 MHz, CDCl3) δ 7.39 – 7.30 
(m, 6H), 6.23 (dt, J = 12.2, 3.3 Hz, 1H), 5.97 (ddd, J = 21.7, 3.3, 1.5 Hz, 1H), 5.11 (s, 1H), 
5.04 (s, 1H), 3.97 – 3.78 (m, 5H), 2.46 – 2.33 (m, 3H), 2.28 (ddd, J = 16.2, 10.6, 5.7 Hz, 
1H), 2.11 (ddd, J = 14.3, 9.2, 6.9 Hz, 1H), 2.06 – 1.92 (m, 3H), 1.82 (ddd, J = 14.0, 10.6, 
5.6 Hz, 1H), 1.72 (q, J = 7.4 Hz, 1H), 1.62 (dd, J = 14.2, 7.3 Hz, 1H), 0.88 (q, J = 7.4 Hz, 
4H). 13C NMR (126 MHz, CDCl3) δ 173.18, 172.88, 169.72, 128.59, 128.37, 128.35, 
128.30, 128.23, 117.28, 117.16, 113.18, 113.00, 110.07, 109.86, 66.54, 66.49, 52.83, 
52.80, 46.99, 46.94, 36.90, 36.55, 34.99, 34.32, 31.73, 31.34, 31.26, 29.83, 29.15, 29.07, 
8.24, 7.80. 
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6.4.3.3 Procedures for the Synthesis of Tronocarpine 
 Methyl 3-(3-Methyl-1H-indol-1-yl)-3-oxopropanoate (151). The general N-
acylation procedure was followed using 3-methylindole (100 mg, 0.762 mmol) and methyl 
malonyl chloride (0.12 mL, 1.14 mmol) in 0.8 mL of anhydrous 1,2-DCE. After 
purification by silica flash chromatography (25% EtOAc/hexanes), compound 151 was 
afforded (173.7 mg, 98% yield). NMR data were consistent with previously published 
results.3 
 Methyl 3-(3-Methyl-1H-indol-1-yl)-2-diazo-3-oxopropanoate (152). The general 
TsN3 diazo transfer procedure was followed using 151 (174 mg, 0.751 mmol), TsN3 (0.14 
mL, 0.901 mmol), and Et3N (0.16 mL, 1.13 mmol) in 7.5 mL of anhydrous MeCN. After 
purification by silica flash chromatography (25% EtOAc/hexanes), compound 152 was 
afforded as a yellow solid (180.3 mg, 93% yield). NMR data were consistent with 
previously published results.3 
2-(((tert-Butyldiphenylsilyl)oxy)methyl)prop-2-en-1-ol (55a). The general mono-
silylation procedure was followed using 2-methylene-1,3-propanediol (500 mg, 5.67 
mmol), TBDPSCl (1.568 g, 5.67 mmol), and NaH (228 mg, 5.67 mmol, 60% dispersion in 
mineral oil) in 68 mL of anhydrous THF. After purification by silica flash chromatography 
(25% EtOAc/hexanes, Rf = 0.46), compound 55a was afforded as a thick, colorless oil 
(1.550 g, 84% yield). NMR data were consistent with previously published results.13 
2-(((tert-Butyldimethylsilyl)oxy)methyl)prop-2-en-1-ol (153). The general mono-
silylation procedure was followed using 2-methylene-1,3-propanediol (1 g, 11.4 mmol), 
TBSCl (1.711 g, 11.4 mmol), and NaH (544.7 mg, 13.6 mmol, 60% dispersion in mineral 
oil) in 23 mL of anhydrous THF. After purification by silica flash chromatography (25% 
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EtOAc/hexanes, Rf = 0.46), compound 153 was afforded as a thick, colorless oil (1.736 g, 
75% yield). NMR data were consistent with previously published results.15 
2-(((tert-Butyldiphenylsilyl)oxy)methyl)allyl Acetate (150a). The general 
acetylation procedure was following using 55a (500 mg, 1.53 mmol), DIPEA (0.32 mL, 
1.84 mmol), DMAP (37.4 mg, 0.306 mmol), and Ac2O (0.17 mL, 1.84 mmol) in 15 mL of 
anhydrous DCM. Compound 150a was afforded without further purification (560 mg, 99% 
yield). 1H NMR (500 MHz, CDCl3) δ 7.68 (d, J = 6.8 Hz, 1H), 7.46 – 7.37 (m, 2H), 4.59 
(s, 1H), 4.20 (s, 1H), 2.03 (s, 1H), 1.07 (s, 2H). 
2-(((tert-Butyldimethylsilyl)oxy)methyl)allyl Acetate (150b). The general 
acetylation procedure was following using 153 (500 mg, 2.47 mmol), DIPEA (0.52 mL, 
2.97 mmol), DMAP (60.4 mg, 0.494 mmol), and Ac2O (0.28 mL, 2.97 mmol) in 25 mL of 
anhydrous DCM. Compound 150b was afforded without further purification (565.7 mg, 
94% yield). 1H NMR (500 MHz, CDCl3) δ 5.23 (d, J = 1.5 Hz, 1H), 5.13 (q, J = 1.3 Hz, 
1H), 4.58 (s, 2H), 4.16 (s, 2H), 2.08 (s, 3H), 0.91 (s, 10H), 0.07 (s, 6H). 13C NMR (126 
MHz, CDCl3) δ 170.69, 143.20, 112.95, 64.67, 63.77, 25.84, 20.91, 18.33, -5.45. 
Methyl 2-(Acetoxymethyl)-2-(((tert-butyldimethylsilyl)oxy)methyl)-1-(3-methyl-
1H-indole-1-carbonyl)cyclopropane-1-carboxylate (154b). The general intermolecular 
cyclopropanation procedure was followed using 152 (100 mg, 0.389 mmol), 150b (123.7 
mg, 0.506 mmol), and Rh2(esp)2 (3.0 mg, 3.89 μmol) in 0.8 mL of anhydrous DCM. After 
purification by silica prep-TLC, compound 154b was afforded (8.7 mg, 6% yield). 1H 
NMR (500 MHz, CDCl3) δ 8.45 (d, J = 8.6 Hz, 1H), 7.49 (d, J = 8.8 Hz, 2H), 7.33 (dtd, J 
= 23.8, 7.4, 1.1 Hz, 3H), 4.75 (d, J = 11.6 Hz, 1H), 4.50 (d, J = 11.6 Hz, 1H), 3.75 (d, J = 
9.8 Hz, 1H), 3.65 (s, 3H), 3.58 (d, J = 10.8 Hz, 1H), 2.27 (d, J = 1.3 Hz, 3H), 2.16 (s, 3H), 
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1.95 (d, J = 5.2 Hz, 1H), 1.78 (d, J = 5.1 Hz, 1H), 0.69 (s, 9H), -0.22 (d, J = 20.8 Hz, 6H). 
13C NMR (126 MHz, CDCl3) δ 170.23, 169.28, 164.15, 131.52, 125.02, 123.71, 123.13, 
118.63, 118.02, 116.88, 62.98, 62.92, 53.11, 38.43, 36.94, 25.59, 22.41, 20.77, 18.06, 9.92, 
-5.93, -6.01. 
Methyl 9-(Acetoxymethyl)-9-(((tert-butyldimethylsilyl)oxy)methyl)-10-methyl-6-
oxo-6,7,8,9-tetrahydropyrido[1,2-a]indole-7-carboxylate (155b). The general 
intramolecular ring-opening cyclization procedure was followed using a crude mixture of 
154b (~184.2 mg, 0.389 mmol) and In(OTf)3 (43.7 mg, 0.778 mmol) in 3.9 mL of 
anhydrous DCM. After 1.5 hours, TLC showed consumption of starting material, but there 
was no evidence of desired product by NMR. 
6.4.3.4 Procedures for the Oxabicyclo[3.1.0]hexane Lactone Ring-Opening Approach to 
Tronocarpine  
160 or 161. Following the published procedure:10 In a flame-dried flask under N2, 
3-methylindole (69.4 mg, 0.529 mmol) was dissolved in 1.9 mL of anhydrous DCM. 
Trimethylaluminum (0.3 mL, 0.605 mmol, 2 M solution in heptane) was added slowly. 
After stirring for 20 minutes, 98 (100 mg, 0.378 mmol) was added as a solution in 1.9 mL 
of anhydrous DCM, then stirred for an additional hour at room temperature. The reaction 
was heated to reflux. After stirring overnight, the reaction was cooled to room temperature 
and quenched carefully with dilute HCl, then the aqueous layer was extracted with DCM 
and the combined organic extracts were dried over anhydrous Na2SO4, filtered through 
celite under reduced pressure, and concentrated by rotary evaporation. After purification 
by silica prep-TLC, the product was afforded as either the cyclopropane 160 or the 
cyclopropane ring-opening cyclization adduct 161 (22.0 mg, 16% yield). 1H NMR (500 
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MHz, CDCl3) δ 7.45 (t, J = 7.4 Hz, 2H), 7.38 (ddd, J = 8.4, 7.2, 1.4 Hz, 3H), 7.18 (d, J = 
7.4 Hz, 1H), 7.12 (td, J = 7.8, 1.2 Hz, 1H), 6.77 (td, J = 7.4, 0.9 Hz, 1H), 6.65 (d, J = 7.8 
Hz, 1H), 4.54 (dd, J = 11.1, 2.4 Hz, 1H), 4.51 (d, J = 3.8 Hz, 1H), 4.45 (d, J = 4.0 Hz, 1H), 
4.14 (d, J = 11.1 Hz, 1H), 3.89 (s, 3H), 3.49 (s, 2H), 3.03 (dd, J = 12.4, 2.5 Hz, 1H), 2.57 
(d, J = 12.4 Hz, 1H), 1.05 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 170.35, 167.12, 150.56, 
138.51, 130.45, 129.07, 128.88, 127.93, 126.09, 123.91, 118.48, 109.88, 75.13, 62.69, 
57.38, 52.96, 51.90, 50.87, 36.00, 27.91. HRAM-MS (EI) m/z [M+H]+ Calcd for 
C22H22O4N 364.1453; Found 364.1543. 
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CHAPTER 7. CONCLUSIONS AND FUTURE OUTLOOK 
7.1 General Conclusions 
 This dissertation delved deeply into the potential advances and applications of the 
Friedel-Crafts reaction toward the total syntheses of three medicinal compounds: 
flubromazepam (and its positional isomers), tronocarpine, and rhazinicine (Figure 7-1). 
These synthetic and natural products were targeted synthetically for their privileged 
scaffolds and unique structural features that presented interesting challenges for 
methodology development. 
 
Figure 7-1: Featured medicinal compounds and corresponding privileged scaffolds. 
Benzodiazepines, thought prolific in literature, have been limited in scope due in 
part to the synergistic preferences of Friedel-Crafts acylations to prepare the crucial 2-
aminobenzophenone intermediate. This thesis evaluated, and in some cases optimized, 
known synthetic methods to effect this transformation, Friedel-Crafts and otherwise, and 
enabled the first total synthesis of eight positional isomers of flubromazepam (plus the 
parent drug). Key challenges to this synthesis were the relatively labile C-Br bond in 
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flubromazepam; and steric hindrance in relevant precursors to the (6,X’)-flubromazepam 
isomers, which are the three targets remaining. 
 
Scheme 7-1: Optimized synthetic route for all except for (6,X')-flubromazepam isomers. 
Significantly, this research offers a template for rapid benzodiazepine isomer 
synthesis, since the key synthetic step, the aryl lithiate addition to Weinreb benzamides, 
enables a highly convergent synthesis originating from inexpensive, commercially 
available starting materials. This tool may be an aid to forensic examiners, should a 
positional isomer of a known designer benzodiazepine be suspected in a case. Furthermore, 
initial analytical studies show promising evidence that positional isomers of 
benzodiazepines may be differentiated using currently available forensic techniques. Thus 
far, IR spectroscopy is the most discriminating method when characterization data are 
available for comparison. 
Tronocarpine, a chippiine-type indole alkaloid, has been the subject of immense 
interest over the last two decades since its isolation from nature. The bridged bicyclic 
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moiety embedded in this scaffold is unique even among other members of the chippiine 
family, as the seven-membered lactam is connected at the bridgehead carbon, and the 
challenge remaining is how to effect synthesis of the pentacycle with adequate tolerance 
for functional handles essential to complete the final decorations to the core structure. 
Endeavors to solve this issue led to an intensive study of an understudied class of 
donor-acceptor cyclopropanes (DACPs). D-A bicyclo[3.1.0]hexanes are DACPs with a 
cyclic tether connecting the acceptor carbon to a vicinal carbon on the cyclopropane. The 
site of this tether significantly affects the synthetic pathways available: when connected to 
the donor carbon, a cyclic, tertiary carbocation forms as the reactive intermediate; when 
connected adjacent to the donor carbon, an exocyclic, secondary carbocation results. 
Intramolecular Friedel-Crafts-type ring-opening cyclizations of this DACP class have been 
largely unexplored, and it was envisioned that such a ring-opening cyclization of an N-acyl 
indole-tethered, C5-substituted D-A bicyclo[3.1.0]hexane would efficiently afford the 
bridged bicyclic moiety of tronocarpine, and that this method could be expanded to 
additional heterocyclic templates (Scheme 7-2). 
 
Scheme 7-2: Hypothesized C5-sub. D-A bicyclo[3.1.0]hexane ring-opening cyclization. 
Despite extensive optimizations of several model systems, both intramolecular 
Friedel-Crafts-type ring-opening cyclizations and intermolecular Friedel-Crafts-type 
additions failed to deliver the desired bridged bicyclic core. Gratifyingly, however, a novel 
formal [3+2] cycloaddition between a C5-substituted D-A oxabicyclo[3.1.0]hexane and p-
 460 
anisaldehyde afforded the anticipated oxabicyclo[4.2.1]nonane scaffold (Scheme 7-3). 
This methodology will be further developed and demonstrates promise toward developing 
an intramolecular ring-opening cyclization in the future. 
 
Scheme 7-3: Successful formal [3+2] cycloaddition of a C5-sub. D-A oxabicyclo[3.1.0]hexane. 
Additionally, a benzofuran-tethered C6-substituted D-A oxabicyclo[3.1.0]hexane 
was employed in an unprecedented intramolecular Friedel-Crafts-type ring-opening 
cyclization in the pursuit of a new total synthesis of propolisbenzofuran B. A surprising 
stereochemical outcome was observed: a cis ring-opening cyclization adduct in contrast to 
the expected trans based on previous literature (Scheme 7-4). This result was further 
supported by in-depth NMR analysis simplified by capping the adduct as an enol triflate, 
which opened the door to a methodology study to further probe the stereochemical 
outcomes of DACPs with cyclic tethers at varying sites on the cyclopropane. Initial efforts 
toward a substrate scope have been conducted, with the intent of probing substituent effects 
as well as tether length (i.e. ring size) on diastereoselectivity of the ring-opening 
cyclization. 
 
Scheme 7-4: Ring-opening cyclization of a C6-sub. oxabicyclo[3.1.0]hexane to exclusively cis adduct. 
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Finally, the total synthesis of rhazinicine was attempted via a recently demonstrated 
Friedel-Crafts-type ring-opening cyclization of N-acyl pyrrole-tethered DACPs. This 
methodology signaled an important advance in the synthesis of pyrrole-containing 
compounds, as pyrrole-based starting materials are notoriously difficult to harness in 
typical heterocyclic synthetic chemistry. Unfortunately, the preceding cyclopropanation 
step proved unreliable with the more complex alkene precursors required for the total 
synthesis, despite previous optimizations. Moreover, a similar cyclopropanation strategy 
employed toward a newly-envisioned total synthesis of tronocarpine also failed to deliver 
a useful cyclopropane precursor. Gratifyingly, however, in the pursuit of this tronocarpine 
system, a novel Weinreb-type amidation was observed between 3-methylindole and a C5-
substituted D-A oxabicyclo[3.1.0]hexane (Scheme 7-5). This result may signal the advent 
of a facile nucleophilic introduction of indole scaffolds, often challenging due to the 
stability of indoles imparted by aromaticity, onto complex DACPs with masked functional 
handles. 
 
Scheme 7-5: Weinreb-type amidation onto a C5-sub. D-A oxabicyclo[3.1.0]hexane to form potential 
precursor to tronocarpine. 
7.2 Future Outlook for Flubromazepam 
 Although nine of the twelve positional isomers of flubromazepam were obained by 
the approach described in Chapter 2, the remaining three isomers have not yet been 
synthesized. Initial efforts toward the preparation of N-benzyl-4-bromo-3-(X-
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fluorophenyl)-3-hydroxyoxindoles, however, have been fruitful. The 4-fluorophenyl 
hydroxyoxindole isomer has been prepared and validated, and the reaction has 
demonstrated scalability at 500 mg. Remaining steps in the synthesis are benzyl 
deprotection by hydrogenolysis, oxidative rearrangement, and N-acylation/imination under 
Sternbach conditions. Syntheses of the 2-fluoro and 3-fluoro isomers will be performed in 
tandem. 
 
Scheme 7-6: Progress toward synthesis of (6,X')-flubromazepam isomers. 
 Additionally, the positional isomers of flubromazolam are prime targets due to their 
facile preparation from flubromazepam and the biological potency displayed by parent 
flubromazolam. The preparation of these twelve compounds is optimistically expected to 
be attainable within a two-month period, after which time they will be validated and fully 
characterized by forensic techniques. 
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Scheme 7-7: Projected synthesis of (X,X')-flubromazolam isomers. 
 Furthermore, there is potential to expand this project by subjecting the prepared 
flubromazepam (and flubromazolam) positional isomers to structure-activity relationship 
studies; targeting additional benzodiazepines of interest and synthesizing their respective 
positional isomers; and developing a synthetic route to benzodiazepine-like analogues such 
as etizolam. Efforts are underway to establish a collaboration for the first aim. 
 Finally, despite promising analytical results toward positional isomer 
differentiation, further studies must be conducted to expand the characterization dataset. 
Each of the flubromazepam isomers will be analyzed by LC-MS, a softer technique than 
GC-MS, to evaluate potential differentiation by LC retention time and/or mass spectral 
analysis. Additionally, the pure positional isomers will be subjected to solid-state FTIR to 
establish a baseline comparison with GC-IR results. Furthermore, to establish 
reproducibility and a standard deviation, at least three experiments by each of these 
instrumental techniques will be performed and the data rigorously analyzed by statistical 




7.3 Future Outlook for Donor-Acceptor Bicyclo[3.1.0]hexane Methodologies 
No research project is ever truly finished, and the progress made toward the 
development of novel ring-opening cyclizations of D-A bicyclo[3.1.0]hexanes is only the 
bright foray into the vast potential this template has to offer. Recommendations will be 
made herein regarding four individual studies that may be pursued further. 
7.3.1 The Intramolecular Friedel-Crafts-type Ring-opening Cyclization of C5-
Substituted D-A Bicyclo[3.1.0]hexanes 
This research project was disappointingly halted before the realization of an 
intramolecular ring-opening cyclization to access bridged bicyclic scaffolds. The current 
leading hypothesis, however, merits deeper investigation: that a heterocyclic-tethered 
DACP with a decarbonylated linker will facilitate Friedel-Crafts-type addition onto the 
intermediary carbocation through improved flexibility and proximity. Of the two synthetic 
routes surveyed, the more promising avenue is likely the benzofuran-tethered system 
(Scheme 7-8), as the appropriate starting materials are more readily available and the 
synthesis, more convergent. Also, given the propensity for N-acyl indole substituents to 
dissociate under strongly basic conditions, and the difficulty encountered with introducing 
indole nucleophilically, the benzofuran model should have greater stability throughout the 
synthesis and be easier to incorporate. 
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Scheme 7-8: Proposed synthesis of decarbonylated benzofuran-tethered model. 
Once the purification issues associated with 2-(bromomethyl)benzofuran are 
resolved, optimization of the base-promoted substitution may proceed. A temperature 
screen will be an essential, as this substitution may require higher temperatures than the 
prescribed -78°C employed for addition onto an acid chloride. The diazo transfer step will 
likely require NaH or a lithium base for deprotonation, but there should be no competing 
acidic sites, which will facilitate this transformation. Finally, the cyclopropanation ought 
to proceed normally but may require optimizations due to removing one of the acceptor 
groups from the diazo precursor. 
The resulting benzofuran-tethered, decarbonylated, C5-substituted 
oxabicyclo[3.1.0]hexane may then undergo a Lewis acid screen to test the formation of the 
bridged bicyclic moiety. Elimination products are certainly still plausible, but this 
undesired pathway may be less thermodynamically favored due to the absence of 
competing enol formation, and the flexibility of the carbon linker bonds should facilitate 
better proximity to the carbocation intermediate. Following proof of concept, various 
heterocyclic nucleophiles, donor groups, and ring sizes may be evaluated, and a 
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determination made as to the viability of this template for the first total synthesis of 
tronocarpine. 
7.3.2 The Intermolecular Formal [3+2] Cycloaddition of C5-Substituted D-A 
Bicyclo[3.1.0]hexanes 
Of the pathways evaluated that employ C5-substituted D-A bicyclo[3.1.0]hexanes, 
the route that displayed the most distinct promise was most certainly the formal [3+2] 
cycloaddition with external benzaldehydes. A model adduct has been successfully 
achieved and validated by NMR and HRAM-MS, and the Lewis acid screen is nearly 
complete. 
Immediate next steps for this project include wrapping up the Lewis acid screen and 
screening other parameters such as solvent and temperature (though initial tests have 
shown degradation at temperatures higher than 80°C). It would also be ideal to grow a 
crystal for X-ray crystallographic analysis, for further confirmation of the observed adduct. 
Finally, a broad substrate scope will be prepared and surveyed, with various aryl and 
heteroaryl aldehydes, differing donor groups as well as acceptor groups on the bicyclic 
tether (e.g. ketones and lactams), and non-aldehyde coupling partners (e.g. maleimides, 
acrylates, and isothiocyanates). 
This study may then be further applied to an intramolecular variant.  
7.3.3 The Intramolecular Friedel-Crafts-type Ring-opening Cyclization of C6-
Substituted D-A Bicyclo[3.1.0]hexanes 
As discussed previously, the implications of this study’s preliminary results are 
astounding. Not only is this Friedel-Crafts-type ring-opening cyclization unprecedented for 
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C6-substituted D-A bicyclo[3.1.0]hexanes, but the stereochemical outcome of this 
transformation is in direct contrast to almost all previous studies into the mechanism and 
diastereoselectivity preferences for trans over cis. The stage is set to evaluate templates 
with varying substitutions, tether sites, and tether lengths to offer a more generalized 
perspective on the stereochemistry of bicyclic DACP ring-opening cyclizations. 
This will be a huge undertaking. The immediate next step will be finalizing synthesis 
of the substrate scope to determine the trends of this particular C6-substituted D-A 
bicyclo[3.1.0]hexane template. Then, various acceptor groups and ring sizes for the 
bicyclic tether will be evaluated, which will require strategic synthesis. Finally, a six-
membered analogue to the 1,2-indanyl cyclopropane will be prepared, to test the effects of 
ring size at that site on diastereoselectivity. 
7.3.4 Weinreb-type Addition of Indoles to D-A Bicyclo[3.1.0]hexanes 
An unexpected but delightful result observed during the pursuit of the total synthesis 
of tronocarpine was the trimethylaluminum-mediated addition of 3-methylindole to the 
lactone moiety of an oxabicyclo[3.1.0]hexane, to prepare either an N-acyl DACP or the 
corresponding Friedel-Crafts-type ring-opening cyclization product. This result first needs 
to be validated, perhaps by X-ray crystallography. Then, two avenues are possible: a short 
methodology study, and the potential total synthesis of tronocarpine. 
The methodology study would survey a small subset of 3-substituted indoles (and 
possibly pyrroles) and bicyclo[3.1.0]hexane templates, since Weinreb amidations are well 
established for other amines including anilines. The subsequent total synthesis of 
tronocarpine would be adapted from the originally hypothesized route involving an 
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intermolecular cyclopropanation. This new approach, if successful, would actually 
streamline the synthesis, as the nucleophilic addition to the lactone results in a free alcohol 
that may be readily oxidized for the HWE step (Scheme 7-9). 
 
Scheme 7-9: Proposed retrosynthetic analysis of tronocarpine based on successful Weinreb-type 
amidation. 
7.4 Closing Thoughts 
The research encompassed by this thesis has been challenging, often frustrating, 
ultimately rewarding. Methodology development necessarily delves into the unknown, and 
every research project endeavoured herein exhibited unexpected, sometimes serendipitous, 
results. There is still so much to be learned from every privileged scaffold and reaction 
template explored, and as I pass the baton to the next PhD candidate, I look forward to one 
day reading a paper that solves any one of the mysteries presented. 
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